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ABSTRACT
Respiratory tract infections are a serious cause ofmorbidity and mortality throughout
the world. The most frequent causes of infection are Streptococcus pneumoniae,
Haemophilus influenzae, Moraxella catarrhalis and atypical pathogens such as
Chlamydophila pneumoniae. These infections are treated traditionally with
antimicrobial agents, mainly the penicillins and macro lides. However, the incidence
ofmacrolide resistance has increased markedly over the past 10 years, particularly in
France, Belgium and Italy. Therefore, new compounds like telithromycin, an
erythromycin derivative called a ketolide (K), have been developed to overcome this
problem.
In this study, clinical isolates ofS. pneumoniae, H. influenzae and
M. catarrhalis were tested in vitro against a range ofantimicrobial agents, including
telithromycin, to investigate the efficacy of this new drug. Telithromycin showed
excellent activity against S. pneumoniae, including macrolide resistant strains, but its
activity was not as high against M. catarrhalis or H. influenzae. For M. catarrhalis
the minimum inhibitory concentration (MIC) of telithromycin was similar to that of
the macrolides. With regard to H. influenzae telithromycin had higher activity than
erythromycin and clarithromycin.
The ermB and mefA/E genes mediate resistance to macrolides in S. pneumoniae in
most cases. The ermB gene confers resistance to macrolide, lincosamide and
streptogramin B (MLSB) antimicrobial agents by methylation ofpart of their
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ribosomal binding site. The mefA/E gene mediates efflux of 14- and 15-membered
macrolides. Recent investigations have also implicated mutations in the 23S rRNA
site ofMLSbK interactions with macrolide and, in certain cases, ketolide resistance.
Alterations of two ribosomal proteins L4 and L22 have also been associated with
increased MLSBK MICs and resistance.
In this study in vitro mutants were generated from three S. pneumoniae strains,
02J1095 (ermB positive), 02J1175 {mefA/E positive) and NCTC 13593 (MLSBK
sensitive), on telithromycin. The MICs of the final generation mutants of each parent
were increased in comparison to the parent but only the mutants from the macrolide
resistant parents, 02J1095 and 02J1175, were telithromycin resistant. In order to
ascertain the mechanism used by these telithromycin resistant mutants to achieve
resistance, the ermB gene and upstream region, the mefA/E gene, the 23 S rRNA
genes encoding domains II and V and the L4 and L22 riboprotein genes were
amplified by PCR and sequenced. No alterations were located in any of the genes of
the 02J1175 mutants investigated. No changes were present in the ermB genes or
upstream regions, the 23 S rRNA genes or the L4 or L22 riboprotein genes of the
02J1095 mutants except J III 8. J III 8 had a telithromycin MIC of>32mg/L and was
a second-generation mutant of 02J1095. In this strain two mutations were present.
The first was a 94K to Q94 amino acid mutation in the L22 riboprotein. The second
was a 208 base pair deletion in the upstream region of the ermB gene containing the
control peptide and one of two ribosome-binding sites. This region controls the
expression of the ermB gene and hence methylase production. These mutations either
alone or together were not present in any other mutant. They have not been described
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previously in S. pneumoniae. These mutations, while novel, do not alone explain the
development of telithromycin resistance in S. pneumoniae. They do however; give an
insight into how telithromycin interacts with the ribosome and the potential
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1.1 Bacterial Respiratory Tract Infections
Community acquired respiratory tract infections (RTI) are among the most prevalent
infectious diseases in the developed world and are associated with a considerable
healthcare burden (Murray et al., 1997). Respiratory tract infections can affect both
the upper and lower respiratory tract. Ofall RTIs, about one third are thought to
involve the lower respiratory tract and these infections are a major cause of death
globally, being responsible for 4.3 million premature deaths in 1990 worldwide
(Murray et al., 1994) and pneumonia is the sixth most common cause of death in the
US (Bartlett et al., 2000). Although upper respiratory tract infections such as
sinusitis, tonsillopharyngitis and otitis media are not generally life-threatening, they
can have serious effects if left untreated. Lower RTIs; such as community acquired
pneumoniae (CAP) and acute bacterial exacerbations of chronic bronchitis (AECB)
are associated with morbidity and mortality.
Up to 80% of community-acquired RTIs are caused by one of three bacterial
pathogens: Streptococcus pneumoniae, Haemophilus influenzae and Moraxella
catarrhalis (Felmingham, 2002). Other important RTI pathogens include
Streptococcus pyogenes, Staphylococcus aureus, anaerobic species and the atypical
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pathogens: Mycoplasma pneumoniae, Legionella pneumophila and Chlamydophila
pneumoniae. While these bacterial pathogens are implicated in RTIs, it is also
important to remember the viral RTI pathogens such as influenza virus, respiratory
syncytical virus, adenovirus and parainfluenza virus.
The most common cause ofCAP is S. pneumoniae and this is the pathogen most
frequently associated with poor outcome and mortality. Streptococcus pneumoniae is
also the most frequently reported pathogen in acute otitis media and sinusitis and is
reported in a significant proportion ofAECB cases. Haemophilus influenzae is the
primary bacterial pathogen ofAECB causing 30% to 50% ofbacterial exacerbations,
and is also associated with a high proportion ofCAP, acute sinusitis and acute otitis
media (Felmingham, 2002). Moraxella catarrhalis is identified in a significant
proportion ofpatients with acute otitis media, acute sinusitis and AECB, and is
particularly prevalent in immunosuppressed and hospitalised patients.
Atypical and intracellular pathogens such as Mycoplasma pneumoniae, Legionella
pneumophila and Chlamydophila pneumoniae are increasingly being recognised as
important aetiological agents ofRTIs, particularly CAP. Unlike other atypical
infections C. pneumoniae infection affects adults of all ages, usually as a co-
pathogen, and has been associated with severe infection and occasionally death (Lim
et ah, 2001).
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1.1.1 Haemophilus influenzae and Moraxella catarrhalis
Haemophilus influenzae and M. catarrhalis are aerobic commensal bacteria of the
throat and nasopharynx. Haemophilus influenzae is a gram-negative rod and
M. catarrhalis gram-negative diplococci. They are both opportunistic pathogens of
the lung and are implicated in diseases such as otitis media, sinusitis, pneumonia,
meningitis and bronchitis. Haemophilus influenzae is the commonest pathogen of
acute exacerbations of chronic bronchitis.
Until the late 1970s, isolates of both species were highly susceptible to ampicillin
and amoxycillin (Livermore, 1995). Nowadays, the activity ofaminopenicillins
without a 8-lactamase inhibitor has essentially been lost against M. catarrhalis and
H. influenzae due to the acquisition of B -lactamases by both bacteria. The
B-lactamase activity also compromises the use of some cephalosporins classes.
Moraxella catarrhalis has thus far not been found to have high levels of resistance to
antibiotics such as macrolides, cephalosporins, tetracyclines, B-lactamase inhibitor
combinations, fluoroquinolones and co-trimoxazole. Occasionally M. catarrhalis
strains resistant to these agents do appear, most frequently tetracycline resistant
(Roberts et al., 1990). In H. influenzae resistance to tetracycline, chloramphenicol,
sulphonamides, trimethoprim and quinolones also occurs (Powell et al., 1991). The
numbers ofH. influenzae strains resistant to ampicillin by mutations in the penicillin
binding proteins, rather than producing B-lactamases, are increasing (Ubukata et al.,
2001).
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1.1.2 Chiamydophila pneumoniae (formerly Chlamydia
pneumoniae)
Chlamydophila pneumoniae is an obligate intracellular pathogen, which has been
associated with CAP, bronchitis, pharyngitis, sinusitis, myocarditis, endocarditis and
atherosclerotic cardiovascular disease (Grayston et al., 1990). It was first isolated in
1965, but was specifically described as C. pneumoniae in 1989 by Grayston et al.
Tetracycline or erythromycin are currently used to treat infections.
Resistance to antimicrobial agents has not been described either in clinical strains of
C. pneumoniae or laboratory generated mutants to date. This is due to their unique
biphasic life cycle and difficulties that it poses to culture the organism in vitro. The
current diagnostic methods of PCR or ligase chain reaction also do not permit
susceptibility testing. Even though resistance has not been reported in C. pneumoniae
there is good reason to suspect that resistance does occur. Hammerschlag et al.,
(1992) described 5 patients with culture-positive C. pneumoniae infections who had




Sternberg in the USA and Pasteur in France first isolated Streptococcus pneumoniae
simultaneously in 1880. In the 1880s the pneumococci was also shown to be capable
of causing meningitis, endocarditis, arthritis and otitis media and experimental
pneumococcal endocarditis in rabbits (Reviewed by Austrian, 1999). Following the
isolation and identification ofS. pneumoniae a number of important scientific
advances were made: The recognition by Klemperers of the protective value of
antiserum against infection with the homologous organism and the observation of the
lytic bile effect on pneumococci by Neufeld in 1900. Recognition of serologically
different types ofS. pneumoniae in 1910 by Neufeld and Haendel led to specific
antisera and thus to the first effective treatment for pneumococcal pneumonia
(Reviewed by Austrian, 1999). Thereafter followed the observations ofAvery,
Heidelberger and Goebel on the chemical structure of structural antigens and their
role in bacterial virulence. Another accolade ofS. pneumoniae history was the
genetic transformation ofpneumococci by DNA, initiated by Griffiths in 1928
(Griffiths, 1928), and elucidated by Avery, MacLeod and McCarty in 1944 (Avery et
al., 1944), which opened the door to molecular genetics.
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1.1.3.2 Morphology, Growth Characteristics and Disease
Streptococcus pneumoniae are gram-positive cocci occurring in pairs or short chains.
They are non-motile, spore forming and when freshly isolated are capsulate. They
are aerobic or facultative aerobic fastidious organisms, growing best on media
supplemented with 5% blood and 5% to 10% CO2 at 37°C. When grown on blood
agar S. pneumoniae produces a green halo of a-haemolysis around each colony. This
typical appearance, a lack of catalase production, and a zone of inhibition around an
optochin disk or solubility in bile salts are sufficient for presumptive identification of
S. pneumoniae (Ross, 1996).
Pneumococci are involved chiefly in infections of the upper and lower respiratory
tracts and are the most frequent bacterial cause of lobar and bronco-pneumonia in
general practice and in hospital (Ross, 1996). Before the introduction of antibiotics
pneumococcal pneumonia carried a mortality of 77% (Tilghman & Finland, 1937).
The mortality rate decreased to 25% for bacteraemia pneumococcal disease between
1952 and 1962, after the introduction of antibiotic treatment and remained at a
similar level of 28% from 1967 to 1970 (Austrian & Gold, 1964; Mufson et al.,
1974).
1.1.3.3 Virulence Factors
The pathogenicity of S. pneumoniae has been attributed to various structures, most of
which are situated on its surface. The high morbidity caused by this microorganism
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is still, however, poorly understood, and the list of virulence factors is probably far
from complete. The disease manifestations are caused primarily by the host response
to infection rather than the production of organism-specific toxin. The pathogenesis
ofS. pneumoniae infection is a complex interplay between pneumococcal virulence
determinants and the host immune response.
The capsule has long been recognised as the major virulence factor of
S. pneumoniae. Encapsulated strains were found to be at least 105 times more
virulent than strains lacking the capsule (Avery & Dubos, 1931; Watson & Musher,
1990). The chemical structure of the capsular polysaccharides (PS) and to a lesser
extent the thickness of the capsule determines the differential ability of serotypes to
survive in the bloodstream and possibly to cause invasive disease. Capsular PS
protect pneumococci from phagocytosis by polymorphonuclear leukocytes (Knecht
et al., 1970). The role of the capsule as a virulence factor is also well illustrated by
the highly protective activity of anti-capsular antibody (AlonsoDeVelasco et al.,
1993). Tuomanen et al (1987) demonstrated that capsular PS were not necessary for
inflammation but do contribute to the progression of the infection by inhibiting
phagocytosis. There are currently 90 different serotypes.
i. Capsular serotypes
On the basis of differences in the capsular polysaccharide structure, S. pneumoniae
may be divided into 90 different serotypes. Two types ofnomenclature have been
developed: one Danish and one American (AlonsoDeVelasco et al., 1995). The
Danish method classifies serotypes according to structural and antigenic
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characteristics e.g. serotypes 6A and 6B differ only slightly from each other. The
American nomenclature assigns the serotype number in the sequence of first
isolation. Therefore, serotypes 6A and 6B are types 6 and 26 respectively in the
American system. The Danish nomenclature is the most widely adopted. This system
is based on the reactions to 48 antisera. Some antisera recognise specific serotypes
whereas others recognise multiple serotypes within a serogroup e.g. serogroup 6
antisera recognises serotypes 6A and 6B. The isolates are first separated into groups
and then each serogroup is further subdivided into the serotypes.
Capsular variability allows different serotypes to avoid immune detection by
antibodies, which enables the organism to avoid phagocytosis and as such is an
important virulence factor. Some serotypes are more associated with invasive disease
than others. Serotypes 6, 14, 19 and 23 are the serogroups most often associated with
serious infection in children (Robbins et al., 1983). As small children often require
antibiotic treatment for the disease, these serotypes are also often associated with
antibiotic resistance (Dagan et al., 1994; Butler et al., 1995).
ii. Cell wall and cell wall polysaccharide
The S. pneumoniae cell wall (CW) is a dynamic structure composed ofmore than a
dozen glycopeptides that are continuously inserted into and released from this
circumferential, extracellular macromolecule (Tomasz, 1981; Garcia-Bustos et al.,
1987). In contrast to the capsular PS, purified peptidoglycan and especially CWPS
have been found to induce inflammation similar to that seen after infection with the
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whole pneumococci. Typical pneumococcal diseases such as otitis media, meningitis
and pneumonia can be mimicked in animals that have been injected with purified
CW or its degraded products (Tuomanen et al., 1985; Tuomanen et al., 1987; Carlsen
et al., 1992). The cell wall or more specifically the CWPS result in inflammatory
effects due to activation of the alternative complement pathway (Winkelstein &
Tomasz, 1977; Winkelstein & Tomasz, 1978). Interleukin-1 production is increased,
which together with tumour necrosis factor, plays a pivotal role in the inflammation
process (Riesenfeld-Orn et al., 1989). The CW has also been shown to mediate the
attachment of unencapsulated S. pneumoniae to endothelial cells (Geelen et al.,
1993). Enzymatic degradation of the cell wall releases components, which are more
potent chemotactic factors that the intact CW. This finding is particularly relevant to
the consequences of bacterial lysis due to antibiotic action (Tomasz & Saukkonen,
1989).
iii. Pneumococcal proteins
Various proteins have been suggested to be involved in the pathogenicity of
S. pneumoniae. However, not all have been confirmed as virulence factors.
Pneumococcal surface protein A (PspA)
Antibody studies have demonstrated that PspA is located on the cell wall of
S. pneumoniae. PspA has been confirmed as a pneumococcal virulence determinant.
The function ofPspA, a protective antigen for pneumococci, appears to be protection
against host complement systems (Crain et al., 1990; Yother & Briles, 1992; Yother
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& White, 1994). Recent work has shown that PspA functions as a specific receptor
for lactoferrin and hence plays an essential role in enabling iron acquisition by
S. pneumoniae (Hammerschmidt et al., 1999).
Adhesion proteins
Pneumococcal surface antigen A (PsaA) is a surface lipoprotein essential for
S. pneumoniae virulence. The PsaA is a component ofan ABC-type manganese
permease membrane transport system and its likely function is to transport Mn2+ and
Zn2+ into the cytoplasm of the bacteria. The psa operon appears to have a regulatory
role in adhesion by affecting the expression of choline-binding proteins on the
S. pneumoniae surface (Novak et al., 1998).
Pneumococcal surface protein C (PspC), formerly known as choline-binding protein
A (CbpA), is a surface protein that cross-reacts with PspA but unlike PspA is
essential for pneumococcal carriage. It is thought to play an important role in the
adhesion ofpneumococci to human cells. It is also essential for pneumococci
penetration of the blood brain barrier.
Neuraminidase is another virulence factor ofS. pneumoniae, encoded by either the
nanA or nanB genes, that is present on all strains of freshly isolated S. pneumoniae
examined (O'Toole et al., 1971; Berry et al., 1996). This enzyme may facilitate
attachment to the epithelial cells by cleaving sialic acid from the glycolipids and
gangliosides found on the cell surface. Other proteins that may enhance the virulence
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ofpneumococci include hyaluronidase, neutrophil elastase inhibitor and peptide
permeases.
iv. Pneumolysin
Pneumolysin is a cytoplasmic toxin released by autolysis of the cell. The toxin first
binds to the target cell membrane and then forms a high molecular weight
transmembrane pore (Bhakdi & Tranumjensen, 1986). This results in leakage of
intracellular solutes and an influx ofwater resulting in lysis of the cell. Using this
mechanism, pneumolysin is able to damage a wide range of eukaryotic cells,
including bronchial epithelial cells, alveolar epithelial cell and pulmonary
endothelium. The action on bronchial epithelium results in slowing of the ciliary
beat, impairing the ability of the mucociliary escalator to clear particles effectively.
Pneumolysin thus may enhance the inflammatory process. Pneumolysin also serves
to facilitate bloodstream invasion by pneumococci and inhibits the respiratory bursts
and chemotaxis of polymorphonuclear leukocytes (PMNC) (Paton & Ferrante, 1983).
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v. Autolysins
Autolysins are members of a widely distributed group of enzymes that degrade the
peptidoglycan backbone of bacterial organisms. The action of these cell wall
degrading enzymes ultimately leads to cell death. One of the direct implications is
the release ofcell wall components shown to be highly inflammatory in some
animals. The indirect implication involves the release of cytoplasmic bacterial
proteins including bacterial virulence factors such as pneumolysin (Berry et al.,
1989). The precise role ofautolysin in S. pneumoniae virulence is still under debate.
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1.1.3.4 Pathogenesis
Streptococcus pneumoniae is carried in the upper respiratory tract by many healthy
individuals. The mechanisms used by S. pneumoniae to transfer from the
nasopharynx to the lung or to the blood are poorly understood (Boulnois, 1992).
Most infections do not occur after prolonged carriage but follow the acquisition of
recently-acquired serotypes (Gray et al., 1980; Boulnois, 1992). This suggests that
the immune status of the host and the virulence of a strain both determine whether
the pneumococci will remain in the nasopharynx or become invasive.
Failure of the specific and non-specific defences of the respiratory tract may
facilitate access of pneumococci to the bronchi and lungs (Boulnois, 1992; Musher,
1992). Simultaneous damage of the epithelial layer by H2O2 (produced by
pneumococci) and by pneumolysin may facilitate direct access to the blood.
Epithelial damage by previous, probably viral, upper respiratory tract infections also
increases the opportunity of pneumococci to reach the blood. From the blood the
bacteria may migrate to the meninges or they may reach the meninges directly from
the nasopharynx (Boulnois, 1992). Unrestrained multiplication ofpneumococci in
the lungs, meninges, or middle ear will result in pneumococci lysis with the release
ofcell wall products and pneumolysin. Pneumococcal lysis will in turn trigger the
inflammatory response. There is increasing support for the hypothesis that such
inflammation may be responsible for the morbidity and mortality caused by
pneumococci infection (Musher, 1992).
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Mosaic genes
In some species, such as streptococci, where genetic exchange occurs frequently,
comparative studies of the structure of selected genes has shown that some strains
contain parts ofgenes that are markedly different from those in other members of the
species, such sequences have been referred to as mosaic genes. Mosaic genes result
from occasional intragenic recombination between genetically distinct alleles. The
resulting genes may express proteins with novel phenotypes, particularly if the newly
incorporated DNA is from a different species or genus and so very different from the
host DNA. Twenty to thirty percent base differences in the recombining genes are
tolerated by RecA-mediated homologous recombination (Lorenz & Wackernagel,
1994).
In a population ofbacteria most mosaic genes will be lost in a divergent population
unless the mosaic gene expresses a phenotype, which confers a selective advantage
to the bacteria and thus bacteria containing the mosaic gene would found a new
population. The use of antibiotics has created a selective pressure, which selects
bacteria with mosaic genes encoding proteins that provide resistance to the
antibiotics, such as the B-lactam antibiotics, the penicillins.
The penicillin-binding proteins (PBPs) in penicillin resistant Neisseria species and in
S. pneumoniae represent some of the most extensively studied examples ofmosaic
genes. Penicillin binding proteins are the target proteins of the penicillin family of
antimicrobial agents and intrinsic resistance (as opposed to B-lactamase mediated
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resistance) is a result of the reduced affinity ofPBPs for penicillin. Four of the six
pneumococcal PBPs have been shown to be phenotypically altered in resistant
isolate, PBPs la, 2a, 2b and 2x (Laible et al., 1991). Three of these PBPs have been
characterised as being encoded by mosaic genes in resistant isolates, PBPs la, 2b and
2x. These PBPs had one or more blocks of sequence in which approximately 20%
divergence had replaced homologous sequences of sensitive strains (Dowson et al.,
1989; Laible et al., 1991; Martin et al., 1992). The resistant sequences were
interspersed with "sensitive sequences" that had less than 1% variation within one
species (Smith et al., 1991). Experiments have shown that in order to be penicillin
resistant, S. pneumoniae must acquire low-affinity variants of the three PBPs
encoded by mosaic genes, PBPs la, 2a and 2x. This initially seems unlikely, but
nucleotide sequence data has shown that this has occurred (Dowson et al., 1989;
Dowson et al., 1993; Kell et al., 1993; Dowson et al., 1994) and led to widespread
penicillin resistance in S. pneumoniae.
No naturally occurring resistant streptococcal species exist that could account for the
PBPs as resistance determinants for highly resistant S. pneumoniae. However, pbp2x
genes from penicillin sensitive Streptococcus oralis and Streptococcus mitis were
less than 4% divergent from the mosaic blocks in homologous genes of resistant
S. pneumoniae (Dowson et al., 1993; Sibold et al., 1994). Also, the mosaic blocks of
pbp2b genes in several resistant S. pneumoniae contained S. mitis DNA (Dowson et
al., 1993). Therefore, commensal streptococci could provide a reservoir of mosaic
genes, which until they are integrated into S. pneumoniae do not result in the
resistance phenotype.
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1.1.3.5 Antibiotic resistance in Streptococcus pneumoniae
Pneumococcal resistance to antimicrobial agents originated in the beginning of the
20th century. Optochin-resistant pneumococci were identified in experimentally
infected mice in 1912 and acquired optochin resistance during therapy ofpatients
was documented in 1917. Clinical use ofoptochin was then limited by its severe side
effects.
In 1939 resistance to the sulphonamide 2-sulphanilylaminopyridene was reported by
the inability of the drug to cure experimentally-infected mice. The development of
resistance during therapy was reported later that year in a human case of
pneumococcal meningitis (Ross, 1939). Sulphadiazine resistance during therapy and
spread of the resistant strain to a second patient was reported in 1943 (Frisch et al.,
1943).
Laboratory derived penicillin-resistant S. pneumoniae were developed in the 1940s
(McKee & Houck, 1943) but it was not until 1965 that the first clinical isolate with
reduced penicillin susceptibility was discovered in Boston (Kislak et al., 1965) and
the first penicillin-resistant clinical strain isolated in Australia reported in 1967
(Hansman & Bullen, 1967). This then spread to New Guinea where 12% of 518 New
Guinean isolates were penicillin-resistant (Hansman et al., 1974). From 1974 to
1980, the reported distribution ofpenicillin-resistant strains became worldwide. In
the UK, resistance increased from 0.1% in 1977 (Howard et al., 1978) to 4% in 1987
(Nair, 1988) and 9.1% in 1997/1998 (Felmingham et al., 2000). The number of
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penicillin-resistant S. pneumoniae is still increasing even though we have been aware
of clinical penicillin-resistant S. pneumoniae for 35 years.
Trimethoprim/Sulphamethoxazole (TMP-SMZ) resistance was identified in
S. pneumoniae for the first time in 1972 (Howe & Wilson, 1972).
Trimethoprim/Sulphamethoxazole resistance is associated with multiple resistant
S. pneumoniae isolated both from children in hospital and healthy children in the
community (Jacobs et al., 1978; Klugman et al., 1986).
Tetracycline was widely used in the 1960s for the management of acute
exacerbations ofchronic bronchitis. The first case of tetracycline-resistant
S. pneumoniae was reported in Australia in 1963 (Evans & Hansman, 1963) and also
in the UK due to an outbreak of 10 resistant strains in Liverpool (Turner, 1963).
Tetracycline resistance increased to 23% in the Liverpool Royal Infirmary by 1968
(Percival et al., 1969). However, pneumococcal resistance to tetracycline declined
after 1969 most likely due to the reduction in tetracycline prescription (Howard et
al., 1978).
Fluoroquinolone resistance surveillance in S. pneumoniae is a relatively recent
occurrence. The levels of resistance are extremely low worldwide. In 1996/1997 the
highest level of pneumococci resistance to ciprofloxacin (>lmg/L) or ofloxacin
(>lmg/L) worldwide was 0.5%. The combined resistances of ciprofloxacin and
ofloxacin were 0.1% and 0.04% for 1996 and 1997 respectively (Felmingham &
Gruneberg, 2000). Between 1997 and 1999 S. pneumoniae resistant to levofloxacin
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or gatifloxacin was >1% for both fluoroquinolones (Hoban et al., 2001b). While the
levels of fluoroquinolone resistance were extremely low we must exercise caution so
that more resistant strains do not emerge in the future.
Multiple resistant S. pneumoniae first emerged in 1977 in South Africa (Jacobs et al.,
1978). This isolate was penicillin, tetracycline, erythromycin, clindamycin,
chloramphenicol, and TMP-SMZ resistant. While the number of isolates with
multiple resistances is low in comparison to resistance to one antimicrobial agent,
multiple resistances are increasing in many countries. In the UK ten years after the
first multiple resistant strain was identified, 40 multiple resistant isolates were
reported (George et al., 1987). Today, isolation ofmultiply resistant S. pneumoniae
from both adults and children has been reported around the world.
The first report oferythromycin-resistant pneumococci, in 1964, was of 6 clinical
strains with erythromycin MICs of >5 mg/L. However, it was Dixon in 1967 who
brought this finding to the medical communities attention in a letter to The Lancet
(Dixon, 1967). During the 1970s and 1980s no erythromycin-resistant isolates were
found in studies conducted in the UK (Howard et al., 1978), Hong Kong (Ling et al.,
1983) or Germany (Federal Republic) (Kaufhold et al., 1987). The current situation
for erythromycin-resistant strains in these countries is UK 13.2%, Hong Kong 72.9%
and Germany 15.7% (Felmingham, 2002). In the last 20 years the situation of
erythromycin-resistant S. pneumoniae has become critical in some countries and
resistance is ever increasing. The idea that resistance may increase in countries where
the drug was widely used evolved during the late 1980s due to the identification of a
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high prevalence of erythromycin-resistant strains, associated with multiple
resistance, in South Africa (Felmingham, 2002).
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1.2 Macrolide antimicrobial agents
The first macrolide to be used clinically was erythromycin A in the 1950s. At this
time erythromycin was a valuable novel drug, which could be used against emerging
penicillin resistant S. pneumoniae and could also treat patients with B-lactam
intolerance. Erythromycin is a natural antibiotic isolated from Saccharopolyspora
erythrea formerly Streptomyces erythreus. It consists of a 14-membered lactone ring
with 2 attached sugar moieties at C3 and C5 as shown in figure 1.
Figure 1. Chemical structure ofErythromycin A.
Erythromycin activity is primarily against gram-positive bacteria but also has activity
against atypical pathogens such as Mycoplasma pneumoniae, Legionella
pneumophilla and C. pneumoniae. Macrolides are mainly bacteriostatic agents but
bactericidal activity may be achieved at high concentrations. They bind to the 23 S
rRNA in the 50S-subunit of the prokaryotic ribosomes and prevent protein synthesis
(Brisson-Noel et al., 1988). Macrolides belong to a chemically distinct but
CH,
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functionally overlapping family ofantimicrobial agents, which are all protein
synthesis inhibitors. This group consists of macrolides (M), lincosamides (L),
streptogramin B (Sb) antimicrobial agents and recently ketolides (K). Although it has
been extensively studied since the 1960s the exact mechanism of action of the
macrolides has not yet been fully elucidated. However, different theories exist on the
way in which macrolides inhibit protein synthesis.
One theory suggests that macrolides act by blocking peptide elongation. During
elongation the peptide chain grows through amino acid addition, which is catalysed
by peptidyl transferase. The peptide chain is translocated from the aminoacyl
acceptor (A) site to the peptidyl (P) donor site (see figure 2). Erythromycin is thought
to block translocation of the peptidyl-transfer RNA (tRNA), which is the tRNA
bearing the nascent peptide, or inhibit peptidyl transferase thus causing peptidyl-
tRNA translocation to cease (Monro & Vazquez, 1967; Brisson-Noel et al., 1988;
Mazzei et al., 1993).
Another proposed theory is that macrolides inhibit protein synthesis by stimulating
the dissociation ofpeptidyl-tRNA from ribosomes. The weakening of the bonds
between the ribosomes and the peptidyl-tRNA during translocation causes protein
synthesis inhibition. The hypothesis is that more peptidyl-tRNA is produced as a
result of repeated ribosome peptidyl-tRNA dissociation with the accumulation of
dissociated peptidyl-tRNA leading to inhibition ofprotein synthesis and cell death.
Menninger (1985) suggested that the blocking ofprotein synthesis by erythromycin
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would occur after dissociation ofpeptidyl-tRNA due to its accumulation (Menninger











































Figure 2. Simplified scheme ofprotein synthesis mechanism (adapted from
Brisson-Noel et al., 1988). A, aminoacyl acceptor site; aa, amino acid; EF, elongation factor;
fMet, formylmethionine; P, peptidyl donor site; RF, releasing factor.
The most recent theory proposed by Champney and Burdine (1995) postulated that
macrolides might secondarily inhibit 50S ribosomal subunit assembly. Erythromycin
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causes the accumulation of a 50S subunit precursor particle in cells. This binds
erythromycin and the stalled 50S subunit particle, containing 23S rRNA and
5S rRNA, is then degraded by cellular ribonucleases. These results suggest a second
target for macro lides and that both the elongation step ofpolypeptide chain
formation and the initial steps of 50S subunit assembly are affected by these
compounds (Champney & Burdine, 1995).
Resistance to erythromycin emerged quite rapidly after its clinical introduction
(Weisblum, 1995a). In order to overcome the problem oferythromycin resistance, a
number of semi-synthetic derivatives such as clarithromycin and azithromycin have
been developed. These macrolides have better pharmacokinetic profdes than
erythromycin, induce fewer gastro-intestinal side effects and offer improved activity
against H. influenzae and atypical pathogens (Neu, 1991; Zuckerman, 2000).
However, resistance to the new macrolides, increased erythromycin resistance and
MLSb resistance have led again to a search for new agents with activity against such
resistant bacteria and also low potential to select for or induce resistance and cross-
resistance. The ketolides, of which telithromycin is the first in clinical use, represent
the new generation of antimicrobial agents to tackle these problems.
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1.3 Telithromycin
Telithromycin is a semi synthetic 14-membered ring macrolide derivative as shown
in figure 3. There are three structural advantages to telithromycin not present in the
macro lides.
1. Telithromycin contains a 3-keto function instead of an L-cladinose moiety, a
neutral sugar long thought to be essential for antibacterial activity, of the macrolides.
This substitution enables telithromycin activity against erythromycin resistant strains
(Bonnefoy et al., 1997).
2. The hydroxyl group at C6 of erythromycin, is replaced by a methoxy group. The
methoxy group and the keto group together give telithromycin excellent acid and
gastrointestinal stability compared with the macrolides (Bryskier, 1998).
3. The carbamate CI 1-CI2 extension gives telithromycin improved binding affinity
to the ribosome and is partly responsible for the activity of telithromycin against
MLSo-resistant ribosomes compared to the macrolides (Hansen et al., 1999;





Figure 3. Chemical structure of telithromycin.
The main target bacteria of telithromycin are the macro lide resistant and MLSb
resistant S. pneumoniae. Telithromycin has excellent activity against macrolide
susceptible S. pneumoniae (Barry et al., 1998; Pankuch et al., 1998; Davies et al.,
2000a) and retains good activity against penicillin resistant (Barry et al., 1998;
Pankuch et al., 1998; Hoban et al., 1999) and erythromycin resistant strains (Barry et
al., 1998; Pankuch et al., 1998; Hoban et al., 1999). Telithromycin has been reported
to have bactericidal activity against S. pneumoniae (Hamilton-Miller & Shah, 1998),
but is generally thought to be a bacteriostatic drug. Telithromycin has similar activity
to the macrolides against gram-negative bacteria (Biedenbach et al., 1998; Wootton
et al., 1999) and atypical respiratory tract pathogens (Roblin & Hammerschlag,
1998; Bebear et al., 2000).
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1.3.1 Mode ofAction
Ketolides inhibit bacterial protein synthesis in a very similar manner to the
macrolides but with greater effect (Hansen et al., 1999; Douthwaite et al., 2000).
Macrolides and ketolides bind to the same region of the 23S rRNA of the assembled
50S subunit but the nature and strength ofbinding differ. Erythromycin,
clarithromycin, azithromycin and telithromycin interact with domain II and V of the
23S rRNA according to foot printing experiments (Xiong et al 1999; Douthwaite et
al 2000). The domain V region of interaction of the 23S rRNA with the macrolides
and ketolides is known as the peptidyl-transferase region.
As amino acids are added together to form a nascent peptide the chain passes through
a "peptide exit tunnel" in the 50S ribosomal subunit close to the peptidyl transferase
region. The MLSb antimicrobial agents and telithromycin bind to the 23S rRNA and
so block the peptide exit channel. The MLSB antimicrobial agents and telithromycin
all protect nucleotide residues Adenine (A) 2058, A2059 and Guanine (G) 2505,
which means that they all bind to each of these sites in domain V of the 23 S rRNA.
Telithromycin also protects A752 in domain II whereas the L-cladinose of
erythromycin and clarithromycin enhance accessibility to it and thus do not bind to
it. This extra binding site affinity is also associated with the CI 1-C12 carbamate link
present in telithromycin but not erythromycin or clarithromycin. The relative
positions of domains II and V in the 23 S rRNA are such that the distance between
the nucleotides binding telithromycin in domain V are close enough to the A752 in
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domain II to be spanned by the carbonl l-carbonl2 carbamate link of telithromycin
(Hansen et al., 1999; Xiong et al., 1999), as indicated in figure 4.
Figure 4. Tertiary structure of23S rRNA domains II and V with spanning from
Douthwaite et al., (2001).
Telithromycin was found to bind approximately 10-fold tighter to the ribosome than
erythromycin. This is thought to be due mainly to the binding of the CI 1-CI 2 link to
domain II. In fact, addition of a CI 1-C12 carbamate to clarithromycin increased
binding affinity approximately 5-fold. The two regions domain II and domain V form
one binding site for telithromycin not two distinct binding sites (Hansen et al., 1999;
Douthwaite et al., 2000). As telithromycin has improved binding capacity and an
additional binding site or sites, compared to erythromycin it follows that it has
improved activity and also activity against macrolide resistant strains.
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1.4 Mechanisms ofMacrolide Resistance
The two main mechanisms ofmacrolide resistance in S. pneumoniae are target
modification and efflux. A methyl-transferase gene mediates target modification:
ermB (erythromycin-resistance methylase). The ermB gene has been located on
transposons and plasmids in both gram positive and gram-negative bacteria. In
pneumococci, the gene is borne only by conjugative transposons related to Tn1545,
Tn/575-like elements, or a Tn9l7-like element that is part of a larger composite
transposon, Tn3872 (McDougal et al., 1998; Trieu-Cuot et al., 1990). The target
modification causes resistance not only to macrolides but also to lincosamides and
streptogramin B antibiotics and is associated with high-level macrolide resistance
(Weisblum, 1995a).
erm genes cause methylation of the binding site of the MLSb antibiotics within the
peptidyl transferase centre of the 23S rRNA. In S. pneumoniae the ermB gene
mediates methylation although recently an ermA gene has been also associated with
macrolide resistant S. pneumoniae (Syrogiannopoulos et al., 2001; Nagai et al.,
2002). Methylation by the erm associated methylase occurs at the adenine at position
2058 (Arthur et al., 1987). Methylation can occur as monomethylation or
dimethylation. It has recently been shown that variations in mono- or dimethylation
lead to different resistance phenotypes (Liu & Douthwaite, 2002). The
monomethylation ofA2058 resulted in intermediate resistance to erythromycin and
clarithromycin, high-level resistance to lincosamides but no resistance to the
ketolides. Dimethylation conferred high-level resistance to macrolides, lincosamides
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and resistance to the ketolides. ErmB and ErmA(TR) are both A2058
dimethyltransferases. This however, is not reflected in the MICs of
S. pneumoniae to date. One of the reasons for this may be in the way in which the
ErmB and ErmA methylate the A2058. Due to metabolic conditions, such as the
availability of S-adenosylmethionine from which the methyl group is removed,
ErmB could only monomethylate the A2058. Thus S. pneumoniae containing a
mixture ofmonomethylated and dimethylated ribosomes could have macrolide
resistant but ketolide sensitive phenotypes (Liu & Douthwaite, 2002). This theory
does require more evidence as little is currently known about this process in
S. pneumoniae. The addition of the methyl group(s) causes conformational changes
in the 50S ribosomal subunit, which prevents the MLSb antimicrobial agents from
binding to their site of interaction with the 23S rRNA and so prevents them from
inhibiting protein synthesis. Expression of resistance due to erm methylation can be
inducible or constitutive.
1.4.1 Inducible resistance
The inducible expression ofMLSb resistance is putatively controlled at a post-
transcriptional level by a regulatory region upstream from the erm gene (Weisblum,
1995b). The regulation is not related to the class oferm gene. When expression is
inducible, ermB mRNA is synthesised but in an inactive conformation I, figure 5,
and becomes active only in the presence of inducing macrolides (conformation II in
figure 5). In the non-induced state the conformation of the control peptide upstream
from the erm gene is such that the ribosome-binding site needed for transcription of
30
the erm gene is not accessible to the ribosome. Only the sequence corresponding to
the control peptide is translated (see figure 5 conformation I). When present,
erythromycin binds to the ribosomes, including those involved in the synthesis of the
control peptide, and causes them to stall. This stalling is thought to cause
displacement of the stem-loop structure by conformational rearrangements (see
figure 5 conformation II). The ribosome-binding site is then available to the
ribosome and so initiation of translation of the methylase may occur. When all of the
ribosomes are methylated stalling does not occur and so the mRNA returns to its
original conformation. High-level cross-resistance to MLSb antimicrobial agents in







Figure 5. Alternative conformations of the mRNA from the inducible ermC gene
from pNEl 94. Shown are the secondary structures of the mRNA in the absence (conformation 1) or
in the presence (conformation II) of erythromycin. Symbols: solid white is the mRNA, solid black is
the sequence of the control peptide, diagonal black lines are the sequence of the methylase, 1, 2, 3 and
4 represent inverted repeats. SDl and SD2 are the ribosome binding sites 1 and 2.
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1.4.2 Constitutive resistance
When expression is constitutive, the ermB mRNA is active (conformation II in
figure 5). The exact mechanism or mechanisms ofconstitutive resistance have not
been fully elucidated in S. pneumoniae. Constitutive expression ofMLSb resistance
in various bacteria has been associated with deletions or mutations in the regulatory
region upstream from the erm gene. Rosato et al (1998) showed a deletion ofmost of
the regulatory region was responsible for constitutive expression of the erm gene
from Streptococcus agalactiae. Constitutive expression in clinical isolates of
S. pneumoniae has been associated with a deletion of the control peptide and one
ribosome-binding site upstream from the ermB gene and also mutations within the
control peptide associated with constitutive resistance in another strain. One strain,
which had constitutive MLSb resistance was, however, without deletion or mutation
in this region and was identical to that of the inducible strains. Therefore,
modifications other than those in the erm upstream region are also possibly
responsible for constitutive resistance (Rosato et al., 1999). Two Streptococcus
pneumoniae clinical isolates with deletions in the leader peptides of their ermB genes
have been isolated, one ofwhich was highly ketolide resistant. In these strains
however there were also other mutations, both had 3 amino acid mutations in the
ErmB protein itself and the ketolide resistant strain also had mutations in the L4
riboprotein (Tait-Kamradt et al., 2001).
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1.4.3 Macrolide efflux
It is only recently that another mechanism, other than methylation, has been
identified. Before 1996 efflux ofmacrolides had not been specifically described in
streptococci even though in 1993, Seppala et al (1993) described Streptococcus
pyogenes strains that were erythromycin resistant and clindamycin susceptible,
known as the MS phenotype. Sutcliffe et al in 1996 described, for the first time, an
efflux mechanism in both S. pneumoniae and S. pyogenes. They noticed that there
was no change in binding ofmacrolides to the ribosomes, indicating no change in
binding site of the macrolides. The efflux pump was distinguishable from the efflux
system in staphylococci also bearing the MS phenotype. Efflux pumps do not modify
either the antimicrobial agent or the antibiotic target, but instead pump the antibiotic
out of the cell, keeping intracellular concentrations low and ribosomes free from
antibiotic.
The macrolide efflux gene, mefE, was detected in S. pneumoniae in 1997
(Tait-Kamradt et al., 1997). The gene was found to have 90% homology to the mefA
gene ofS. pyogenes. Both have since been put into the same class of macrolide efflux
genes. In S. pyogenes strains with an M phenotype the mefA encodes a 44.2 KDa
protein with homology at amino acid level to other efflux proteins. The protein
encoded by mefE in S. pneumoniae is also a hydrophobic protein with homologies to
other transporters or efflux proteins. Streptococcuspneumoniae strains with mefE
genes are resistant to 14- and 15-membered macrolides but clindamycin and
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streptogramin B sensitive. The macrolide resistance is of a lower level than those
with either an ermB gene or ribosomal changes.
orfI or/2 orf5 trtefA or/5 or/6 orp orfX
1 kb
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Figure 6b. The mefE genetic element mega.
The mefA genetic element was first described in 2000 (Santagati et al., 2000) as a
chromosomal element designated Tnl207.1, 7244 base pairs in size as shown in
figure 6a. The entire element consisted of 8 open-reading frames (orf) with the mef
gene between orfs 3 and 5. Adjacent to the mefgene was an orfhomologous to
msr(SA) and vga(A). msr(SA) confers resistance to macrolides and streptogramin B
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and vga(A) confers resistance to streptogramin A antibiotics in Staphylococcus
aureus (Roberts et al., 1999). Gay and Stephens (2001) described a 5.4 or 5.5 Kb
genetic element containing a mefE gene called mega, shown in figure 6b. This had
similarities and differences to Tn7207.1. The first 4 orfs ofmega and orfs 4 to 7 of
Tn 1207.1 had >94% identity at nucleotide level. In mega the orf sequence 3' of the
mefE gene was designated mel. The meI orf is also a homologue ofmsrA in
staphylococci, which encodes an ATP-binding cassette to provide the energy for
efflux. The mefE and mel are co-transcribed, which suggests that both are required
for efflux. One important difference between mefA and mefE is their site insertion
into the chromosome. The mefA element was found to be integrated at a single site in
the chromosome whereas mefE was inserted at different chromosomal locations. In
light of this information it may be wise to refer to the mefgenes seperately as mefA
and mefE.
Resistance in mefpositive strains is stable. However, resistance to macrolides was
found not to be stable in mutants derived from parent strains containing mefgenes.
The macrolide and telithromycin MICs reverted to the parent MIC after 10 passages
on antibiotic-free medium (Davies et al., 2000b).
The efflux mefmediated system is a current threat to 14- and 15-membered
macrolides, but a mefmediated macrolide resistant S. pneumoniae infection would be
the easiest macrolide resistant infection to treat as it could still be treated with
lincosamides and streptogramin B or ketolides. This is currently the situation but
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there is always potential for the efflux pump to change and also pump these
antimicrobial agents out of the cell.
1.4.4 Macrolide resistance worldwide patterns
ermB and mefgenes are disseminated throughout the world in S. pneumoniae.
However, there is an uneven distribution of each gene. In the US and Canada
surveillance studies revealed that the macrolide resistant (M) phenotype associated
with the mefgene and efflux predominates. In Europe and the Asia-Pacific rim, the
majority ofmacrolide resistant S. pneumoniae had an MLSb resistance phenotype
linked to the ermB gene (Hoban et ah, 2001b). This variation in distribution could be
related to different antibiotic consumption and differential selective pressures or the
clonal spread oferythromycin resistant strains or determinants within specific
geographical areas.
1.4.5 mefand erm genes
While the resistance genes ermB and mefare usually isolated alone, there have been
reports from South Africa (McGee et al., 2001), Japan (Nishijima et al., 1999),
France (Marchandin et al., 2001), Spain (Morosini et al., 2001), Great Britain and
Ireland (Farrell et al., 2001) and Canada (Hoban et al., 2001a) of S. pneumoniae
strains with both genes present. The ermB-mefpositive strains identified to date have
all been clinical isolates. The percentage ofermB-mefpositive strains is low in
comparison to those containing only 1 of the genes.
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The largest number ofS. pneumoniae isolated in one study with both genes was in
South Africa where a total of36 strains were isolated from 4 different cities in 1999.
All strains showed high-level resistance to erythromycin and clindamycin which is
associated with the ermB gene, but in addition these strains also showed high level
penicillin resistance, as well as resistance to chloramphenicol, tetracycline and
trimethoprim-sulphamethoxazole. Using BOX-PCR and pulsed-field gel
electrophoresis (PFGE), 30 of the 36 isolates were shown to belong to a single
multiply resistant clone (McGee et al., 2001). The relatedness of this clone to the
ermB-mefpositive strains from other countries remains to be determined.
The ermB-mef isolates from around the world all showed high level resistance to
erythromycin and clindamycin, which is the same resistance pattern as strains
harbouring only the ermB gene. Therefore, it appears that the ermB gene is
predominately expressed over the mefgene. Phenotypic tests alone are therefore not
sufficient to investigate the presence of the mefgene when it exists in association
with the ermB gene. The MIC of telithromycin against 6 of the ermB-mefpositive
strains tested was <0.002 to 0.06 mg/L (Hoban et al., 2001a). Due to the low number
of strains it is impossible to extrapolate much information from these results, except
that telithromycin had good activity against these 7 strains.
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1.4.6 Ribosomal mutations
Macrolide resistance in clinical isolates and laboratory-derived strains of
S. pneumoniae have been linked to alterations of specific nucleotides in the 23 S
rRNA of the ribosomal subunit, described in figure 7. Mutations at A2058 are the
most frequently identified ribosomal mutations associated with macrolide resistance
in 23S rRNA (Vester & Douthwaite, 2001). Specifically in S. pneumoniae mutations
have been located at nucleotides 2058, 2059, 2062 and 2611 (Tait-Kamradt et al.,
2000a; Depardieu & Courvalin, 2001; Farrell et al., 2002; Pihlajamaki et al., 2002).
These ribosomal mutations were identified in clinical isolates, which did not contain
the ermB or mefA genes. In addition to these mutation sites a mutation in the hairpin
35 region of the domain II of the 23S rRNA has been associated with macrolide and




Figure 7. Secondary structure of domain V of23S rRNA in E. coli (adapted from
Leclercq & Courvalin, 2002). Nucleotides which are protected by erthromycin are circled.
Arrows indicate mutations conferring macrolide resistance on S. pneumoniae. Capital letters
correspond to the antibiotic groups; M, macrolides; Ml6, 16-membered macrolides; K, ketolides.
Small capital letters denote low-level resistance.
Streptococcus pneumoniae has 4 copies of the 23 S rRNA gene. The level of
resistance depends not only on the type or position ofmutation but also the number
of copies containing the mutation. A laboratory-derived mutant with A2058G
changes in 2 copies of the gene resulted in high-level macrolide resistance
(Tait-Kamradt et al., 2000b). In clinical isolates no such mutant has so far been
isolated, however, 3 isolates with A2058G mutations in 3 of the 4 copies were highly
macrolide resistant (Farrell et al., 2002). Adenine to uracil (U) mutations in 3 copies
of the genes at position 2058 also conferred macrolide resistance in vitro (Canu et
al., 2002). Both A2059G (Tait-Kamradt et al., 2000a; Farrell et al., 2002) and
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A2059C (Pihlajamaki et al., 2002) have been identified in clinical isolates. The
A2059G mutation has also been created in laboratory-derived mutants (Tait-Kamradt
et al., 2000b). Clinical strains with the A2059G in 1, 2, 3 or 4 copies of the 23S
rRNA have been isolated. It appears however, that the A2059G mutations in at least
2 copies of the genes are required to confer macrolide resistance. The A2059C
mutation in 2, 3 or 4 copies resulted in the same high-level macrolide resistance
(Pihlajamaki et al., 2002).
The A2062C mutation has only been identified in 1 clinical isolate of S. pneumoniae,
which was in all 4 copies of the 23S rRNA genes (Depardieu & Courvalin 2001).
This set ofmutations lead to resistance to 16-membered macrolides and
streptogramins only. A mutation from cytosine to guanine at nucleotide 2611
resulted in macrolide resistance in clinical strains with 3 or 4 mutated alleles (Farrell
et al., 2002; Pihlajamaki et al., 2002) and also laboratory-derived mutants with 4
altered alleles (Tait-Kamradt et al., 2000b). However, laboratory mutants with
cytosine to adenine or uracil changes were macrolide sensitive (Tait-Kamradt et al.,
2000b; Canu et al., 2002). Only laboratory-derived mutants with a C2610U mutation
have so far been identified but these were macrolide sensitive (Canu et al., 2002).
One laboratory derived S. pneumoniae strain was found to have a 1 adenine deletion
in the series of 4 located at positions 749 to 752 in the hairpin 35 of domain II (Canu
et al., 2002). The MIC ofmacrolides increased between 250 to 1000-fold to greater
than 32mg/L and the MIC of telithromycin also increased 500-fold to an MIC of
4mg/L. This finding is consistent with previous reports of a single point mutation,
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U754A, in a laboratory strain of E. coli, which was sufficient to render the cells
resistant to telithromycin (Xiong et al., 1999). It also confirms the importance of
domain II, hairpin 35 in telithromycin binding.
Although reports ofmutations of the 23 S rRNA genes associated with macro lide
resistance in clinical isolates ofS. pneumoniae are low this does not make it any less
important. Recently, the first report of azithromycin treatment failure due to an
A2059G mutation was published. The patient was a 53-year-old woman with no
history of smoking or alcohol abuse (Kays et al., 2002).
The mechanism behind the 23S rRNA mutations causing resistance is thought to be
the prevention ofMLSB antimicrobial agents binding to their site of ribosome
interaction. The deletion or alteration of the domain II binding site confers the same
fate to the ketolide telithromycin. Even though mutations in the domain V of the 23S
rRNA have not been linked to telithromycin resistance in S. pneumoniae, laboratory
derived mutations have shown an increase in telithromycin MIC due to the
alterations (Tait-Kamradt et al., 2000b; Canu et al., 2002). The A2058G mutation in
2 or 3 copies of the genes increased the telithromycin MIC 10-fold and 16-fold
respectively. The A2059G mutation in 2 and 4 copies of the 23 S rRNA genes caused
3-fold and 4-fold increases in telithromycin MICs respectively. The mutation at
nucleotide 2611 from cytosine to guanine in all 4 alleles, in vitro, caused the highest
increase of a 130-fold increase in telithromycin MIC in vitro. Other mutations at this
nucleotide from cytosine to adenine or uracil resulted in less than 10-fold increases in
telithromycin MIC. These in vitro experiments suggest that the C2611G mutation is
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the most potent mutation in domain V to date against telithromycin and thus is
involved in telithromycin binding. Only a few studies have been carried out to date
on telithromycin resistance and drug binding and as such no definite conclusions
regarding binding sites can be made.
The ribosome consists not only of rRNA but also riboproteins, which interact with
the rRNA to form the ribosomal subunits of the ribosome. Two such riboproteins are
L4 and L22. Mutations in both of these proteins have been implicated in macro lide
resistance. Mutations conferring resistance to erythromycin were first identified in
ribosomal proteins L22 and L4 of E. coli (Wittmann et al., 1973). Macrolide
resistance mutations have also been located in a Bacillus subtilis (Tipper et al., 1977)
homologue of the E. coli L22 and in the L4 ofBacillus stearothermophilus (Sharrock
et al., 1981; Schnier et al., 1990). Recently, mutations in both of these riboproteins
have been associated with macrolide resistance in S. pneumoniae.
Riboprotein L4 is a 207 amino acid protein and L22 a 114 amino acid protein in
S. pneumoniae (Tettelin et al., 2001). In the assembly of the 50s ribosomal subunit
L4 and L22 bind directly to the domain I region of the 23 S rRNA. The primary
binding sites of L4 and L22 are not yet fully elucidated. Positively-charged residues
ofboth L4 and L22 interact with the negatively-charged phosphate groups of the
RNA forming nucleic-acid-protein complexes (Unge et al., 1998; Worbs et al.,
2000). Erythromycin resistance mutation studies of these riboproteins implied that
they also have interactions with the central loop of domain V of the rRNA. Gregory
and Dahlberg (1999), also showed that these proteins have multiple contacts with
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rRNA in domains II, III and V of the rRNA. L22 binding is strongly dependent on
L4.
In protein formation by the ribosome, the nascent peptide chain exits the ribosome
via a tunnel. This tunnel is fenced by long extensions of L4 and L22 riboproteins.
Escherichia coli studies suggested that the opening and closing of the tunnel could be
an inherent part of the ribosome, which could, in part be regulated by the L4 and L22
proteins. As L4 and L22 riboproteins are an integral part of the ribosome binding site
ofmacrolides and ketolides it is then logical to suggest that resistance to these agents
may also be mediated by changes in both or either of L4 and L22 (Gabashvili et al.,
2001).
Mutations in the L4 riboprotein and L22, to a lesser extent, have been associated
with macrolide and, on occasion, telithromycin resistance either alone or in
combination with 23S rRNA mutations or the presence of an ermB gene. The most
common mutation identified clinically to date in S. pneumoniae, is a 69GTG71 to
69TPS71 amino acids change. These mutations have lead to high-level erythromycin
resistance in S. pneumoniae isolated in Eastern Europe (Nagai et al., 2002). One
strain harbouring these mutations was also isolated from Canada. The Canadian
strain not only had the L4 mutation but also contained an ermB gene with a 10 amino
acid truncated leader peptide (Tait-Kamradt et al., 2001). This strain was reported to
have high-level telithromycin resistance.
Other mutations in the L4 riboprotein identified in clinical isolates were an amino
acid mutation at position 20 from serine to asparagine in combination with an
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A2062C mutation in all 4 23S rRNA alleles (Depardieu & Courvalin, 2001). This
strain was resistant only to 16-membered macrolides and not to 14- or 15-membered
macrolides. Two insertions of amino acids into L4 have also been identified in
clinical S. pneumoniae; a GTGREK insert at amino acid 72 (Tait-Kamradt et al.,
2000a) and an RRQ insert at amino acid 68 (Nagai et al., 2002). The region ofL4
from amino acid 63 to 74 is highly conserved in different species ofbacteria.
In laboratory derived strains other L4 amino acid mutations were also described. The
mutants had been passaged in azithromycin. One strain had a G69C mutation and
another an SQ insertion at amino acid position 68 (Tait-Kamradt et al., 2000b). A
third laboratory-derived mutant had an L4 G71R mutation in combination with an
L22 G95D change (Canu et al., 2002). These mutants were described as macrolide
resistant but their erythromycin MICs would not be classified as resistant.
From the studies carried out to date it appears that the L4 amino acid region from 67
to 72 is the hotspot for mutations conferring macrolide resistance. The mutations
from GTG to TPS do not result in a change in the charge of the amino acids. Both the
GTG and TPS sets of amino acids have no charge and therefore cannot be involved
in the electrostatic binding to the RNA. However, both threonine and serine have
aliphatic hydroxyl side chains whereas glycine does not and proline a secondary
rather than a primary amino group. These subtle changes could be responsible for an
alteration in the L4 conformation, which would prevent the macrolides binding and
thus cause macrolide resistance.
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Mutations in L22 associated with macrolide resistance have been mainly described in
laboratory-derived strains ofS. pneumoniae. In fact, only two types of L22 mutation
have been identified in clinical isolates. These are a G95D amino acid change, which
together with an A2059G mutation in all 4 23S rRNA alleles resulted in
erythromycin MICs of 64mg/L to 128mg/L (Farrell et al., 2002) and a six amino acid
insertion (RTAHIT) at amino acid 109, this occurred during therapy and the patient
later died (Musher et al., 2002).
The G95D amino acid mutation has also been described in laboratory-derived
macrolide resistant and sensitive S. pneumoniae. The resistant strains were selected
on erythromycin and roxithromycin and had erythromycin MICs of 1 mg/L and
0.25mg/L respectively. These strains had a G95D mutation alone. Other strains had
two-fold mutations, a G95D mutation in L22 and a G71R change in L4, as
previously mentioned. The second double mutations were an A93E mutation in L22
and C2611A mutations in 3 of the 4 23S rRNA genes, which resulted in
erythromycin resistance. A P99Q change in L22 failed to render the cells macrolide
resistant. A triple mutation of A93E, P91S and G83E also failed to produce
erythromycin resistant strains. When the L22 genes conferring the G95E, A93E and
the triplet mutations were each transformed into the macrolide sensitive CP 1000
none of the resulting transformants were macrolide resistant. Although some of the
L22 mutations did not confer erythromycin resistance they did cause an increase in
erythromycin MIC of either 8-fold or 16-fold (Canu et al., 2002).
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Three strains selected on telithromycin were identified recently with 2 types ofL22
mutations; one strain had a G95D mutation and the others an A97D change. These
strains were not telithromycin resistant but the mutation did cause the telithromycin
MIC to increase 32-fold for the G95D mutant and 8- or 16-fold for the A97D
mutants (Sutcliffe et al., 2000).
C terminus
Figure 8. An a-carbon trace of the L22 riboprotein of Thermus thermophilics from
Unge et al., 1998).
The L22 protein crystal structure of Thermus thermophilus has been deduced and
published by Unge et al (1998) as shown in figure 8. The tip of the L22 is mainly
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positively charged. This most likely interacts with the negatively charged RNA. The
amino acid residues in T. thermophilus contributing to this positive charge are three
arginines at positions 88, 90 and 92 (Unge et al., 1998). By sequence comparison in
S. pneumoniae the amino acids at corresponding positions are an arginine at amino
acid 88, a lysine at 90 and a serine at 92. Although serine is not charged, arginine and
lysine are both positively-charged and would, therefore, also interact with the RNA.
The area between amino acids 83 and 99 has been so far the main region of mutation.
It is interesting to note that all the mutations described to date, except one, resulted in
a charge change from an uncharged amino acid to a negatively-charged amino acid.
How important this charge change is, remains to be seen. The amino acid mutations
also conferred conformational changes on the structure of the L22 protein, which
could in turn perturb the assembly of the 50S ribosomal subunit due to mutations
affecting the RNA-protein recognition.
There have only been a small number of reports regarding alterations in the L22
riboprotein responsible for macrolide resistance in S. pneumoniae. However, the
importance of these mutations is not only to determine resistance mechanisms but
also to elucidate the ways in which antimicrobial agents interact with bacteria in
order to devise new and more effective antimicrobial agents to overcome these
resistant bacteria.
With respect to the identification of ribosomal mutations and association of specific
nucleotide changes or amino acid alterations in the ribosomal proteins, the findings
in S. pneumoniae are at a very early stage. The first mutation in the 23 S rRNA genes
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associated with increases in macrolide MIC and the L4 protein were published in
August of 2000 (Tait-Kamradt et al., 2000b) and mutations in L22 were first
published in September of 2000 (Sutcliffe et al., 2000). Therefore, although there
have only been few strains isolated with ribosomal mutations responsible for
macrolide resistance this has only been recently investigated over the past two years.
The topic ofmacrolide resistance in S. pneumoniae has recently been reviewed
(Leclercq & Courvalin, 2002).
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1.5 Factors contributing to resistance development
The problem of antibiotic resistance overcomes the boundaries of countries and has
managed to infiltrate every environment in which people live. This widespread
dissemination is due not only to the practices and advances ofmedicine but has been
influenced also by social, economic and industrial changes brought about over the
past century. The bacteria involved have managed to adapt and evolve to overcome
the antibiotics but we too have helped in their adaptation. Although the problem of
antibiotic resistance has been realised since their development and use, the origin and
evolution ofantibiotic resistance and its determinants has not received much
attention.
1.5.1 Origin and development
The development of antibiotic resistance is one of the best current examples of
evolution. The most popular theory on the development of antibiotic resistance to
date has been that antibiotic resistant bacteria arose by their selection following the
use of large amounts of antibiotic. This is one theory but others do also exist, which
also explain where resistant bacteria have come from.
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i. Selective compartments
Generally, it has been assumed that resistant bacteria emerge due to high-level
concentrations ofantibiotics, which inhibit sensitive bacteria and allow resistant
bacteria, not inhibited by the antimicrobial agent, to emerge and develop. Another
theory suggests that selective compartments ofvarying concentrations of
antimicrobial agent may select resistant bacteria over time (Bacquero & Blazquez,
1997; Bacquero & Negri, 1997). In classical Darwinism, the accumulation of
successive minor changes by natural selection may lead to improved fitness. The
transition ofhousekeeping genes in bacteria to high-level resistance genes probably
follows this Darwinism logic. This would require successive generations of selection.
Antimicrobial agents used in the human body reach a high diversity of concentration
gradients in different compartments of the body. These gradients are created by the
pharmacokinetics of the drugs. The variant bacteria can be selected in each
compartment only within a narrow range of drug concentrations, but the range may
vary depending on the populations present. If the bacterial population is serially
selected then the number of variations increase such that the bacteria survive even
high-level resistance. These genetic advantages may then also be transferred to other
bacteria if they are incorporated onto mobile elements.
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ii. Selective pressures
The main source of selective pressure for antibiotic resistance is generally thought to
be antimicrobial agents. This is certainly true for antibiotic producing bacteria but
antibiotics are not necessarily required to select for antibiotic resistant bacteria in
vivo or in the environment.
A variety of compounds may be effluxed out of the bacterial cell. Such compounds
including heavy metals, biocides, organic solvents and detergents are capable of
selecting bacteria with increased expression ofmulti-drug resistance determinants.
Mobile elements may also contain a variety of selective markers including antibiotic
resistance genes (Alonso et al., 2001). Heavy metal resistance genes and antibiotic
resistance genes are often encountered together in environmental bacteria. A
macrolide resistance determinant, phosphotransferase mphBM, is flanked by
cadmium resistance efflux pump gene cadA in Stenotrophomonas maltophilia
(Alonso et al., 2000). Selection of these resistant bacteria may have occurred as a
result ofheavy metal antibiotic selective pressure in the environment, prior to human
infection by these bacteria.
Furthermore, human activities also cause dramatic changes in the environmental
bacterial populations. Modern farming practices require the use ofprobiotics and
antibiotics. Links have been made between the use of avoparcin antibiotic as a
growth promoter and vancomycin-resistant enterococci in the human population
(Van Den Boggard & Stobberingh, 2000). The ban of avoparcin in animal feeding
52
has curbed the development of resistance in European Union countries (Bager et al.,
2000). However, antibiotic use alone is not the only link to human resistance
development as the type ofantibiotic used is also important. If the antibiotic gets
broken down into harmless compounds on contact with the environment then it does
not have the opportunity to select resistant bacteria. However, environmentally stable
drugs such as the quinolones do pose a threat to humans and their bacteria.
Environmental bacteria may be readily exposed to these antimicrobial agents and so
select for resistant bacteria (Grave et al., 1996).
Finally, multidrug efflux systems may also be regulated by stress conditions such as
osmotic or oxidative shock, the presence of bile salts or medium-chain fatty acids or
iron starvation as with the MexAB-Opr-D multidrug efflux system of Pseudomonas
species (Ma et al., 1995). High-level antibiotic resistance may develop in these
bacteria when introduced into an environment of low iron, or other factor, as the
population evolves to optimise its pumps for multipurpose functions.
iii. Medical pressure
The most prevalent theory on the emergence or reason for antibiotic resistance is that
resistance in pathogenic bacteria has developed due to the use and abuse of
antimicrobial agents. Macrolide consumption and macrolide resistance vary for
different countries, as does the variety ofmacrolides available. Using the data
produced from the Alexander Project (1992-1996), it can be seen that countries with
the highest consumption ofmacrolides have the highest percentage ofmacrolide
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resistance in S. pneumoniae (Bacquero, 1999). Conversely, in Finland a reduction in
macrolide consumption from 2.40 to 1.38 defined daily doses per 1000 population in
1 year was followed by a decrease in resistance in S. pyogenes from 17% in 1992 to
9% in 1996 (Seppala et al., 1997). The link between macrolide consumption and
resistance does depend on the type ofmacrolide prescribed. Macrolides with shorter
half-lives appeared to have no correlation with the increased resistance levels,
whereas a high correlation between resistance and long-acting macrolides e.g.
clarithromycin prescribing, was noted by Bacquero (1999). Despite this information
there has been a tendency to switch from erythromycin to clarithromycin prescribing
in recent years. Therefore, careful consideration of the individual drug, as well as the
class of drug must be taken to prevent or alleviate the numbers of resistant
pathogens.
1.5.2 Emergence ofResistance
The emergence of resistance in bacteria as a whole can be examined from two points
of view, that of the human resistance influences and the bacterial changes that have
occurred to overcome antibiotics.
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i. Human
The main factor of human influence is the use and misuse of antimicrobial agents
which has already been discussed in relation to the prescribing practices and
resistance. In this section the focus will be on the social and economic influences
affecting antibiotic resistance. In 1992 the Institute ofMedicine USA report (Institute
ofMedicine, 1992) on factors influencing emerging infectious disease identified 5
main factors, which contributed to the emergence of infectious disease these include
changes in human demographics, changes in technology and industry, economic
development and land use, international travel and commerce and a breakdown of
public health. These influences are also contributing, to varying effects, to the
emergence of antimicrobial resistance either by affecting antimicrobial use and/or the
transmission of infectious diseases.
a. Changes in human demographics
Changes in demographics include an increasing percentage ofpeople susceptible to
disease requiring antibiotic treatment in the population in the developed world, an
increase in the use of day care facilities and changing patterns of immigration. The
increasing numbers of susceptible people include those over the age of 65, those with
compromised immune systems due to HIV infection (Piot et al., 2001) or diabetes
and those who are receiving immunosuppressive drugs e.g. cancer chemotherapy
(American Cancer Society, 2002).
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Another demographic change has been the increased use of day care centres. This
has increased due to the increase in one-parent families or families in which both
parents work outside the home. The day care centre provides ample opportunity for
transmission of bacteria e.g. S. pneumoniae, and resistant bacteria to and from young,
susceptible children treated with multiple and/or broad-spectrum antimicrobial
agents, which cause increased risk of carriage and infection with antibiotic resistant
S. pneumoniae (Bogaert et al., 2001).
Immigration patterns have in the past influenced the emergence of resistance in the
USA. Between 1986 and 1995 a large increase occurred in immigration from
countries with high-level antibiotic resistance problems e.g. over 350,000 people
immigrated from Southeast Asia and India bringing with them not only tuberculosis
(TB), but also multiple drug resistant TB (Centers for Disease Control and
Prevention, 1996). The influence of the increase in numbers ofpeople arriving into
Western Europe from areas such as Eastern Europe with high-level antibiotic
resistant S. pneumoniae has not yet been quantified but this could potentially increase
the levels of antibiotic resistant S. pneumoniae in Western European countries.
b. Changes in technology
There has been increased development of medical technology and products over
recent years. The medical technology and products currently available have helped
the emergence of antibiotic resistant microbes. These advances have prolonged the
lives ofpeople and their hospitalisation after diseases, organ failure or severe
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injuries, which require antibiotic treatment, thus increasing antibiotic use and
infection with antibiotic resistant microorganisms. Such medical advances include
the success of cancer treatment, organ transplant and survival of low-birth weight
babies.
Intensive food production in the latter halfof the last century and this century, relies
heavily on growth promoters and antimicrobial use. Similar to day care centres,
many animals, especially young animals, are crowded together. This results in the
transmission of bacteria requiring antibiotic treatment and thus antibiotic resistant
bacteria emerging.
c. Economic development and land use
Worldwide population growth is leading to serious environmental changes and
pollution. The increase in population density not only increases the transmission rate
of drug resistant bacteria but also puts pressure on the systems such as water and
sanitation. The emergence of these problems may not currently affect resistance but
they could lead to an increase in the variety of bacterial infections, both in the
number of infections and the species of bacteria associated with the infections, which
would in turn require yet more antimicrobial agent use.
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d. International travel and commerce
The ease with which people and products travel around the world also means
antibiotic resistant bacteria may too travel with such ease. An example of this is the
clonal spread of antibiotic resistant bacteria such as penicillin resistant, serotype 23 F
S. pneumoniae, travelling from Spain to the rest ofEurope and the world.
e. Breakdown ofpublic fear
Since the introduction and use of antibiotics people have become complacent about
infectious disease. Changes in morbidity and mortality and faith in drugs has lead to
over-confidence towards control of infectious diseases. Unfortunately, the reign of
antibiotics has started to decline due to resistance. There have been few drugs
developed recently with new mechanisms of action. On the most part the available
"new" antimicrobial agents are derivatives of older antimicrobial agents to which
resistance has already developed. The public must be made aware of the dangers of
overuse, misuse and complacency towards antimicrobial agents, so that we can
preserve their use until new methods of combating bacteria and antibiotic resistant
bacteria can be developed.
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ii. Bacteria
In recent years the molecular mechanisms used by bacteria to become resistant to
antibiotics have begun to be understood. The rapid spread of resistance mediated by
plasmids, phages, transposons and other mobile genetic elements have been the main
focus of attention, but resistance can also develop through changes in the
chromosome. As each antimicrobial agent was introduced into clinical use a gene
expressing resistance to it ultimately emerged. Emergence in this context means that
the resistance gene, wherever its origin, had spread enough to get itself into a strain
of a species that was isolated and noticed as resistant by a clinical laboratory
(O' Brien, 2002).
If a resistance gene has developed on the chromosome of a strain, then the spread of
the gene and resistance depends mainly on that strain and thus is restricted by the
bacterial fitness and environment of the strain. The mobile elements, however, can
move the resistance gene to another strain or species (Salyers & AmabileCuevas,
1997; Reichmann et al., 1997). This gene may not have been accessible previously
by this new host. Integrons and transposons may move the gene into a new plasmid
and then be transferred to yet more bacteria. This process extends the range of
resistance and enables resistance to penetrate more environments and bacteria.
Ultimately, antibiotic pressure may select not only antibiotic resistance genes, but
also the mechanisms required to transfer them to other bacteria.
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A resistant strain in one host selected due to antibiotic therapy is more likely to be
among the strains transferred to a second host. Similar selection in the next host
would increase its chances of survival and transfer again. This theory suggests that
resistant strains travel from host to host that are treated with antimicrobial agents and
so selected out. This trend would continue until the strain meets another resistant
strain with which it competes or a different selective environment. Then, the strain
with additional mechanisms of resistance would be selected when the host was
treated with another drug. As the strain went through various hosts it added to its
armoury of resistance elements to ensure the fittest possible. Thus, if the strain had
many plasmids conferring different advantages, such as antibiotic resistance and
plasmid stability, on the strain it would be continually selected. Therefore, the
resistance vector emerging from the hosts would be more competitive and persistent
than either the original vector or the vectors it passed along the way. The most
resistant and competitive strain would emerge.
Clonal spread of resistance works on the same theory that if a chromosomal gene
conferred an advantage, e.g. resistance, to the strain then it would be selected out
from the susceptible population. This gene would then be transferred vertically down
the generations as the cells divide, which would in turn give these strains an
advantage over susceptible strains. The result would be only the resistant strains
surviving and propagating. The swiftness with which bacterial antibiotic resistance
has arisen and spread reflects the diversity of the bacterial gene pools, the mobility of
genes across species and genus boundaries and the short generation times and large
population sizes ofbacteria (O' Brien, 2002).
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1.5.3 Prevention of further spread and management of
resistance
The greatest fear about antibiotic resistance is that it will herald the end of the
antibiotic era and our current limit on infectious disease in the developed world.
Solutions are needed to overcome these resistant strains. The resistance problem is
not limited by country but is a worldwide threat. Therefore, the solutions must be
global rather than local.
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1.6 Aims
• Evaluate the in vitro activity of telithromycin against common respiratory tract
pathogens in comparison to a wide range of antimicrobial agents.
• Develop telithromycin resistant Streptococcus pneumoniae mutants in vitro from
parents with either an ermB or a mefE gene and a macrolide sensitive strain.
• Assess the mechanisms ofmacrolide resistance in S. pneumoniae for their
potential to develop telithromycin resistance by:
1. Investigating the influence of the ermB and mefE genes and their control
regions on the development of telithromycin resistance in S. pneumoniae.
2. Screening the 23S rRNA macrolide and ketolide binding regions of the
ribosome for mutations that could explain telithromycin resistance.
3. Exploring the L4 and L22 riboproteins for alterations associated with





The bacterial strains used in this study are shown in table 1. The clinical isolates of
S. pneumoniae, M. catarrhalis and H. influenzae were collected from various centres
throughout the United Kingdom, except for the macrolide resistant S. pneumoniae
strains, which were donated by researchers in Belguim, Italy, Canada and USA. The
Chlamydophila pneumoniae strains TW 183, ATCC 2023 and AR 39 were obtained
from the American Type Culture Collection, USA and strain D 1 was donated from
Ninewells hospital, Dundee.
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Table 1. Isolate origin and culture collection.














Penicillin resistant strains from
















































The letters in brackets refer to the different culture collections.
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2.2 Storage of cultures
The S. pneumoniae strains were stored in Todd Hewitt broth (Oxoid, UK) with 10%
glycerol and sterile distilled water mix (50% v/v) at -70°C. The M. catarrhalis and
H. influenzae were stored in Brain Heart Infusion broth (Oxoid, UK) also with 10%
glycerol and sterile distilled water mix (50% v/v) at -70°C.
2,3 Growth media
The growth media for S. pneumoniae, M. catarrhalis and H. influenzae were
obtained from Oxoid and prepared according to the manufacturer's instructions. The
growth media of Chlamydophila pneumoniae was purchased from Sigma-Aldrich,
UK. The Hep-2 cells and HL cells were kindly provided by the City hospital,
Edinburgh.
2.3.1 Blood and Chocolate Agar
Streptococcus pneumoniae and M. catarrhalis were subcultured on blood agar plates.
These consisted of 95% Columbia agar base (Oxoid, UK) and 5% defibrinated horse
blood (E & O laboratories, Scotland). Haemophilus influenzae strains were
subcultured on chocolate blood agar, which also consisted of 95% Columbia agar
base and 5% defibrinated horse blood but was heated at 55°C until the agar turned
from blood red to chocolate brown in colour.
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2.4 Chemical reagents




Antimicrobial Agent Susceptibility Testing
3.1 Introduction
In order to treat a bacterial infection with the appropriate antimicrobial agent we first
need to know the efficacy of the drugs available and also the ability of new drugs to
inhibit bacterial growth. The most common method of testing the antimicrobial effect
of these drugs in vitro is the minimum inhibitory concentration (MIC) test. This
information may then be used to decide the course of treatment or to determine if
resistance to the drug is emerging. Several methods are used to test the MIC such as
Epsilon test, disk diffusion test, microtitre plates and agar doubling dilution test. The
two major sets of guidelines for each method are the NCCLS and the BSAC
guidelines (Phillips et al., 1991). In this study the BSAC guidelines and the agar
doubling dilution method were used. The agar doubling dilution method consists of
agar plates containing doubling dilutions of antimicrobial agent, which are inoculated
with a fixed concentration of bacteria.
The environmental factors involved in MIC testing such as medium or incubation
conditions can affect the in vitro results (Biedenbach et al., 1999; Johnson et al.,
1999). Susceptibility testing of lower respiratory tract pathogens is often carried out
in a C02-rich environment. The MIC ofmacro lides is affected by the pH of the
medium (Goldstein et al., 1986; Spangler et al., 1994). Thus, when the MIC plates
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are incubated in C02 the pH falls and so the macrolide MICs are elevated giving a
false reading, perhaps false resistance results (Fernandes et al., 1986). As
telithromycin is a macrolide derivative the effect of incubation in 5% C02 on
telithromycin MIC was investigated.
The purpose of this study was to evaluate the in vitro activity of telithromycin in
comparison to a variety of antimicrobial agents against Streptococcus pneumoniae,
Moraxella catarrhalis and Haemophilus influenzae.
3.2 Materials and Methods
3.2.1 Bacterial strains
One hundred strains each ofStreptococcus pneumoniae, Moraxella catarrhalis and
Haemophilus influenzae were investigated. The Streptococcus pneumoniae were
isolated from Leeds and Edinburgh, the Moraxella catarrhalis from Edinburgh,
Leeds and Wales and the Haemophilus influenzae from Edinburgh and Glasgow. The
control strains consisted ofStreptococcus pneumoniae NCTC 13593, Staphylococcus
aureus NCTC 6571, Haemophilus influenzae NCTC 11931 and a laboratory
reference strain ofMoraxella catarrhalis.
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3.2.2 Antimicrobial Agents
Table 2. Antimicrobial agents
Antimicrobial
agent
Source % Potency Diluent
Telithromycin Aventis Pharma
Ltd









Azithromycin Pfizer Ltd 94.4 Ethanol + SDW (50:50)
Clindamycin Sigma-Aldrich 92 SDW

















Faropenem Bayer AG 81 SDW
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The antimicrobial agents were stored and prepared according to the manufacturer's
guidelines. Amoxiclav consisted of fixed concentrations of 2mg/L of clavulanic acid
per plate and doubling dilutions ofamoxycillin.
3.2.3 Minimum Inhibitory Concentrations
The minimum inhibitory concentration was defined as the lowest concentration of
antimicrobial agent required to inhibit visible growth of bacteria in vitro. The MICs
were performed on Columbia agar base supplemented with 5% defibrinated horse
blood for Streptococcus pneumoniae and Moraxella catarrhalis and on chocolate
Columbia agar plates for Haemophilus influenzae according to the British Society for
Antimicrobial Chemotherapy guidelines for susceptibility testing (Phillips et al.,
1991). The MICs were determined by the standard agar doubling dilution method.
The MIC plates containing telithromycin were incubated both in air and 5% CO2,
both at 37°C. All other plates were incubated in air at 37°C.
The S. pneumoniae strains were grown overnight in 5% CO2 on blood agar plates.
They were then inoculated into 0.85% sterile saline solutions. The turbidity of
S. pneumoniae was adjusted to 0.5 McFarland standard, which is equivalent to 107
cfu/rnL. This was then reduced to a final concentration of 105 cfu per spot on the
MIC plates. The Moraxella catarrhalis and Haemophilus influenzae were inoculated
into Brain Heart Infusion broth and incubated in 5% CO2 overnight. The cultures of
both were diluted in 0.85% sterile saline and inoculated at a final concentration of
104 cfu per spot on the antibiotic plates. The plates were inoculated using a
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multipoint inoculator (Denley Tech, Billinghurst, UK). A control plate containing no
antimicrobial agent was included for each set ofMIC tests. The inoculated petri
plates were incubated for 16 to 18 hours at 37°C in air or 5% CO2. The MIC tests
were repeated at least once for each strain.
The antimicrobial agent breakpoints were according to the BSAC guidelines
(MacGowan & Wise, 2001) except for telithromycin for which the NCCLS
breakpoint (NCCLS, 2000) was used. Resistance to the antimicrobial agents was
assigned at the following MIC values: telithromycin > 4mg/L,




3.3,1 Effect of CO? Incubation
When the MIC plates containing telithromycin were incubated in 5% CO2 there was
an increase in MIC regardless ofwhether the bacteria was S. pneumoniae,
M. catarrhalis or H. influenzae as shown in tables 3, 4 and 5. The range and MIC90
for S. pneumoniae increased by 1 doubling dilution and the MIC50 increased by 2
doubling dilutions. The telithromycin breakpoint for S. pneumoniae is lmg/L. The
S. pneumoniae range endpoint increased from lmg/L to 2mg/L when incubated in
CO2, table 3. With a telithromycin MIC of 2mg/L a S. pneumoniae strain is no longer
considered sensitive to telithromycin. Therefore, some strains tested changed from
telithromycin sensitive to non-sensitive when incubated in CO2.
With regard to M. catarrhalis and H. influenzae the MIC50 and MIC90 both increased
by 1 doubling dilution when incubated in CO2 indicated in tables 4 and 5. The
proposed telithromycin breakpoint for H. influenzae was 2mg/L. With the CO2 effect
the number ofH. influenzae strains that were not sensitive to telithromycin increased
from 18% to 63% so that the MIC90 value effectively changed to the MIC50 value.




The MIC results ofS. pneumoniae are shown in table 3 and figure 9. Telithromycin
had the second lowest MIC90 of all the antimicrobial agents tested against
S. pneumoniae. It was merely 1 doubling dilution higher than that of the lowest
MIC90, which belonged to gemifloxacin. The closest comparators to telithromycin,
by mode of action, are the macrolides. The telithromycin MIC90 was 5 doubling
dilutions lower than the lowest macrolide MIC90. The lincosamides were represented
by clindamycin, which are also protein synthesis inhibitors. While the MICgoof
clindamycin was the same as telithromycin the upper limit of the range was
substantially higher for clindamycin at 32mg/L in comparison to lmg/L for
telithromycin. The fluoroquinolones had four representatives: levofloxacin,
ciprofloxacin, moxifloxacin and gemifloxacin. Gemifloxacin and moxifloxacin both
had excellent activity against S. pneumoniae with their highest MICs at 0.12mg/L
and 0.5mg/L respectively. Levofloxacin and ciprofloxacin did not perform as well
and had low activity relative to telithromycin and the newer fluoroquinolones.
Linezolid belongs to a new family ofantimicrobial agents called the oxazolidinones.
However, it did not perform as well as the other antimicrobial agents. Amoxycillin
and amoxiclav both had MIC90S lower than those of the macrolides but they were
still higher than that of telithromycin by two doubling dilutions. Faropenem, a novel
carbapenem, also had good activity against S. pneumoniae.
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Telithromycin CO2 0.016-2 0.12 0.25
Telithromycin air 0.008-1 0.032 0.12
Erythromycin 0.008-128 0.06 8
Clarithromycin 0.016-32 0.06 4
Azithromycin 0.008-16 0.12 16
Clindamycin 0.008-32 0.06 0.12
Moxifloxacin 0.032-0.5 0.12 0.25
Levofloxacin 0.12-2 1 2
Ciprofloxacin 0.032-8 1 4
Gemifloxacin 0.008-0.12 0.032 0.06
Linezolid 0.12-4 1 2
Amoxycillin 0.004-2 0.032 0.5
Amoxiclav 0.004-2 0.016 0.5
Faropenem 0.002-1 0.008 0.12
Figure 9. Streptococcus pneumoniae MICs. Minimum inhibitory concentration
(mg/L) vs. antimicrobial agent.
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3.3.3 Moraxella catarrhalis
The MIC results ofM. catarrhalis are shown in table 4 and figure 10. The
fluoroquinolones had the greatest activity of the antimicrobial agents tested against
M. catarrhalis. Their MIC90S ranged from 0.016mg/L to 0.06mg/L. In comparison to
this the MIC90S of the macrolides were 0.12mg/L and 0.25mg/L. There was little
difference between the performance of telithromyin and the macro lides.
Clindamycin, linezolid and amoxycillin all had low activity against M. catarrhalis in
vitro with MIC90S of4mg/L. However, when clavulanic acid was added to
amoxycillin the potency was dramatically increased, from an MIC90 of4mg/L to an
MIC90 of 0.12mg/L. The faropenem MIC90 of 1mg/L was higher than that of
telithromycin, the macro lides and the quinolones by at least two doubling dilutions.
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Table 4. Moraxella catarrhalis MIC results.
Antimicrobial Agents Range MIC50 MIC90
(mg/L) (mg/L) (mg/L)
Telithromycin CO2 0.032-1 0.12 0.25
Telithromycin air 0.032-0.5 0.06 0.12
Erythromycin 0.06-1 0.25 0.25
Clarithromycin 0.032-0.25 0.12 0.12
Azithromycin 0.032-0.25 0.06 0.12
Clindamycin 1-8 2 4
Moxifloxacin 0.016-0.12 0.06 0.06
Levofloxacin 0.016-0.12 0.032 0.06
Ciprofloxacin 0.016-0.06 0.032 0.06
Gemifloxacin 0.002-0.016 0.008 0.016
Linezolid 2-8 4 4
Amoxycillin 0.016-8 1 4
Amoxiclav 0.002-0.25 0.032 0.12
Faropenem 0.032-1 0.25 1




The MIC results of II. influenzae are shown in table 5 and figure 11. Telithromycin
had relatively low activity against H. influenzae with an MIC90 of2mg/L. It had
lower MIC50 and MIC90 values than erythromycin and clarithromycin by at least two
*
dilutions. For H. influenzae clindamycin and linezolid had the same MIC90S as
clarithromycin of 16mg/L. Once again the fluoroquinolones performed with the
highest activity and low MIC90S of0.004mg/L to 0.016mg/L. Amoxycillin had
improved activity when combined with clavulanic acid to form amoxiclav. The
MIC90 decreased from 4mg/L to lmg/L. Faropenem had the same activity in vitro as
amoxiclav against H. influenzae.
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Table 5. Haemophilus influenzae MIC results.
Antimicrobial Agents Range MIC50 MIC90
(mg/L) (mg/L) (mg/L)
Telithromycin CO2 0.008-8 2 4
Telithromycin air 0.032-4 1 2
Erythromycin 0.12-16 4 8
Clarithromycin 0.06-16 4 16
Azithromycin 0.06-8 1 2
Clindamycin 0.032-32 4 16
Moxifloxacin 0.004-0.12 0.016 0.016
Levofloxacin 0.008-0.5 0.016 0.016
Ciprofloxacin 0.002-0.5 0.008 0.016
Gemifloxacin 0.002-0.12 0.002 0.004
Linezolid 0.5-64 8 16
Amoxycillin 0.032-32 0.5 4
Amoxiclav 0.016-8 0.5 1
Faropenem 0.06-4 0.5 1


















































The MICs of the individual isolates ofStreptococcuspneumoniae, Moraxella
catarrhalis and Haemophilus influenzae are shown in appendix 1.
3.3.5 Resistance levels
Table 6. Resistance levels of telithromycin, macrolides and clindamycin.
Antimicrobial Streptococcus Moraxella Haemophilus
agent pneumoniae (%) catarrhalis (%) influenzae (%)
Telithromycin 0 0 0
Erythromycin 20 1 8
Clarithromycin 19 0 0
Azithromycin 14 0 1
Clindamycin 4 100 97
Telithromycin had the lowest resistance levels of the macro lides and lincosamide,
with no resistance in S. pneumoniae, M. catarrhalis or H. influenzae as shown in
table 6. In comparison, about one fifth of the S. pneumoniae population were
erythromycin and clarithromycin resistant. With regard to S. pneumoniae 4% were
resistant to clindamycin.
In M catarrhalis the entire population were found to be clindamycin resistant while
one strain was also erythromycin resistant. No resistance to telithromycin,
clarithromycin or azithromycin occurred.
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Clindamycin resistance was also a major problem in H. influenzae with 97% of the
strains resistant. Erythromycin resistance was at 8% for H. influenzae, whereas
azithromycin and clarithromycin resistance levels were 1% and 0% respectively.
3.4 Discussion
Respiratory tract infections are a major cause ofmorbidity and mortality in the
community and hospitals. Streptococcus pneumoniae, Moraxella catarrhalis and
Haemophilus influenzae are common causes of lower respiratory tract infections and
upper respiratory tract infections. Worldwide, the annual incidence ofcommunity
acquired pneumoniae (CAP) is estimated to be 1.1-4.0 per 1000 population. In the
UK CAP accounts for 5-12% of cases ofLRTIs among adults approximately 20-42%
ofwhich require hospitalisation (Finch, 2001). Macrolide resistance is currently an
increasing problem in Streptococcus pneumoniae throughout the world. France and
Hong Kong have extremely high levels of resistance in community acquired
S. pneumoniae. (Felmingham & Griineberg, 2000)
The need for standard, reproducible methods of testing the efficacy ofantimicrobial
agents is widely accepted as being important. This includes the incubation conditions
of the MIC plates after inoculation. This study has shown that the MIC of
telithromycin increased when incubated in 5% C02 in comparison to air incubation.
This increase could have a dramatic effect on the apparent emergence of resistance to
telithromycin. From this study alone S. pneumoniae and H. influenzae strains
changed from telithromycin sensitive to non-sensitive merely due to the incubation
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conditions. Standardisation of conditions for MIC testing and incubation conditions
are required in order to assess the true percentage ofbacteria that are resistant to
antimicrobial agents. There is also a need to take the effect ofCO2 into account when
defining breakpoints ofantimicrobial agents to ensure that the breakpoint value
allows for the increase in MIC when incubated in CO2.
In this and previous studies macrolide resistance has been associated mainly with
S. pneumoniae rather than M. catarrhalis or H. influenzae (Felmingham &
Griineberg, 2000). In the Alexander project survey erythromycin resistance in
S. pneumoniae, in the UK was at 13.6% in 1996 and 7.2% in 1997. The results in this
chapter suggests that erythromycin resistance has increased to 20% for the
S. pneumoniae tested from two British cities. The percentage ofH. influenzae
resistant to erythromycin is also worrying at 11%; however, almost all are
clarithromycin and azithromycin sensitive.
Telithromycin has previously been shown to have activity against macrolide resistant
bacteria. This finding has been borne out in the results. Telithromycin had
consistently lower MICs than erythromycin against all the bacteria tested. No
resistance to telithromycin for either S. pneumoniae, M. catarrhalis or H. influenzae
was found. The high overall activity of telithromycin against the three respiratory
pathogens and no resistance indicates that telithromycin has good potential as a





Chlamydophila pneumoniae (formerly Chlamydia pneumoniae) is an intracellular
pathogen responsible for respiratory tract infection. A recent British survey of the
microbial aetiology of community-acquired pneumonia (CAP) indicated that
C. pneumonia is responsible for 13% ofCAP and is the second highest bacterial
cause ofCAP (Lim et al., 2001). It has been associated with bronchitis, pharyngitis,
sinusitis, myocarditis, endocarditis and coronary artery disease (Grayston et al.,
1990).
In order to treat C. pneumoniae infections it is first essential to know the efficacy of
the available antimicrobial agents against this pathogen. Minimum inhibitory
concentration (MIC) tests are used to investigate the in vitro capabilities of
antimicrobial agents on bacteria. Therefore, MIC testing ofC. pneumoniae needs to
be carried out before an antimicrobial agent may be used to treat the infection.
Culturing of C. pneumoniae must occur before MIC tests can be performed.
Chlamydophila pneumoniae is known to be very difficult to culture and is far more
difficult than other chlamydial species (Grayston et al., 1990). Many methods of
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culturing C. pneumoniae have been proposed with differing cell lines, centrifiigation
conditions and incubation times.
There is no standard method for culturing C. pneumoniae nor for testing the MIC of
antimicrobial agents against it. However, a meeting was recently convened by the
Centers for Disease Control and Prevention (Atlanta, USA) and the Laboratory
Centre for Disease Control (Ottawa, Canada) to review current diagnostic tests and
procedures used with C. pneumoniae and provide recommendations for standardised
approaches (Dowell et ah, 2001). The recommendations for the culture conditions
that should be used however, suggested two different cell lines and centrifugation
conditions varying from 900g to 3000g. There is no agreement on optimal culture
conditions between different laboratories and even within the same laboratory. For
C. pneumoniae to be a viable organism in the sense that it may be tested with
regularity in vitro, a reliable method of culturing is required.
The initial aim of this investigation was to culture C. pneumoniae and test the
efficacy of telithromycin in comparison to macrolides against C. pneumoniae. After
some difficulty was had in culturing C. pneumoniae this aim changed to firstly
culturing C. pneumoniae using previously published methods.
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4.2 Materials and Methods
4.2.1 Bacterial strains
The three strains TW 183, ATCC 2023 and AR 39 were from the American Type
Culture Collection, the fourth strain, D 1, was received from Ninewells hospital,
Dundee. The D 1 strain had been successfully cultured using an in-house culture
method in Dundee. All strains were stored at -70°C.
4.2.2 Cell lines
Hep-2 cells (City Hospital, Edinburgh) were cultured in Eagles Minimum Essential
Medium (EMEM) supplemented with sodium bicarbonate, 5% denatured foetal
bovine serum, 2mM L-Glutamine, 10% tryptose phosphate broth, 1%
amphotericin B, 1% streptomycin and 1% vancomycin.
HL cells (sourced from the Washington Research Foundation) were grown in
Dulbeccos Modified Eagles Medium with 2% of 1M HEPES buffer, 1.5% of sodium
bicarbonate, 10% denatured foetal bovine serum, 1% L-Glutamine, 1% vancomycin
and 1% gentamicin.
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Vancomycin was obtained from Edinburgh Royal Infirmary hospital pharmacy and
Fisher Scientific, UK, supplied cycloheximide. All the other reagents used in these
experiments were obtained from Sigma-Aldrich Co., UK.
4.2,3 Harvesting and Passaging Cells
A monolayer of Hep-2 cells and a monolayer ofHL cells were grown in 75cm2 tissue
culture flasks and passaged weekly using aseptic techniques. The growth medium
was poured off and the cell layer washed 3-4 times with approximately 20mL of
sterile phosphate buffered solution (PBS). One millilitre of versene/trypsin
(0.5%/l%) was added and incubated at 37°C for one minute. The versene/trypsin
mixture was poured off and the cells left for 5-10 minutes. The cell sheet was
examined periodically and when the sheet started to detach from the flask wall 1 OmL
of growth medium was pipetted into the flask. The flask wall on which the cells were
growing was rinsed and the cells pipetted up and down several times with minimal
frothing to break up any clumps of cells. The cells were counted using an Improved
Neubauer Counting Chamber and diluted in growth medium as appropriate for
further use. If the cells were to be used to seed 75cm2 flasks then 1.5 x 106cells/ml
were required but if shell vials were seeded 0.5 x 106cells/ml were added to each
shell vial. The cells were regularly passaged and incubated at 37°C.
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4.2.4 Chiamydophilapneumoniae culture in Hep-2 cells
Two different inoculation methods ofHep-2 cells with C. pneumoniae were
attempted. The first procedure was adapted from Sriram et al (1999) and the second
was adapted from Roblin et al (1992).
1. A monolayer ofHep-2 cells was grown up in shell vials for either 24 or 48 hours
prior to inoculation. The C. pneumoniae strains were diluted from 1 in 100 to
1 in 109 in EMEM growth medium. lOOpl of each dilution were added to 400pl
ofEMEM growth medium in the shell vial. These were centrifuged at 4°C and
1800g for 1 hour. The medium was decanted and replaced with 1 ml ofgrowth
medium containing 20% denatured foetal bovine serum, 4pg/ml cycloheximide
and 4mM L-Glutamine in each shell vial. These were incubated for 7 days at
37°C with further centrifiigation on days 4, 5 and 6.
2. The same cells and dilutions were used as method 1. The shell vials were
centrifuged at 37°C and 1700g for 1 hour and incubated at 37°C for 1 hour. The
medium was decanted and replaced with 2mls ofgrowth medium with 10%
denatured foetal bovine serum and 1 pg/ml cycloheximide for each shell vial.
They were incubated at 37°C for 72 hours.
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Negative controls consisted of a shell vial containing uninoculated cells and were
included in each run. All the negative controls were processed before processing
those thought to contain C. pneumoniae.
4.2.5 Chlamvdophila pneumoniae culture in HL cells
HL cells had previously been inoculated in Dundee with D 1 using this procedure. A
monolayer ofHL cells was grown up in shell vials for 24 or 48 hours prior to
inoculation. The growth medium was removed from the shell vials and the cells
rinsed with l-2mL of sterile PBS. Each shell vial was inoculated with 300pL of each
of the strains. The vials were then centrifiiged at 2400g at 35°C for 1 hour. The
medium was removed and replaced with HL medium containing 1.3 pg/mL
cycloheximide but without vancomycin and gentamicin. The vials were incubated at
37°C for seven days with additional centrifugations on days 3, 4 and 5. On day seven
the vials were sonicated in an ultra sonicating water bath. Three hundred microliters
of the sonicated medium was added to freshly prepared monolayers and the
procedure was repeated. All the negative controls were processed before processing
those thought to contain C. pneumoniae.
Shell vial coverslips from each passage of each method were tested for the presence
ofC. pneumoniae inclusions. The cultures were fixed and stained using direct and
indirect antibody tests. The direct antibody test utilised a genus-specific monoclonal
antibody to Chlamydia lipopolysaccharide antigen present in all known strains of
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Chlamydiae and a specific direct antibody test for C. pneumoniae. These tests were
DAKO Imagen™ tests. The test was carried out according to the manufacturer's
instructions. The indirect test utilised a mouse monoclonal anti-Chlamydia
pneumoniae antibody and a rabbit anti-mouse fluorescent isothiocyanate conjugated
(FITC) antibody. Both antibodies were diluted in PBS according to the
manufacturer's instructions. The indirect identification procedure was repeated but
rabbit serum was also added at the same time as the mouse monoclonal
anti-Chlamydia pneumoniae antibody to block the excess rabbit anti-mouse FITC
antibody. Inclusions when present should appear as apple-green circles within the
cell.
4.3 Results
The four C. pneumoniae strains were succesively passaged in varying growth
conditions, each time one parameter would be altered so as to optimise the culture
technique. Flowever, no inclusions were found in any of the shell vials tested. The
cells were washed a varying number of times and the growth medium and PBS were
filtered in order to eliminate bacterial contamination, these steps were carried out
each time the cells, growth medium and PBS were used. Each of the three different
methods were implimented using the four different strains and two different cell
lines. For each coverslip recovered two different staining procedures were used but
neither resulted in identification of a single C. pneumoniae inclusion. If the ATCC
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strains had been non-viable then the strain from Dundee should at least have
provided a positive result.
4.4 Discussion
The lack of inclusions suggests that either the C. pneumoniae were not viable or the
methods used were not easy to reproduce. As the D 1 strain had previously been
cultured this strain was viable and so this strain at least should have resulted in the
identification of inclusions. This lack of reproducibility is a common problem with
C. pneumoniae.
Development of new methods will not alter the problem ofC. pneumoniae culturing.
Standardisation of the existing methods so that they are reproducible not only in the
same laboratory but also in different laboratories is the only way that data,
particularly information about the antibiotic profile ofC. pneumoniae, may be
generated. Therefore, standard, reproducible methods, which are agreed upon by
more than one laboratory are needed not only for culturing but also for the
investigation ofantibiotic resistance in C. pneumoniae. A working party of
Chlamydia scientists is needed that will create culture guidelines and antimicrobial
agent testing guidelines with defined parameters similar those created by the BSAC





Acquisition and further spread ofantibiotic resistance determinants and selection of
resistant strains among virulent bacterial populations is the most pressing problem
for the treatment of infectious disease. There are different theories on the emergence
ofantibiotic resistant bacterial strains. Theory 1: the bacteria acquire resistance
genes, for instance by plasmid-mediated transfer, which allow the hosts to survive in
the presence of the antimicrobial agent. Theory 2: bacteria within the population
have a selective advantage, such as an efflux pump, which prevents the antimicrobial
agent taking effect and so are preferentially selected out from a population that
normally does not contain such mechanisms. In this case, the antibiotic does not
cause resistance but rather provides an environment that selects for certain strains.
Theory 3: the presence of an antimicrobial agent causes a chemical or metabolic
change in the bacteria, which leads to antibiotic resistance. How and by which
method bacteria overcome the effect ofantibiotics is still not fully elucidated.
Regardless of the mechanism used to achieve resistance, mutation studies are
efficient in vitro methods to select resistant strains so that further investigation of
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resistance can be performed. Mutation studies are therefore the first step required to
identify the changes that occur along the pathway from a sensitive strain to a
non-sensitive strain and finally a resistant strain.
5.2 Material and Methods
5.2.1 Bacterial strains
Twenty-nine erythromycin-resistant Streptococcus pneumoniae were collected from
the USA, Canada, Belgium and Italy. They were either macrolide, lincosamide and
streptogramin B (MLSb) resistant or resistant only to macrolides. The strains
02J1095, with an ermB gene, 02J1175, with a mefA gene and an MLSb sensitive
strain NCTC 13593 were used as the parents for the step-wise selection of
telithromycin resistant mutants.
5.2.2 Minimum Inhibitory Concentrations
The MIC of the macrolide resistant strains were tested according to the BSAC
guidelines but all plates were incubated in 5% C02 (Phillips et al., 1991). The
antimicrobial agent breakpoints were according to the BSAC guidelines (MacGowan
& Wise, 2001) except for telithromycin, for which the NCCLS breakpoint (NCCLS,
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2000) was used. Resistance to the antimicrobial agents was assigned at the following
MIC values: telithromycin > 4mg/L, erythromycin > lmg/L,
clarithromycin > lmg/L, azithromycin > 2mg/L and clindamycin > lmg/L.
5.2.3 Mutation Studies
Each of the three parent strains were inoculated into Todd Hewitt broth and
incubated in 5% C02 overnight. Varying dilutions of the cultures were spread on
Columbia agar plates supplemented with 5% defibrinated horse blood containing
telithromycin at concentrations equal to the MIC or 2 x MIC of the strain. Each
concentration was carried out in triplicate for the MIC, the 2 x MIC and the control
with no antibiotic. All plates were incubated in 5% C02 for 48 hours. The resulting
mutants were subcultured twice on plates with the appropriate telithromycin
concentration of either the MIC or 2 x MIC. The MICs of telithromycin against the
mutants were tested at this point according to the BSAC guidelines (Phillips et al.,
1991). Successive generations were derived in the same way as the first generation.
This process was repeated until high-level telithromycin resistance occurred or the
MICs of successive generations remained the same. The stability of a representative
ofeach generation was investigated by serially subculturing the mutants on




5.3.1 MICs ofMacrolide Resistant Strains
The MICs of the 29 macrolide resistant clinical isolates were tested. The results are
shown in table 7. As there were only 29 isolates the MIC50 and MIC90 values were
not calculated. The individual strain MICs are detailed in appendix 2.
Table 7. Macrolide resistant S. pneumoniae MIC results.
Telith Ery Clar Azith Clind
Range (mg/L) 0.032-2 4->64 l->64 8->64 0.06->32
Median (15) 0.12 >16 >16 >32 >16
% Resistance 0 100 100 100 69
All 29 S. pneumoniae, which were erythromycin resistant, were not resistant to
telithromycin (table 7). Three strains were, however, not sensitive to telithromycin
with MICs of2mg/L. All three had macrolide and lincosamide (ML) resistance
phenotypes as they were resistant to macrolides and the lincosamide clindamycin.
These strains were all from Italy. It is most probable that the clindamycin-sensitive
strains were mefA positive and thus were macrolide resistant by the efflux
mechanism. Telithromycin showed good activity against both the macrolide (M) and
ML resistance phenotypes. There does not appear to be a correlation between the M
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orML resistance phenotype and telithromycin resistance, although the three
telithromycin non-sensitive strains were all of the ML phenotype.
5.3.2 Mutation studies
Telithromycin resistant mutants were created from the macrolide resistant strains
02J1095 and 02J1175. The plating of the macrolide sensitive NCTC 13593 strain on
agar containing telithromycin from concentrations of 0.016mg/L for the first
generation to 0.5mg/L for the fourth generation, failed to produce telithromycin
resistant mutants, as shown in table 10. The NCTC 13593 strain, which was
macrolide sensitive, had a telithromycin MIC of 0.016mg/L. This increased
sequentially to 0.032mg/L, 0.12mg/L, 0.5mg/L and 0.5mg/L for the four mutant
generations respectively. There was decreased susceptibility to telithromycin with an
increase in telithromycin MIC from 0.016mg/L for the parent strain to a
telithromycin MIC of0.5mg/L for the third and fourth generation mutants. This is
greater than a 20-fold increase in MIC over three generations.
The MIC of 02J1095 and its mutants increased from 0.06 mg/L for the parent to
>32mg/L over two generations, as illustrated in table 8. The first generation
contained one strain with a telithromycin MIC of 8mg/L. The second generation
which had all been selected on agar which a telithromycin concentration of 1mg/L
were highly telithromycin resistant with MICs ranging from 4mg/L to >32mg/L.
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With regard to 02J1175, the telithromycin MIC of the parent strain was 0.5mg/L.
This increased over four generations to 2mg/L, 4mg/L and 8mg/L respectively, as
shown in table 9. While the increase in the telithromycin MIC was not as marked as
for strain 02J1095 the telithromycin MICs did increase sequentially from 0.5mg/L to
8mg/L. The final generation strain M IV was selected from an agar plate with 8mg/L
but also had a telithromycin MIC of 8mg/L.
Table 8. Mutation study results of 02J1095.
Parent Gen 1 Gen 2
02J1095 (0.06) JII 1-10(0.06-1) J III 1-9 (4->32)
J II 1-8 [0.06] J III 1-9 [1]
J II 9, J II 10 [0.12]
( ) = Telithromycin M 1C (mg/L)
[ ] = Telithromycin plate concentration that the strain was selected from (mg/L).
Gen = Generation
Table 9. Mutation study results of 02J1175
Parent Gen 1 Gen 2 Gen 3 Gen 4
02J1175 (0.5) MI 1-10(1-4) Mil 1-18 (2-4) Mill 1-3 (8) M IV (8)
MI 1-10 [0.5] Mil 1-10 [1] M III 1-3 [4] M IV [8]
Mil 11-18 [2]
( ) = Telithromycin MIC (mg/L)
[ ] = Telithromycin plate concentration that the strain was selected from (mg/L).
Gen = Generation
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Table 10. Mutation study results ofNCTC 13593.
Parent Gen 1 Gen 2 Gen 3 Gen 4
NCTC 13593 NI 1-10 Nil 1-9 N III 1-12 N IV 1-5
(0.016) (0.016- (0.032-0.12) (0.12-0.5) (0.25-0.5)
0.032) Nil 1-4 N III 1-6 N IV 1-5
N I 1-10 [0.032] [0.12] [0.5]




( ) = Telithromycin MIC (mg/L)
[ ] = Telithromycin plate concentration that the strain was selected from (mg/L).
Gen = Generation
5.3.3 Mutation Frequencies
The frequency ofmutation is highest overall for the NCTC 13593 mutants, as
indicated in table 11. The lowest frequency ofNCTC 13593 mutants per population
was 1 in 100. Although this is extremely high, no mutants could be created with a
telithromycin MIC of higher than 0.5mg/L. The first generation mutation frequency
of the 02J1095 mutants was 1 mutant per 1000, as shown in table 11. The second
generation mutation frequency was 1 per 106. This is obviously less frequent than the
first generation but the fact that a jump in MIC of such magnitude can occur is of
interest. These increases were stable, such that when the mutants were serially
subcultured 10 times without the selective pressure of telithromycin the MIC of
telithromycin for each strain did not decrease. The first generation mutation
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frequency of 02J1175 mutants was 2 per 10,000 (table 11). This decreased to 3 per
100,000 for the second generation and 3 per million for the third generation.
Interestingly, after the third generation, mutants were selected more readily at a
frequency of 3 per 100,000. However, when the final generation strains were
subcultured they did not grow well and as a result only one strain survived as a
fourth generation mutant.





02J1095 (ermB) 0.06 Parent
J II 1 1 1 1 x 10"J
J III 1 4 2 1 x 10-6
J III 8 >32 2 1 x 10"6
02J1175 (mefA) 0.5 Parent
M I 2 2 1 2 x 10"4
Mil 15 4 2 3 x 10"5
Mill 3 8 3 3 x 10-6
M IV 8 4 3x 10"5
NCTC 13593 0.016 Parent
N I 1 0.032 1 2 x 10"2
Nil 7 0.12 2 3 x 10"2
N III 11 0.5 3 6x 10"1
N IV 3 0.5 4 2x 10"2
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5.3.4 Revertant Strains MICs
Representative mutants were serially subcultured ten times without the selective
pressure of telithromycin to investigate if the mutants required the presence of
telithromycin in order to maintain the elevated telithromycin MICs or if the
mechanism used by the bacteria to prevent telithromycin activity persisted even in
the absence of telithromycin. There was no decrease in the telithromycin MIC of
J II 1, J III 1 or J III 8, with telithromycin MICs of lmg/L, 4mg/L and >32mg/L
respectively, after serial passage. There was also no decrease in the telithromycin
MIC of selected NCTC 13593 mutants with telithromycin MICs of 0.06mg/L,
0.12mg/L and 0.25mg/L. Therefore, the 02J1095 and NCTC 13593 mutants with
elevated telithromycin MICs had stable mechanisms ofpreventing telithromycin
activity, which did not require the selective pressure of telithromycin.
Table 12. Revertant telithromycin MICs.
Parent ► Revertant
Telithromycin MIC (mg/L) Telithromycin MIC (mg/L)
M I 2 2 MI 0.5
Mil 15 4 Mil 2
Mill 3 8 Mill 4
M IV 8 MIV 1
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The 02J1175 mutants selected with telithromycin MICs from 2mg/L to 8mg/L were
not stable (table 12). When the mutants were serially subcultured on
telithromycin-free agar ten times, the resulting strains differed from the original
strains in that they had increased susceptibility to telithromycin. The MIC of
telithromycin for the most resistant strain M IV reverted from 8mg/L to lmg/L after
10 passages in antibiotic-free medium. The MIC ofeach generation representative
also decreased but not as dramatically as the fourth generation mutant. For the third
generation strain, M III 3, the decrease in telithromycin MIC meant that it remained
telithromycin resistant with an MIC of4mg/L. When the M IV reverant was mutated
on agar plates containing either lmg/1 or 2mg/l all the resulting mutants returned to
an MIC of 8mg/l, the same as M IV. The M IV strain was selected from agar plates
with a telithromycin concentration of 8mg/L. Thus while the strains were not stable
they merely required the presence of telithromycin to activate the resistance
mechanism as the concentration required to increase the revertants telithromycin
MIC was lower than that ofM IV. The frequency ofmutants was also very high at
1 per 10. Therefore, in order for S. pneumoniae with a mefA gene to maintain their
telithromycin MIC the selective pressure must be applied. This is not true for those
strains that contained the ermB gene or do not have either gene. Once resistance or
elevated telithromycin MICs had been achieved in these strains, they remained stable
whether or not there was selective pressure.
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5.4 Discussion
The findings of the mutation study suggest that in order for telithromycin resistance
to occur in S. pneumoniae either an ermB or mefA gene must be present. The mutants
generated from a strain with the ermB gene were stable whereas the mutants from a
mefA positive strain were not (table 12). However, the mefA revertants only required
the presence of telithromycin to return to the highest telithromycin MIC once more.
They did not return to the telithromycin MIC of 8mg/L by stepwise selection but
merely in one step. Strain NCTC 13593 did not have either the ermB or mefA gene.
The highest telithromycin MIC ofany NCTC 13593 mutant was 0.5mg/L (table 10),
which is still sensitive under the NCCLS breakpoint of lmg/L. The MIC of the final
generation NCTC 13593 mutants was greater than 20-fold higher than that of the
parent NCTC 13593. While this is still sensitive it is a large increase in telithromycin
MIC.
The frequency ofmutant generation was greatest for the NCTC 13593 mutants
(table 11). Although this did not produce telithromycin resistance it must be noted
that the final generation were mutated at high frequency. If these were to acquire
another advantage over telithromycin then there would be a large population base
that could potentially become telithromycin resistant. With regard to the ermB
generated mutants there is a large difference in the number ofmutants formed from
parent to first generation in comparison to first generation to second generation
(table 11). This indicates that another mechanism has probably been created or
acquired by the second generation mutants. For the mefA mutants the mutation
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frequencies did not vary greatly from one generation to the next (table 11). Thus
there was probably one mechanism of resistance at work that was refined and
improved from one generation to the next as the concentration of telithromycin
increased.
Overall these results should be taken as a warning that when S. pneumoniae is
exposed to telithromycin in vitro the MIC will increase markedly. This is more
important when the strains are already resistant to macrolides as the potential for the
propagation of telithromycin resistant strains is increased. If telithromycin resistance
can be generated in vitro with such ease, it is probable that telithromycin resistant
S. pneumoniae will emerge in the community when the drug is released.
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Chapter 6
Macrolide resistance genes ermB and mefA
6.1 Introduction
Macrolide resistance is an ever-increasing problem in Streptococcus pneumoniae.
The two main known mechanisms of resistance to macrolides in S. pneumoniae are
target modification and efflux. Target modification is mediated by the ermB gene,
which encodes a 23S rRNA methylase. Methylation results in the S. pneumoniae
being resistant to macrolide, lincosamide and streptogramin B (MLSb) antibiotics
(Leclercq & Courvalin, 1991). Erm methylase synthesis can be inducible or
constitutive. Bacteria resistant to erythromycin due to methylation are also resistant
to azithromycin and clarithromycin (Nagai et al., 2002). The mefA gene encodes an
efflux pump, which confers resistance to 14 and 15 membered macrolides only.
Therefore, strains containing the mefA gene are sensitive to lincosamides and
streptogramin B antibiotics (Sutcliffe et al., 1996b; Tait-Kamradt et al., 1997;
Roberts et al., 1999). Recently another methylase gene, ermA was identified in
S. pneumoniae. The strains containing the ermA were erythromycin resistant or
intermediate, inducibly clindamycin resistant and streptogramin sensitive
(Syrogiannopoulos et al., 2001; Nagai et al., 2002).
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Telithromycin is a semi synthetic 14-membered-ring macrolide derivative, which is
characterised as having a 3-keto function instead of an L-cladinose moiety and a
CI 1-C12 carbamate link (Bryskier, 1998). These features are believed to enhance the
telithromycin performance. It has been shown to be active against macrolide
sensitive and resistant S. pneumoniae (Hamilton-Miller & Shah, 1998; Giovanetti et
al., 2000; Jalava et al., 2001).
The aim of this study was to investigate the influence of the ermB and mef'A genes in
S. pneumoniae parent strains and mutants of varying telithromycin sensitivities. This
involved screening the strains for the presence of the genes and then further
molecular experiments to test if any mutations were present in these genes that could
account for the decreased telithromycin susceptibilities.
6.2 Materials and Methods
6,2.1 Bacterial strains
Strains were selected as representative telithromycin derived mutants from each
parent strain as shown in table 13.
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Table 13. Representative telithromycin resistant mutants.
Parent NCTC (0.016mg/L) 02J1095 (0.06mg/L) 02J1175 (0.5mg/L)
Generation 1 N I 1 (0.016mg/L) J II 1 (lmg/L) M I 3 (2mg/L)
N I 7 (0.032mg/L) M I 5 (2mg/L)
Generation 2 N II 7 (0.12mg/L) J III 1 (4mg/L) M II 15 (4mg/L)
J III 8 (>32mg/L)
Generation 3 N III 1 (0.25mg/L) M III 3 (8mg/L)
Generation 4 M IV (8mg/L)
6.2.2 Isolation of Chromosomal DNA
The strains were grown on Columbia agar supplemented with 5% defibrinated horse
blood and the appropriate telithromycin concentration overnight. The parent strains
and the NCTC mutants were inoculated onto telithromycin-free plates. Colonies were
emulsified in 200 pL ofMilliQ water in an eppendorf tube. They were boiled for 10
to 15 minutes in a boiling waterbath. The supernatant containing the extracted DNA
was used as the DNA template in further experiments.
6.2.3 PCR conditions
The PCR conditions and the primers for the detection and amplification of the ermB
and mefA genes were as previously described (Sutcliffe et al., 1996b) and are
described in table 14. The primers were supplied by MWG Biotech AG (Germany)
and had been HPSF purified. The PCR reagents were obtained from Promega UK.
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6.2.4 Primers
Table 14. PCR primers for ermB and mefA amplification.
Primer Name Sequence 5' to 3'
ermB forward
ermB reverse
GAA AA(AG) GTA CTC AAC CAA ATA
AGT AA(CT) GGT ACT TAA ATT GTT TAC
mefA forward
mefA reverse
AGT ATC ATT AAT CAC TAG TGC
TTC TTC TGG TAC TAA AAG TGG
The reaction mixture for the amplification of the ermB gene consisted of 1 pL ofTaq
DNA polymerase (5U/pL), lOpL of 10 x reaction buffer (50mM Tris-HCl (pH 8.0 @
25°C), lOOmM NaCl, O.lmM EDTA, ImM DTT, 50% glycerol, 1% Triton® X-100),
lpL of lOOmM dNTP mix (0.25pL ofeach dNTP), 8pL ofMgCl2 (25mM), lpL of
primer mix (forward 13pinole/pL, reverse 25pmole/pL), 5pL ofDNA template and
74pL of sterile MilliQ water. The Taq DNA polymerase was stored at -20°C and
added to the mixture last. The reaction mixture was vortexed briefly and added to the
PCR cycler. The PCR was performed in a Techne Thermal Cycler (Techne
Cambridge Ltd., UK) under the conditions indicated in table 15.
105
Table 15. The PCR cycling conditions ofermB and mefA.






The positive control 02J1095 and a negative control, consisting of the PCR reaction
mixture with 5pL of sterile MilliQ water instead ofDNA template, were included in
each PCR run.
For the mefA amplification the reaction mixture was the same as that of the ermB
PCR mixture except for the MgCf concentration, the primers and the amount of
MilliQ water. In the case of the mefA the PCR mixture contained 16pL ofMgCl2
(25mM), 1 pL ofmefA primer mix (forward 17 pmol/pL and reverse 9 pmol/pL) and
66juL of sterile MilliQ water. The PCR cycling parameters were the same as those
for the ermB amplification as shown in table 15. The positive control 02J1175 and a
negative control were included in each PCR run.
The PCR samples were kept at 4°C until they were run on an agarose gel. If they
were to be kept longer than one day, they were stored at -20°C.
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6.2.5 Agarose Gel Electrophoresis
Two grams ofelectrophoresis grade agarose (Gibco BRL, Life Technologies,
Paisley) was added to lOOmL of 1 x TAE (10 x TAE: 48.4g Tris, 11.4mL glacial
acetic acid, 20.0mL EDTA (pH 8.0) and 500mls of sterile distilled water, diluted 1 in
10 with sterile distilled water to produce 1 x TAE). The solution was heated in a
microwave with swirling every 30 seconds until the agarose was dissolved. This was
allowed to cool and then poured into the electrophoresis tank with the appropriate
comb to a depth ofabout 2cm. The tank was transferred to the fridge to set before the
comb was removed.
The solidified gel was submerged in 1 x TAE buffer. Ten micoliters ofPCR product
was mixed with 2pL ofblue/orange 6 x loading dye (15% Ficoll®400, 0.03%
Bromophenol Blue, 0.03% Xylene Cyanol FF, 0.4% Orange G, lOmM Tris-HCl
(pH 7.5) and 50mM EDTA). The mixture was then pipetted into a well in the gel. For
the ermB and mefA PCR product gels, a 5pL of 100 base pair ladder and 1 pL of
6 x loading dye mixture was run in 1 well ofeach gel. The electrophoresis was
performed at 100 volts for 35 to 40 minutes. This allowed the ladder to separate and
the PCR products to move down the gel.
The gel was immersed in ethidium bromide solution (20pL of a lOmg/mL solutions
added to 200mLs ofdistilled water) for approximately 20 minutes. If the gel was not
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sufficiently stained it was reimmersed in ethidium bromide solution. The DNA in the
gel was visualised using Biorad imaging and diversity database computer software.
6.2.6 Purification and Quantification ofPCR Products
The PCR products were purified using a QIAquick PCR purification kit (Qiagen
Ltd., Crawley, UK) according to the manufacturer's instructions. The purified DNA
was eluted in 30pL of sterile MilliQ water into an eppendorf tube. Two microliters of
the purified DNA was run with blue/orange 6 x loading dye in a 2% agarose gel as
previously described. In order to ascertain the quantity ofDNA in the sample 4pL of
1 Kb ladder or X DNA/Hind III marker was also run on the same gel. The gel was
run, stained and visualised in the same way as the PCR product gels. The amount of
DNA in the sample was quantified by comparing the brightness of the sample band
with the bands of the 1Kb ladder or X DNAJHind III marker.
6.2.7 Automated DNA sequencing
The primers used for the PCR amplification were also used for the DNA sequencing.
Each primer was diluted in sterile MilliQ water to a final concentration of 3 pmol/pL
for each sample. The DNA concentration of each sample was between 30 and 90ng.
DNASHEF Technologies, Edinburgh, performed the sequencing. The DNA sequence
was determined by the chain termination method (Sanger et al., 1977). Individual
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PCR fragments were set up in the Ready Reaction Format for fluorescence based on
the dideoxy cycle sequencing (PE Applied Systems, UK).
The sequences were compared to previously published sequences ofS. pneumoniae
ermB and mefA genes using BLAST online search facility
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). The ermB gene comparator was
accession number X52632 and the mefA gene comparator was accession number
U83667.
6.2.8 Efflux pump inhibition
In order to investigate the effect ofefflux pumps on telithromycin resistance the
parent strains 02J1095 and 02J1175 and the mutant strains M I 2, M I 5, M II 15,
M III 3, M IV, J II 1, J III 1 and J III 8 were inoculated onto blood agar plates
containing carbonyl cyanide m-chlorophenylhydrazone (CCCP) (Sigma-Aldrich,
UK). CCCP is a proton motive force inhibitor, which inhibits the mefA efflux pump
(Sutcliffe et al., 1996a).
Each of the strains were inoculated onto blood agar plates with a fixed concentration
ofCCCP at 1Omg/L or 1OOpM per plate and varying concentrations oferythromycin
or telithromycin and onto blood agar plates with varying concentrations of
erythromycin or telithromycin and no CCCP, using a Denley Multipoint inoculator.
The isolates were inoculated at a concentration ofeither 105 or 106 cfu per spot and
incubated in 5% CO2 overnight.
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6.3 Results
The parent strain 02J1095 and the telithromycin derived mutants J II 1, J III 1 and
J III 8 were all tested for the presence of the ermB gene. A 639 bp product was
expected and this was amplified from each of the strains as shown in figure 12. The
NCTC 13593 strain and the representative mutants were also investigated for the
presence ofermB genes. No ermB genes were found in any of these strains as
indicated in figure 13. The positive control included in each run did result in a PCR
product corresponding to 639 bp each time the experiment was performed.
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6.3.1 ermB Gels
Figure 12. ermB gene PCR gel of 02J1095 and representative mutants.
1 2 3 4 5 6
fcvV.H \
Lane 1 02J1095 -
Lane 2 J II 1
Lane 3 J III 1
Lane 4 J III 8
•
Lane 5 Negative 1 700bpiii BP
control 1—>m— ^
— 5OObp
Lane 6 1OObp •H.'
ladder
Figure 13. ermB gene PCR gel of 02J1095 positive control, NCTC 13593 and its
representative mutants.
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The 02J1175 parent and its representative mutants were screened for the mefA gene.
The corresponding 348 bp product was amplified from each strain, as shown in
figure 14. The NCTC 13593 parent and mutants were also screened for the mefA
gene. No products were amplified from any of these strains, as indicated in figure 15.
A 348 bp product was amplified from the positive control every time.
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6.3.2 mefA Gels
Figure 14. mefA gene PCR gel of02J1175 and representative mutants.
1 2 3 4 5 6 7 8
Lane 1 02J1175
Lane 2 M I 3
Lane 3 MI 5
Lane 4 MII 15
Lane 5 M III 3








Figure 15. mefA gene PCR gel of 02J1175 positive control, NCTC 13593 and its
representative mutants.
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13593
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The ermB gene ofeach of the parent, 02J1095, and its mutants were sequenced.
There were no changes in nucleotide sequence between the parent and any of the
mutants tested. Even though the variation in telithromycin MIC was greater than
600-fold. There was however variation in each of the sequenced ermB genes and the
ermB sequence ofS. pneumoniae deposited in the NCBI website. The parent and the
mutants all had the same mutations and are listed in table 16. Three mutations
resulted in amino acid changes and one did not.
Table 16. ermB gene mutations.
Nucleotide change Amino acid change
C to T None
T to C I to T
G to A StoN
A to G H to R
As all of these changes were present in all of the strains, including the telithromycin
sensitive strains, they do not appear to be associated with increased telithromycin
MIC.
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The sequences of the portion of the mefA gene of the parent 02J1175 and its mutants
were identical to each other and the mefA gene sequence in the NCBI website. The
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mefA gene in the NCBI website was isolated from 02J1175. The 02J1175 strain used
in these experiments was therefore identical to the NCBI strain. The mutants
however had elevated telithromycin MICs in comparison to its parent, which cannot
be attributed to changes in the mefA gene as none were found.
6.3.4 mefA sequence and translation (portion of total mefA
gene)
gtatcattaatcactagtgccatcctgcaaatggcgattattttt
















6.3.5 Efflux pump results
No growth was observed on any of the plates containing CCCP including control
plates with no antimicrobial agent. All of the isolates grew on the plates without
CCCP and had the same MICs as previously recorded. As none of the isolates
survived in the presence ofCCCP it is impossible to say what the influence ofCCCP
inhibited efflux pumps has on telithromycin MIC as the concentration required to
inhibit the pumps also inhibited the bacterial growth.
6.4 Discussion
The ermB and mefA genes have been widely accepted as the main causes of
macrolide resistance in S. pneumoniae. The ketolide telithromycin is an
erythromycin derivative and so has a similar mechanism ofaction to the macrolides.
Thus, it could be expected that resistance to telithromycin could result from
mutations or adaptations of the resistance mechanisms already widespread to the
macrolides. However, the ermB methylase and the mefA efflux mechanisms are not
capable of causing resistance to telithromycin. Also, from the results presented in
this study S. pneumoniae has not been able to alter these genes to overcome the
antibacterial effect of telithromycin. Streptococcus pneumoniae has managed to
adapt to become telithromycin resistant and highly resistant to telithromycin. The
mechanism used however is not an alteration ofmethylase production controlled by
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the ermB gene or adapting the efflux mechanism associated with the portion of the
mefA gene amplified and sequenced. The NCTC 13593 parent and its mutants were
ermB and mefA negative as expected as they were all macrolide sensitive.
The mutations identified in the ermB genes were present in all of the strains. The
lowest telithromycin MIC of strains with the mutated ermB gene was 0.06mg/L,
which was telithromycin sensitive. So even though there were three amino acid
changes in the methylase gene sequence they do not appear to affect the ErmB
methylase or its activity.
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Chapter 7
23S rRNA Gene Mutation
7.1 Introduction
Erythromycin interacts with the domains II and V of the 23S rRNA ofStreptococcus
pneumoniae (Menninger & Otto, 1982; Brisson-Noel et al., 1988, Leclercq &
Courvalin, 1991; Weisblum, 1995a; Garza-Ramos et al., 2001; Zhanel et al., 2001).
The central loop of domain V is known as the peptidyl transferase region of the
ribosome. Mutations in the ribosome have previously been shown to cause macrolide
resistance in bacteria (Meier et al., 1994; Versalovic et al., 1996; Ross et al., 1997;
Vester & Douthwaite, 2001). Tait-Kamradt et al., (2000b) described the first
mutations in the domain V of the 23 S rRNA in S. pneumoniae which resulted in
macrolide resistance. These mutations were identified in laboratory derived mutants.
They also determined that S. pneumoniae has four copies of the gene encoding the
23S rRNA. The number of genes with a mutation in the peptidyl transferase region of
the 23 S rRNA varied from one to four. The S. pneumoniae with mutated 23 S rRNA
did not contain either the ermB or mefA genes. Two of the ribosomal mutations
located by Tait-Kamradt et al., (2000b) have since also been identified in macrolide
resistant clinical isolates (Pihlajamaki et al., 2002).
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There are two different systems of numbering nucleotides in a gene or sequence. The
most common method is to use the nucleotide number associated with the position of
that nucleotide in the Escherichia coli sequence. The second nucleotide numbering
scheme originates from its position in the bacteria of study, in this case, in the
S. pneumoniae genome. The numbers are within a few positions of each other e.g.
nucleotide number 2058 in E. coli is number 2060 in S. pneumoniae. Unless
specifically stated E. coli numbering is assumed.
The sites ofmutation within the domain V were initially 2058, 2059 and 2611.
Another mutation at 2062 was later also classified in macrolide resistant
S. pneumoniae (Depardieu & Courvalin, 2001). Mutations U2609C and A2058G
together, lead to telithromycin resistance in E. coli (Garza-Ramos et al., 2001). This
phenomenon has not been associated with telithromycin resistance in S. pneumoniae
as no strain with such mutations has been generated or clinically isolated.
Xiong et al (1999), Hansen et al., (1999) and Douthwaite et al., (2000) have all
highlighted the interaction oferythromycin and telithromycin with the hairpin 35 of
domain II of the 23 S rRNA ofE. coli. Telithromycin had a strong affinity for hairpin
35 particularly at adenine 752. Recently, Canu et al., (2002) revealed that a deletion
ofone adenine in the series of four located between 749 and 752 in the domain II of
S. pneumoniae lead to a 500-fold increase in the telithromycin MIC of the strain.
This increase resulted in the strain being telithromycin resistant. The mutant was a
laboratory-generated strain selected on clarithromycin.
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As such mutations have been associated with macrolide resistance and later ketolide
resistance it was logical to assume that the telithromycin resistant generated mutants
created from 02J1095 and 02J1175 could also have mutations in either domain II or
V of the 23 S rRNA. Therefore, we decided to look for mutations in any of the four
23S rRNA genes in domains II and V which could account for the telithromycin
resistance.
7.2 Materials and Methods
7.2.1 Bacterial strains
The parents 02J1095 and 02J1175 and the representative mutants J II 1, J III 1,
J III 8, M I 3, M II 15, M III 3 and M IV, previously described in tables 8, 9 and 13,
were investigated in this study.
7.2.2 PCR
In order to detect mutations in the peptidyl transferase region of the 23 S rRNA all
four contigs of the domain V were amplified using four downstream (DS) primers as
described by Tait-Kamradt et al., (2000b) and in table 17. The Domain II portion of
23 S rRNA of J III 8 and M IV were amplified using the 23 S 5' primers described by
Tait-Kamradt et al., (2000b) as shown in table 17. Problems were encountered
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obtaining reproducible sequence data for the nucleotide section from 2350 to 2650
(S. pneumoniae numbering) of the four domain V genes. As a result primers were
designed using the primer design website Primer 3 at
http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi to amplify this
inner portion seperately see table 17 for details.
DNA was isolated from each strain as described in the previous chapter and used for
the domain V and domain II gene amplifications. Purified domain V PCR products
were used as the DNA template for the amplification of the inner portion of the
genes.
Table 17. Primers for the PCR amplification of the peptidyl transferase regions of
23 S rRNA.
Primer name Sequence 5' to 3'
Forward 23S 3' CGG CGG CCG TAA CTA TAA CG
Reverse
DS 18 GCC AGC TGA GCT ACA CCG CC
DS 23 TAC ACA CTC ACA TAT CTC TG
DS 30 TTT TAC CAC TAA ACT ACA CC
DS 91 TAC CAA CTG AGC TAT GGC GG
Inner primers
Forward GTT CCC TCA GAA TGG TTG GA
Reverse CAT AGC TAC CCA GCG ATG C
Domain II
Forward GGT TAA GTT AAT AAG GGC GC
Reverse TTT CGA CTA CGG ATC TTA GC
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7.2.3 PCR reagents
The PCR reaction contents were the same as the PCR mixture of ermB except for the
modifications described in table 18.
Table 18. 23S rRNA PCR reaction mixtures.




DS 18 2 74 66/47
DS 23 2 74 66/81
DS 30 2 74 66/82
DS 91 3 70 66/21
Inner segment 2 74 91/79
Domain II 4 66 29/39
The setup of the PCR reaction mixture and the storage of the PCR products were the
same for that of the ermB PCR products. The PCRs were also performed in a Techne
Thermal Cycler under the following conditions described in table 19.
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Table 19. 23S rRNA PCR cycle parameters
PCR product Number of Temperature Time (minutes)
cycles (°C)
DS 18 1 94 3




DS 30 1 94
DS 91 35 94 1
Inner section 35 54 1
Domain II 35 72 1
1 72 10
7.2.4 Agarose Gel Electrophoresis
The PCR products were run on 2% agarose gels, stained and visualised as described
in the previous chapter.
7.2.5 Purification and Quantification ofPCR Products
All PCR products except DS 18 were purified as previously described using a
QIAquick PCR purification kit. The amplification of the DS 18 gene segment
resulted in two PCR products represented by two bands on the gel, which can be seen
in figure 16. The DS 18 PCR products were run on 2% low melting temperature
(LMT) agarose (Nusieve) to enable isolation of the DNA from the 2000 nucleotide
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band. The LMT agarose was poured into the electrophoresis gel tank until the
agarose filled the tank up to the top of the comb wells and was allowed to solidify in
the fridge. The LMT agarose gels took longer to set than the standard agarose gels.
The DS 18 PCR products (90 pL) were mixed with 6 x loading dye and pipetted into
the gel wells. A 1 kb ladder was included in each gel. The gel was run at 100 V for 40
minutes in 1 x TAE. The gel was stained for approximately 30 minutes in ethidium
bromide solution. The bands were visualised on a UV transilluminator
(UV products). The band at 2000 bp was cut out of the gel and purified using a
QIAquick gel extraction kit (Qiagen Ltd., Crawley, UK). The purified product was
eluted in 30 pL of sterile MilliQ water. All purified products were run on a 2%
agarose gel and the DNA quantified as previously described.
7,2.6 Automated DNA Sequencing
The PCR products of J III 8 and M IV for each of the amplified portions of the
domain V and domain II segments of the 23 S rRNA genes were sequenced by
DNASHEF Technologies, Edinburgh. Each of the sequences were analysed for
mutations by comparison with the 23S rRNA sequence ofS. pneumoniae TIGR 4
(http://www.tigr.org/tigr- scripts/CMR2/rna.spl?db=bsp). The sequences of J III 8 or
M IV and the nucleotide sequence of23S rRNA ofTIGR 4 were entered into the
BLAST pairwise analysis program to align the nucleotides.
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7.3 Results
Figure 16. DS 18 23S rRNA PCR products gel.
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Figure 17. DS 23 23S rRNA PCR products gel.
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Figure 18. DS 30 and DS 91 23S rRNA PCR products gel.
1 2 3 4 5 6 78 9 10 11 12 13 14 15
Lanes 1, 8 02J1095
Lanes 2, 9 MI 3
Lanes 3, 10 MI 5
Lanes 4, 11 Mil 15
Lanes 5, 12 M III 3
Lanes 6, 13 MIV
Lanes 7,14 Negative
control
Lane 15 lkb ladder
1500 bp
lOOObp
Lanes 1 to 7 contain DS 30 23 S rRNA PCR products and lanes 8 to 14 contain DS 91
23S rRNA PCR products.
Figure 19. Inner section of23S rRNA for DS 18 and DS 23 PCR products
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Lane 1 J III 8 DS 18
Lane 2 J III 8 DS 23
Lane 3 MIV DS 18
Lane 4 MIV DS 23






Figure 20. 23 S rRNA Domain II PCR products
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The primers used to amplify the four copies of the 23 S rRNA gene each had unique
reverse downstream primers as shown in table 20. The downstream reverse primers
were designed such that they amplified a segment outside of the 23 S rRNA gene,
which was unique to that copy. This resulted in four gene segments, each of a
different size described in table 20. The use of these primers enabled the peptidyl
transferase region from all four alleles of 23 S rRNA to be separately amplified, as
shown in figures 16 to 18, and purified for DNA sequencing. Downstream (DS) 18
PCR products consisted of the 23 S rRNA region from 1899bp to lOOObp past the end
of the 23 S rRNA gene. The resulting bands of2000 bps are shown figure 16. The
DS 23 PCR product, in figure 17, consisted of approximately the same distance past
the end of the 23 S rRNA but the gene amplified was not the same as that ofDS 18.
The DS 30 and DS 91 PCR products, figure 18, each amplified from 1899bp to
300bp and 200bp respectively past the end of the 23 S rRNA genes.
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Table 20. Position of the downstream primers in relation to the 23 S rRNA genes
Downstream gene 23 S rRNA gene (bp) Number of nucleotides
after the 23 S rRNA gene
DS 18 1899 to 2902 + 997
DS 23 1899 to 2902 + 997
DS 30 1899 to 2902 + 297
DS 91 1899 to 2902 + 197
The downstream 23S rRNA genes were amplified from each of the parents, 02J1095
and 02J1175, and also the representative mutants as shown in figures 16 to 18. Only
the four domain V genes of J III 8 and M IV were entirely sequenced. The sequences
from the DS 30 and DS 91 genes were obtained using only the 23S rRNA and
downstream primers and not the inner primers. The sequencing results of the DS 18
and DS 23 genes were incomplete using the downstream primers. The inner portion
from 2350 to 2650 (S. pneumoniae numbering) contained many unknown
nucleotides. The inner segments were separately amplified, which can be seen in
figure 19, and sequenced for J III 8 and M IV. When the entire sequences of the four
copies of the 23 S rRNA domain V genes were obtained they were compared to the
23S rRNA gene sequences ofTIGR 4. No nucleotide changes, insertions or deletions
were located in any of the four copies of the 23S rRNA domain V genes of J III 8 or
M IV.
The domain II portion of the 23 S rRNA genes were also amplified as shown in figure
20, and sequenced for J III 8 and M IV using primers which amplified the first 1011
nucleotides of the 23 S rRNA genes. This 1011 nucleotide portion of 23 S rRNA
contains the domain II region. Only one copy of the genes were sequenced.
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Mutations would be shown by heterogeneity in the nucleotide sequence. The region
of interest in domain II was hairpin 35, which stretched from nucleotide 734 to 762
(E. coli numbering). No changes, insertions or deletions were identified in this region
or in the nucleotides surrounding this region of J III 8 and M IV in comparison to
TIGR 4.
7.4 Discussion
Mutations in the domain V and domain II of the 23S rRNA genes ofS. pneumoniae
have previously been associated with increased macrolide and ketolide MICs
(Tait-Kamradt el al., 2000b; Canu el al., 2002). The four genes of the domain V of
the telithromycin resistant strains J III 8 and M IV contained no such mutation,
neither did the genes encoding domain II of these strains. The domains V and II of
the telithromycin resistant strains were identical to those of the telithromycin
sensitive TIGR 4.
The changes in the domain V or domain II of the 23 S rRNA that have previously
been identified were in ermB and mef'A negative strains. In these cases the mutations
in the 23S rRNA alone were responsible for the macrolide resistance. Only a deletion
in the domain II has previously been associated with telithromycin resistance in
S. pneumoniae.
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The results generated by this study question firstly the role of the mutations in
domain V on telithromycin resistance in S. pneumoniae, secondly the importance of
the mutation associated with telithromycin resistance in domain II and thirdly the
association between the mutations in E. coli leading to telithromycin resistance in
domain V and its implications for S. pneumoniae. The fact that J III 8 and M IV
contained ermB and mefA genes respectively has been shown not to cause
telithromycin resistance in these strains. However, it is uncertain if the presence of
either one of these genes would prevent mutations in the 23 S rRNA, as a mechanism
ofmacrolide resistance already exists. In conclusion, telithromycin resistance in
S. pneumoniae with either an ermB or mefA gene is not mediated by mutations in
either the domain V or domain II regions of the 23S rRNA. Therefore, the binding
sites of telithromycin, as presently known, were not mutated in order to prevent
telithromycin binding to the 23S rRNA.
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Chapter 8
L4 and L22 Gene Mutations
8.1 Introduction
The ribosome consists of both rRNA and ribosomal proteins. The way in which both
interact together has not yet been fully elucidated. The L4 and L22 riboproteins are
two such ribosomal proteins, which form part of the 23S rRNA region of the
ribosome. The first reports of ribosomal structural changes in erythromycin resistant
mutants ofE. coli described ribosomal protein alterations of L4 and L22 (Wittman et
al., 1973; Aravelo et al., 1988). Both L4 and L22 have been shown to interact
directly with the 5' portion of the 23S rRNA which contains the domain II region
strongly associated with ketolide binding (Rohl & Nierhaus, 1982). Therefore, these
proteins form an important part of the ribosomal region associated with the
macrolide and ketolide ribosomal interaction and when mutated could also have a
role in macrolide and ketolide resistance.
The first report ofmutations in L4 associated with increased macrolide MICs in
S. pneumoniae was published in August 2000 (Tait-Kamradt et al., 2000b). The
mutations consisted of a glycine to cysteine change at amino acid 69 and a
6 base-pair in-frame insertion between amino acid 67 and 68. The two mutations
occurred in two different strains and neither resulted in erythromycin nor
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telithromycin resistance. Clinical isolates of S. pneumoniae were soon discovered in
Eastern Europe and Canada with mutations in the same conserved region of the L4
protein. These however, were macrolide and lincosamide resistant (Tait-Kamradt et
al., 2000a).
Mutations in L22 associated with decreased macrolide and ketolide activity have
recently been located in laboratory derived S. pneumoniae mutants. The amino acid
mutations were located at amino acid positions 83, 91, 93, 95 and 99 (Canu et al.,
2002). There have only been three clinical isolates of pneumoniae identified with
an L22 mutation. This was a G95D amino acid substitution and was in combination
with an A2059G mutation in all 4 copies of the 23S rRNA genes (Farrell et al.,
2002). These clinical strains were erythromycin resistant but telithromycin sensitive.
None of the S. pneumoniae isolates with L4 or L22 mutations contained either mefA
or ermB genes. The number of macrolide resistant S. pneumoniae strains, resistant
due to either methylation by the ermB gene or efflux by the mefA gene is higher than
those resistant because of ribosomal mutations (Farrell et al., 2002).
As the mutants generated in this study did not contain mutations in the 23S rRNA
genes I looked to the L4 and L22 ribosomal proteins for answers to the question of
telithromycin resistance. The hypothesis was that mutations in both L4 and L22 have
previously lead to increased telithromycin MICs in S. pneumoniae and so, if mutated,
could cause an increase in telithromycin MICs.
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8.2 Materials and Methods
8.2.1 Bacterial strains
The parent strains 02J1095 and 02J1175 and the mutants J III 8 and M IV were
investigated for mutations in the L4 riboprotein .The L22 proteins of strains 02J1095,
JII 1, J III 1, J III 4, J III 5, J III 6, J III 7, J III 8, J III 9, 02J1175 and M IV were
also checked for mutations. These strains have previously been described in tables 8,
9 and 13.
8.2.2 PCR
The L4 and L22 genes of the bacterial strains were amplified using PCR. DNA was
isolated from each strain as described in the previous chapters. The primers used to
amplify the L4 and L22 genes were those of Tait-Kamradt et al., (2000b) and are
listed in table 21.
Table 21. Primers used to amplify the L4 and L22 genes.
Primer name 5' to 3'
L4 forward
L4 reverse
AAA TCA GCA GTT AAA GCT GG
GAG CTT TCA GTG ATG ACA GG
L22 forward
L22 reverse
GCA GAC GAC AAG AAA ACA CG
ATT GGA TGT ACT TTT TGA CC
134
8.2.3 PCR reagents
The PCR reaction mixture consisted of the same contents as those for the ermB gene
PCR mixture except for the primers listed in table 21. The L4 primers were
39pmo 1/pL for the forward primer and 75pmol/pL for the reverse primer. The L22
forward and reverse primer concentrations were 66pmol/pL and 44pmol/|uL
respectively.
8.2.4 PCR cycle parameters
The reaction mixture was set up in a Techne Thermal Cycler under the conditions
described in table 22 for the L4 PCR amplification and table 23 for the L22 PCR
amplification..
Table 22. L4 PCR cycle parameters.







Table 23. L22 PCR cycle parameters.






8.2.5 Agarose gel electrophoresis
The PCR products were run on 2% agarose gels stained and visualised as previously
described.
8.2.6 Purification and Quantification ofPCR Products
The L4 PCR products were purified as previously described using a QIAquick PCR
purification kit. The amplification of the L22 gene resulted in two PCR products
represented by two bands on the gel. The L22 PCR products were run on 2% low
melting temperature agarose and purified in the same way as the DS 18 PCR
products in the previous chapter.
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8.2.7 Automated DNA Sequencing
The purified L4 and L22 genes were sequenced by DNASHEF technologies,
Edinburgh. The nucleotide sequences ofL4 and L22 genes were compared to
previously published sequences ofS. pneumoniae L4 and L22 genes using the
BLAST online search facility (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). The L4
genes were compared to the sequence ofTIGR 4 accession number AE 007335.1
from nucleotide 7367 to 7990 and the L22 to nucleotide 9534 to 9878 ofTIGR 4.
The nucleotide sequences were also translated using the ExPaSy online translate tool
at http://www.expasy.ch/tools/dna.html and the amino acid sequences were
compared with those ofL4 and L22 ofTIGR 4.
8.2.8 Transformation
To access the role of the mutated L22 gene in telithromycin resistance the resistant
alleles of the L22 gene of J III 8 were amplified and purified. Transformation of the
mutated L22 gene into Streptococcus pneumoniae NCTC 13593 was attempted as
previously described by Canu et al (2002).
Competent cells were prepared as follows: Streptococcus pneumoniae NCTC 13593
was inoculated into lOmL ofCAT broth (lOOOmL sterile distilled water, 5g NaCl
(Sigma), lg yeast extract (Sigma), 5g Todd Hewitt broth (Oxoid), lOg enzymatic
casein hydrolysate (Oxoid)) with 0.2% glucose (Sigma) and 15mM K2HP04 (BDH
137
laboratories) (CAT I) and incubated in 5% CO2 overnight. One hundred microliters
of the overnight culture was inoculated into CAT I supplemented with 0.2% bovine
serum albumin (Promega) and ImM CaCfi (Sigma) (CAT II). The broth culture was
incubated in 5% CO2 overnight. The cells were centrifuged at 3900 rpm for 10
minutes in a Sorvall RT7 Plus centrifuge. The pellet was resuspended in 1mL of
CAT II with 15% glycerol. The competent cells were split into 100 pL aliquots and
stored at -70°C.
For transformation the cells were thawed on ice and 1 OpL was added to 1 OmL of
CAT II, which had been adjusted to pH 7.8. The mixture was then incubated in 5%
CO2 at 37°C for 15 minutes. Ten microliters ofpurified L22 gene PCR product were
added to lmL of the culture and the reaction mixture was incubated in 5% CO2 and
37°C for varying times of 1 hour, 2 hours, 3 hours, 3 hours 35 minutes, 5 hours, 5
hours 15 minutes and overnight. A negative control with 1 OpL of sterile milliQ water
instead ofpurified PCR product was added with each run.
One hundred microliters of the resulting cultures were spread on Columbia agar
plates supplemented with 5% defibrinated horse blood and telithromycin
concentrations of4mg/L. Control plates with no antibiotic were also included in each
assay. All plates were incubated in 5% CO2 for 48 hours.
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8.3 Results
The L4 and L22 ribosomal protein genes of the isolates were amplified and the
corresponding PCR bands at 720 bp and 420 bp were visualised on the agarose gels
shown in figures 21, 22 and 23.
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Figure 21. L4 PCR products gel
1 2 3 4 5 6
Lane 1 02J1095
Lane 2 J III 8
Lane 3 02J1175
Lane 4 M IV
Lane 5 Negative
control




Figure 22. Purified L22 PCR products gel
1 2 3 4 5 6 7 8
Lane 1 02J1095
Lane 2 J II 1
Lane 3 J III 1
Lane 4 J III 8
Lane 5 02J1175
Lane 6 M IV
Lane 7 Negative
control




Figure 23. L22 PCR products gel.
1 2 3 4 5 6 7
Lane 1 J III 4
Lane 2 J III 5
Lane 3 J III 6
Lane 4 J III 7
Lane 5 J III 9
Lane 6 Negative
control
Lane 7 1 Kb
ladder
Neither the nucleotide nor the amino acid sequences of the L4 riboproteins of
02J1095, J III 8, 02J1175 orM IV contained any mutations in comparison to those of
T1GR 4. The L22 nucleotide and amino acid sequences of 02J1095, JII1, J III 1,
J III 4, J III 5, J III 6, J III 7, J III 9, 02J1175 andMIV were also the same as those
ofTIGR 4. The parent strains 02J1095, 02J1175 and JII 1 were erythromycin
resistant but telithromycin sensitive, whereas J III 1 to J III 9 and M IV were
macrolide and telithromycin resistant. A mutation in the sequence of the L22 of
J III 8 at nucleotide position 9813 (S. pneumoniae numbering) from adenine to
cytosine was the only mutation identified as shown in the amino acid sequence
below. This altered the amino acid sequence also, by changing the lysine residue at
amino acid 94 to glutamine. The L22 gene sequences of the other ermB positive
mutants with telithromycin MICs between lmg/L and greater then 32mg/L did not
contain any mutation.
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This is the first incidence of a 94K to Q94 change in L22 associated with telithromycin
resistance. The mutation was only in the highly telithromycin resistant J III 8 strain.
After this mutation was discovered further strains were investigated. The L22 genes
of J III 4, J III 6, J III 7 and J III 9, with telithromycin MIC values of 16mg/L,
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32mg/L, >32mg/L and >32mg/l respectively, were amplified as shown in figure 23,
and sequenced. None of these strains contained any mutation in their L22 genes.
In the transformation experiments growth was observed at each time point on the
non-selective plates with no telithromycin. However, no colonies were present on the
transformant selective plates containing telithromycin from any of the time points.
Therefore the effect of the L22 mutation alone on the development of telithromycin
resistance could not be determined as the mutated L22 was not transformed into the
telithromycin sensitive NCTC 13593 strain.
8.4 Discussion
The L4 and L22 proteins are both associated with a tunnel in the 50S ribosome
subunit through which nascent peptides exit from the ribosome (Gabashvili et al.,
2001). Macrolides are a group of antibiotics that act in the vicinity of the
peptidyltransferase centre and the entrance of the polypeptide tunnel. Arevalo et al.,
(1988) suggested that erythromycin could physically block this tunnel. Mutations in
either the L4 or L22 proteins could alter their conformations and prevent macrolide
or ketolide binding to the rRNA (Gregory & Dahlberg, 1999). Both L4 and L22
mutations have been associated with erythromycin resistance (Weisblum, 1995a).
Mutations in L4 and L22 have also been identified in S. pneumoniae with increased
telithromycin MICs and erythromycin resistance both in laboratory derived mutants
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and clinical isolates (Tait-Kamradt et al., 2000a; Tait-Kamradt et al., 2000b; Canu et
al., 2002; Farrell et al., 2002; Nagai et al., 2002; Pihlajamaki et al., 2002).
The L4 proteins of isolates with either a mefA or ermB gene, which were all
erythromycin resistant and some were telithromycin resistant, had no changes from
the macrolide and ketolide sensitive T1GR 4 strain. None of the mutants except
J 111 8 had changes in the L22 protein. Therefore, in these cases the increase in
telithromycin MICs were not due to alterations in the L4 or L22 proteins.
The J III 8 strain had the highest telithromycin MIC of>32mg/L and was ermB
positive. The L22 amino acid mutation was from a lysine to a glutamine at amino
acid 94. This change was located between two previously documented mutations in
S. pneumoniae: G95D and A93E. The G95D mutation resulted in a 16 or 32-fold
increase in telithromycin MIC and the A93E mutation, in combination with P91S and
G83E mutations or a 23S rRNA mutation, enabled a 32-fold or 16-fold telithromycin
MIC increase respectively (Canu et al., 2002). Interestingly, the G95D mutation was
also identified in combination with a 23S rRNA mutation in three clinical isolates
from Japan (Farrell et al., 2002). However, none of these changes caused
telithromycin resistance.
The G95D and A93E amino acid changes are both from neutral amino acids to
negatively charged amino acids. The K94Q change in J III 8 is from a positively
charged amino acid to neutral. The positively charged residues ofL22 primarily
interact with the negatively charged phosphate group of the RNA (Unge et al., 1998).
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The mutation and the change in amino acid charge could affect the conformation and
binding of the L22 to the 23S rRNA and its location in relation to the nascent peptide
chain exit tunnel. This could in turn prevent telithromycin binding to the 23S rRNA.
It is also interesting to note that the only glutamine present in the L22 protein was the
one caused by this mutation. As yet it is unknown exactly how the K94Q mutation
affects the L22 protein but it is certain that the mutation was present in a highly
telithromycin resistant strain which had an ermB gene. Why the other strains with
equally high telithromycin MICs did not have such a mutation is still however,
unanswered, as too is the mechanism of telithromycin resistance in these strains.
As the NCTC 13593 strain could not be transformed with the mutated L22 gene, it is
not possible to identify the importance of this mutation alone in the development of
telithromycin resistance. Transformation depends on achieving a specialised cellular
state know as competence. In S. pneumoniae this state is transitory and the
development of competence under laboratory condition is influenced by many
factors including culture pH, medium composition, the bacterial strain used and
variations in temperature (Chen & Morrison, 1987). The lack of transformation could
be attributed to the fact that the cells are not competent and therefore could not be
transformed with the DNA.
The results of this study indicate that the L22 mutation occurred only at high-level
telithromycin resistance. The lack ofmutation in the other strains suggests that




Investigation of the ermB upstream region and
induction of the ermB gene
9.1 Introduction
The upstream region of the ermB gene in S. pneumoniae consists of a promoter
region, ribosome-binding site 1, a 27 amino acid control peptide and
ribosome-binding site 2. The total region comprises 269 base pairs. In streptococci
expression of the ermB gene may be inducible or constitutive. In staphylococci,
inducible resistance is conferred mainly by 14- and 15-membered-ring macrolides
but not lincosamides or 16-membered-ring macrolides or ketolides (Leclercq &
Courvalin, 1991; Weisblum, 1995a; Bonnefoy et al., 1997), recently resistance has
also been induced by lincosamides and 16-membered-ring-macrolides (Clarebout et
al., 2001). Streptococci have cross-resistance between MLSB antibiotics, which are
all efficient inducers (Horinouchi et al., 1983).
Mutations and deletions in the ermB upstream region have been associated with
macrolide resistance changing from inducible resistance to constitutive resistance.
The upstream region controls the methylase production and therefore this region
determines how the gene is expressed, which in turn determines if the methylase
gene may be turned on or offor just turned on in the case of constitutive resistance.
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The upstream region of the ermB genes of the parent strain 02J1095 and mutant
strains were investigated for alterations. Also, the ability of erythromycin and
clarithromycin to induce telithromycin resistance in these strains was explored.
9.2 Materials and Methods
9.2.1 Bacterial strains
The ermB upstream regions of the parent strain 02J1095 and mutants J II 1, J III 1,
J III 4, J III 5, J III 6, J III 7, J III 8 and J III 9, described in tables 8 and 13, were
investigated. The strains 02J1095, J II 1, J III 1, J III 8 and the control strain
S. pneumoniae NCTC 13593 were tested in the induction experiments.
9.2.2 PCR
The ermB upstream region was amplified using PCR. DNA was extracted from each
strain as previously described. The forward primer was designed using the primer
design website Primer 3 at
http://www-genome.wi.mit.edu/cgi- bin/primer/primer3_www.cgi and the reverse
primer was the same as the reverse primer used to amplify the ermB gene as
described in table 24.
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Table 24. ermB upstream primers




GAA GCA AAC TTA AGA GTG TGT TGA 951 bp
ermB upstream
reverse
AGT AA(CT) GGT ACT TAA ATT GTT TAC
9.2.3 PCR reagents and cycle parameters
The PCR mixture was the same as that of the ermB gene PCR except the MgCh
concentration was 3mM and the forward primer ermB upstream forward was
46 pmol/pL. The cycle parameters were the same as those of the ermB PCR.
9.2.4 Agarose gel electrophoresis
The PCR products were run on 2% agarose gels stained and visualised as previously
described.
9.2.5 Purification and Quantification ofPCR Products
The ermB upstream region PCR products were purified as previously described using
a QIAquick PCR purification kit.
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9.2.6 Automated DNA Sequencing
The purified genes were sequenced by DNASHEF technologies, Edinburgh. The
nucleotide sequences were compared to previously published sequences of the
S. pneumoniae ermB gene using the BLAST online search facility
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). The gene comparator was accession
number X52632.
9.2.7 Transformation
To access the role of the mutated ermB upstream region in telithromycin resistance
the resistant alleles of the ermB attenuator of J III 8 were amplified and purified.
Streptococcus pneumoniae NCTC 13593 was used as the recipient strain. The
competent cells preparation and transformation experiments were adapted from the
method used by Canu et al., 2002.
Competent cells were prepared as follows: Streptococcus pneumoniae NCTC 13593
was inoculated into lOmL ofCAT broth (lOOOmL sterile distilled water, 5g NaCl
(Sigma), Ig yeast extract (Sigma-Aldrich, UK), 5g Todd Hewitt broth (Oxoid), lOg
enzymatic casein hydrolysate (Oxoid)) with 0.2% glucose (Sigma-Aldrich, UK) and
15mM K2HPO4 (BDH laboratories) (CAT I) and incubated in 5% CO2 overnight.
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One hundred mico liters of the overnight culture was inoculated into CAT I
supplemented with 0.2% bovine serum albumin (Promega) and 1 mM CaC^
(Sigma-Aldrich, UK) (CAT II). The broth culture was incubated in 5% C02
overnight. The cells were centrifuged at 3000g for 10 minutes in a Sorvall RT7 Plus
centrifuge. The pellet was resuspended in 1 mL ofCAT II with 15% glycerol. The
competent cells were split into 100pL aliquots and stored at -70°C.
For transformation the cells were thawed on ice and lOpL was added to lOmL of
CAT II, which had been adjusted to pH 7.8. The mixture was then incubated in 5%
C02 at 37°C for 15 minutes. Ten microliters of purified ermB upstream PCR product
was added to 1 mL of the culture and the reaction mixture was incubated in 5% C02
at 37°C for varying times of 1 hour 10 minutes, 3 hours and 18 hours. A negative
control with IOjiL of sterile milliQ water instead of purified PCR product was
included in each run.
One hundred microliters of the resulting cultures were spread on Columbia agar
plates supplemented with 5% defibrinated horse blood and telithromycin
concentrations of 0.5mg/L or lmg/L. Control plates with no antibiotic were also




The strains were each inoculated into 4.5mL of sterile distilled water and adjusted to
a turbidity of 0.5 McFarland standard. Using a sterile swab each strain was spread
onto separate Columbia blood agar plates. Disks containing 15pg ofeach of the
following agents - erythromycin, clarithromycin and telithromycin - were placed
onto the plate approximately 2cm apart. Each strain was tested in duplicate and the
NCTC 13593 strain was used as a control.
ii Induction assays
In order to investigate inducibility further two induction assays were performed.
1. The parent 02J1095 was subcultured on erythromycin, clindamycin and
lincomycin and the resulting mutants were tested for induction of telithromycin
resistance. 02J1095 was inoculated into sterile saline and adjusted to 0.5 McFarland
standard. One hundred microliters of the solution was spread on Columbia blood
agar plates containing 0.5, 1 and 2 mg/L each of erythromycin, clindamycin,
lincosamide and a control plate with no antibiotic and incubated in 5% CO2
overnight. Colonies were randomly chosen from each plate and subcultured on plates
with 2 mg/L ofeach antimicrobial agent and incubated overnight in 5% CO2. The
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MIC of telithromycin against these mutants was investigated as previously described.
Streptococcus pneumoniae NCTC 13593 and S. aureus NCTC 6571 and E. coli
NCTC 10418 were all used as controls in the MIC tests.
2. The MICs of telithromycin in the presence oferythromycin (0.06 mg/1) of
02J1095, J II 1, J III 1 and J III 8 were determined as previously described. Control
strains consisted of the S. pneumoniae NCTC 13593 and S. aurues NCTC 6571.
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9.3 Results
Figure 24. ermB promoter region PCR gels
1 2 3 4 5 6
Lane 1 02J1095
Lane 2 J II 1
Lane 3 J III 1







Lane 1 J II 1
Lane 2 J III 1
Lane 3 J III 4
Lane 4 J III 5
Lane 5 J III 6
Lane 6 J III 7
Lane 7 J III 8
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The corresponding bands of approximately 1000 base pairs of the ermB upstream
region PCR products of 02J1095, J II 1, J III 1, J III 4, J III 5, J III 6, J III 7 and
J III 9 were visualised on the gels as shown in figure 24. As illustrated in the gel
photos in figure 24 the J III 8 band was just above the 750 bp band of the 1Kb ladder.
The sequencing results showed some anomalies not only in J III 8 but also in each of
the other strains, in comparison to the ermB upstream sequence of the Tn7545 of
S. pneumoniae in the NCBI website. These are listed in table 25.




02J1095 (0.06) a292g c297t ta318, 319ag
J II 1 (1) a292g c297t ta318, 319ag
J III 1 (4) a292g c297t ta318,319ag c324a
J III 4 (16) a292g c297t ta318,319ag c307t
J III 5 (32) a292g c297t ta318, 319ag
J III 6 (32) a292g c297t ta318, 319ag
J III 7 (>32) a292g c297t ta318, 319ag g302a
J III 8 (>32) 207 bp deletion from 113 to 319
J III 9 (>32) a292g c297t ta318,319ag t322g
The 292g, 297t and 319g are all present in the ermB carrying plasmid pAM 77 of
Streptococcus sanguis and the 318a mutation has previously been identified in an
oral streptococcus. The nucleotide sequences of the ermB upstream regions 02J1095,
J III 8, pAM77, pAMB-1, Tn9/7 and Tn1545 are compared in appendix 3. The c297t,
a292g and the ta318, 319ag mutations have been located in clinical isolates of
S. pneumoniae, which had inducible expression of the ermB gene. The mutations,
which were present only in J III 1, J III 4, J III 7 and J III 9 have not been previously
identified.
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Deletions of large fragments of nucleotides upstream of the ermB gene similar to that
found in J III 8 have been located in S. agalactiae, and S. pneumoniae, which had
constitutive ermB expression. The plasmid pAMpl ofS. pneumoniae also contained
the same deletion as these strains (Rosato et al., 1998; Rosato el al., 1999). However,
in these strains this deletion removed the first ribosome binding site (rbs) and the
control peptide but J III 8 had a deletion of the second rbs and the control peptide.
In the transformation experiments growth was observed at each time point on the
non-selective plates with no telithromycin. However no colonies were present on the
transformant selective plate containing telithromycin from any of the time points.
Therefore the effects of the ermB attenuator region mutation alone on the
development of telithromycin resistance could not be determined as the mutated
ermB attenuator region was not transformed into the telithromycin sensitive NCTC
13593 strain.
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9.3.1 Induction experiment results











On both plates, with 02J1095 and J II 1, the zone of inhibition around telithromycin
had two straight edges, one each from erythromycin and clarithromycin, which can
be seen in figures 17 and 18. The D-shaped zone indicates that the antimicrobial
agent to the left of the D induces resistance. From these photographs it can be seen
that erythromycin and clarithromycin both induce telithromycin resistance. The
growth of J III 1 to J III 9 were either up to the discs or within 1mm of the discs and
so were recorded as resistant to the 3 antimicrobial agents and as such had
constitutive expression of the ermB gene.
9.3.2 Induction assays results
The MICs of the mutant strains derived from growth of 02J1095 on erythromycin,
clindamycin or lincomycin are shown in table 26. (E2, L2 and C2 are the mutant
strains subcultured on 2mg/L of erythromycin, lincomycin or clindamycin
respectively. No antibiotic is the negative control, which was subcultured on blood
plates without antibiotic). The telithromycin MICs of the strains tested in the
presence of 0.06mg/L oferythromycin are shown in table 27.
157
Table 26. Telithromycin MIC results of strains mutated in the presence of
erythromycin, lincomycin and clindamycin.
Strain Telithromycin MIC (mg/L)
02J1095 0.06
No antibiotic 0.12
E2 1 to 3 0.12
L2 1 to 3 0.12
C2 1 to 3 0.12
The set ofMICs shown in table 26, indicate that when 02J1095 was subcultured in
the presence oferythromycin, lincomycin or clindamycin, the telithromycin MIC did
not increase any more for the "mutant" strains than for the negative control strain,
which had been subcultured on antibiotic-free plates. They did however, all increase
by one doubling-dilution but this is not as a result of changes induced by the
antimicrobial agents but merely an inaccuracy of the way in which MICs are tested.




Telithromycin MIC (mg/L) with
0.06mg/L of erythromycin per plate
02J1095 (0.06) 0.25
J II 1 (1) 1
J III 1 (4) 32
J III 8 (>32) >32
With regard to the second MIC test, the MICs of 02J1095 and J III 1 did increase as
shown in table 27. The telithromycin MIC of the parent 02J1095 increased by 2
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doubling dilutions, from 0.06mg/L to 0.25mg/L and that of J III 1 increased by 3
doubling dilution from 4mg/L to 32mg/L. While the MICs of these 2 strains did
increase the telithromycin MIC ofJII 1 remained the same. Therefore, although the
disc diffusion results suggest that erythromycin induces telithromycin resistance, this
conclusion has not been backed up conclusively by the MIC assays.
9.4 Discussion
Deletions in the erm gene attenuator region in S. pyogenes, S. pneumoniae and
S. agalactiae have all been associated with constitutive expression of their Erm
methylases. In S. pyogenes deletions of 163 base pairs or 6 base pairs and a
duplication of 101 base pairs in the erm(TR) upstream region resulted an increase in
clindamycin MIC from lmg/L to 128mg/L when transformed into E. coli. (Fines et
al., 2001). The S. pyogenes strains with mutated attenuators were mutants which had
been selected on clindamycin, the parent strain was inducibly intermediate to
erythromycin and fully susceptible to clindamycin. Tait-Kamradt et al., (2001)
described two S. pneumoniae clinical isolates with truncated ermB leader peptides of
15 and 19 amino acids. These 2 strains had telithromycin MICs of lmg/L and
256mg/L respectively and both also had 3 amino acid changes in the gene itself. The
strain with the 256mg/L telithromycin MIC also contained an L4 riboprotein amino
acid mutation of69GTG71 to 69TPS71.
The results of the PCR experiments of the ermB upstream region performed with the
parent 02J1095 and the mutants derived from it showed that the J III 8 strain had a
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large deletion of206 bps in this section removing the second ribosome binding site
and the control peptide. This result is very similar to that found with the clindamycin
resistant S. pyogenes. Therefore, it is possible that a mechanism of resistance exists
that alters the ermB attenuator of strains inducibly resistant to erythromycin in order
to confer resistance to other antimicrobial agents within the same group, such as
clindamycin and telithromycin. The results ofTait-Kamradt et al., (2001) are also
similar to the findings of this study in that the telithromycin resistant strains both had
truncated regions upstream from the ermB gene. The other mutants investigated in
this study, which were also highly telithromycin resistant did not however have such
a deletion. Therefore, while the mutation in the ermB attenuator may be at least
partly responsible for telithromycin resistance in J III 8, this is not the case for the
other 5 highly telithromycin resistant strains.
The mutated nucleotides at positions 292, 297 and 319 of the strains investigated are
the same nucleotides as those ofplasmid pAM 77 from S. sanguis and the nucleotide
change at position 318 was found previously in an oral streptococci. These mutations
were in the parent 02J1095 and all the mutants, except J III 8, and as such do not
appear to be involved in the development of telithromycin resistance. It is, however,
interesting to note the nucleotide changes at 318 and 319 are just at the end of the
deletion in J III 8. Two previously reported S. pneumoniae isolates with the same 318
and 319 mutations were both inducibly erythromycin resistant but sensitive to the
ketolide HMR 3004 (Rosato et al., 1998). The other single mutations in J III 1,
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J III 4, J III 7 and J III 9 have not previously been associated with changes in
resistance patterns. But as each strain has a different mutation it is not likely that
these mutations individually lead to telithromycin resistance.
In order to investigate the effect of the truncated ermB attenuator region on
telithromycin resistance the corresponding PCR product would need to be
transformed into a sensitive strain and the telithromycin MIC of the transformant
tested. As the transformation experiments did not work it is impossible to assess the
effect of the individual mutation on telithromycin resistance. The lack of
transformation is probably due to problems with the competency of the telithromycin
sensitive NCTC 13593 strain rather than with the mutated ermB attenuator region
DNA. The concentration at which S. pneumoniae develops competence varies with
the composition of the medium, the bacterial strain used and the medium pH (Chen
& Morrison, 1987). Any one of these factors could have contributed to the
prevention of transformation of the NCTC 13593 strain with the mutated ermB
attenuator region DNA.
The disk diffusion experiments indicated from the D-shaped zones of inhibition
around the telithromycin disc that erythromycin and clarithromycin are both inducers
of telithromycin resistance in the strains 02J1095 and J II 1. However, when the
02J1095 strain was subcultured in the presence of erythromycin the mutants did not
result in an increase in telithromycin MIC in comparison to the negative control.
When the telithromycin MICs of the four strains were investigated in the presence of
erythromycin the telithromycin MICs of 02J1095 and J III 1 did increase but that of
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JII 1 did not. Thus there is a conflict between the 3 sets of results as to the extent
that erythromycin induces telithromycin resistance. It is possible that the differences
arise due to the varying concentrations oferythromycin used in each experiment, but
this is unlikely. There does however, appear to be a relationship between
erythromycin and telithromycin resistance but further studies are required to
investigate if this is the case with a larger number of isolates.
When the results of the experiments are taken together the overall conclusion is that
erythromycin and clarithromycin induce telithromycin resistance but that this cannot
be verified by the MIC assays. Also, the high-level telithromycin MICs of the
mutants are not all caused by the same mutation in the ermB attenuator. Although the
large deletion in J III 8 is such that it is probably part of the mechanism used by this
strain to overcome telithromycin. The mechanism(s) of resistance in the other
mutants, however, remain to be identified.
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Chapter 10
Investigation of the mefupstream and
downstream nucleotide regions
10.1 Introduction
The chromosomal insertion elements containing the mefgene in S. pneumoniae have
recently been characterised. The region downstream from mef is an open reading
frame (orf) called mel. The predicted protein of this orf showed 36.2% amino acid
identity to the erythromycin resistance ATP-binding protein MsrA ofStaphylococcus
epidermidis. Reverse-transcriptase (RT)-PCR demonstrated that mefE and mel were
co-transcribed (Gay & Stephens, 2001). Tait-Kamradt has also discovered that
knocking out the mefgene from the mega operon stops expression of both mefand
mel whereas knocking out the mel gene also eliminates macrolide resistance but not
transcription ofmef (personal communication). The region upstream from the mef
gene contained a 944-bp region with no predicted orf. It did, however, contain a
putative promoter region. Deletions or mutations within the promoter region, control
peptide region and ribosome binding site upstream from ermB have been associated
with changes in gene expression from inducible to consititutive. Therefore, both the
upstream region containing the promoter and the downstream mel region are
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necessary for meffunction. Changes in the mefencoded efflux pump could be
controlled by alterations of either of these two sections.
The aim was to investigate if the telithromycin resistant mefpositive mutants
contained the same mel and upstream regions as the sensitive strains.
10.2 Materials and Methods
10.2.1 Bacterial strains
The parent 02J1175 and the mutants M I 3, M II 15, M III 3 and M IV were
analysed, described in tables 9 and 13.
10.2.2 PCR
The mel gene and mefupstream region of the bacterial strains were amplified using
PCR. DNA was isolated from each strain as described in the previous chapters. The
primers used to amplify the mel genes and upstream regions were previously
described by Gay and Stephens (2001) and Sutcliffe et al., (1996b), except for the
mefupstream forward primer, shown in table 28. This was designed using the primer
design website Primer 3 at
http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi. The mefupstream
reverse primer was the same as the reverse primer used to amplify the mefgene and
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the mel forward primer was the forward primer used to amplify the mefgene as
described in table 28. The mef upstream region PCR product was 614 bps and the
mel PCR product was 1680 bps.
Table 28. mega operon primers.
Primer Name Sequence 5' to 3'
mefupstream forward GAG CAT TCA TTA GTT ACG GTG AGG
mefupstream reverse TTC TTC TGG TAC TAA AAG TGG
mel forward AGT ATC ATT AAT CAC TAG TGC
mel reverse CTT CAC GGT CTA AAT GGC TCG
10.2.3 PCR reagents
The PCR reaction mixtures consisted of the same contents as those for the mefA gene
PCR mixture except for the MgCf concentration of the mel PCR mixture, which was
1.5 mM and the primers. The mefupstream forward primer was 60 pmol/p.L and the
mel reverse primer was 67 pmol/pL.
10.2.4 PCR cycle parameters
The reaction mixture was set up in a Techne Thermal Cycler under the same
parameters as the mefA amplification for the mefupstream region PCR and the
conditions described in table 29 for the mel PCR.
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Table 29. Cycle parameters for the mel PCR amplification






10.2.5 Agarose gel electrophoresis
The PCR products were run on 2% agarose gels, stained and visualised as previously
described.
10.3 Results
The mefupstream region PCR products and the mel genes of the strains were
amplified and the corresponding PCR bands at 614 bp and 1680 bp respectively were
visualised on the agarose gel as shown in figure 27. Lanes 1 to 6 are the PCR
products of the mefupstream region and lanes 8 to 13 are the mel PCR products.
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Figure 27. mefupstream region PCR products and mel PCR products gel.
1 2 3 4 5 6 7 8 9 10 11 12 13
I
Lane 1 02J1175
Lane 2 MI 3
Lane 3 M II 15
Lane 4 M III 3











Lane 9 MI 3
Lane 10 MII 15
Lane 11 Mill 3
Lane 12 M IV
Lane 13 Negative
control
There were no changes in the sizes of the mefupstream region, containing the
promoter, or the downstream mel region in any of the mutants.
10.4 Discussion
The sizes of the upstream and downstream regions from the mefgenes suggest that
no large nucleotide deletions have occurred. However, nucleotide changes could be
present but these would not have been detected by PCR amplification. Likewise, the
PCR gels would not have shown deletions of small numbers of nucleotides. The
presence of the mel genes in these strains confirms previous studies of the mef
operon, which suggested the presence of the mel gene downstream from the mef
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gene. As the primers were not specific for either the mega element or the transposon
Tnl207.1, which also contains the mefgene, it is still unclear as to which element is
present. From this study it can be seen that deletions of large numbers of nucleotides
from either the upstream or downstream nucleotide regions of the mefgene are not
responsible for the increase in telithromycin MIC and resistance. Further studies,
such as sequencing of the two regions either side of the mefgene are required to
determine if nucleotide mutations or deletions of small numbers of nucleotides are
present. A change in the efflux pump protein encoded by the mefgene and/or the
transporter mediated by mel could be required to change the efflux pump sufficiently




Telithromycin has been reported as the antimicrobial agent that will overcome MLSb
resistance and be used against respiratory tract infections with great activity. The
novel features of telithromycin enable it to overcome the macrolide resistance
mechanisms used by S. pneumoniae. Furthermore, as telithromycin does not induce
macrolide resistance its use will not increase the amount ofmacrolide resistance
already present, particularly in S. pneumoniae (Bonnefoy et al1997). Macrolide
resistance is currently a problem in many countries and the prospect of an
antimicrobial agent capable of combating macrolide resistance is ofgreat hope,
particularly in countries with high levels ofmacrolide resistance and also in countries
such as the UK where macrolide resistance is increasing.
The aims of this study were firstly, to investigate the efficacy of telithromycin
against S. pneumoniae, M. catarrhalis and H. influenzae, secondly, to investigate the
way in which telithromycin works by generating telithromycin resistant mutants and
thirdly to identify the mechanism(s) of resistance generated. As telithromycin has
already been launched in some countries, it is vital to know how easily resistance to
telithromycin may be generated, not only from the macrolide sensitive
S. pneumoniae populations, but also the main target of telithromycin; the macrolide
resistant S. pneumoniae.
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In order to access the efficacy of telithromycin it was tested in vitro in comparison to
a range ofantimicrobial agents against strains of S. pneumoniae, M. catarrhalis and
H. influenzae. The activity of telithromycin was also tested specifically against
macro lide resistant S. pneumoniae from around the world with different resistance
mechanisms. Telithromycin had high activity against both the clinical isolates of
S. pneumoniae gathered from various UK centres and the macrolide resistant
S. pneumoniae strains. Twenty per cent of the UK isolates and 100% of the
macrolide resistant isolates were erythromycin resistant, but there was no resistance
to telithromycin in either group ofS. pneumoniae. From these results it appeared that
telithromycin would be an excellent choice ofantimicrobial agent to combat
macrolide resistant S. pneumoniae. The erythromycin resistance breakpoint in
S. pneumoniae is >lmg/L (MacGowan & Wise 2001) and that of telithromycin
>4 mg/L (NCCLS, 2000). Even if both telithromycin and erythromycin resistant
strains were required to have an MIC of >1 mg/L then there would only be 1% or 1
strain in the UK isolates which would be telithromycin resistant and approximately
10% (9.6%) of the macrolide resistant strains, which would be telithromycin
resistant. Therefore, the strains that are already macrolide resistant have higher
telithromycin MICs than those that are sensitive and so appear to be able to prevent
telithromycin inhibiting S. pneumoniae to it's lull extent.
Three S. pneumoniae strains were used in the mutation studies. Two were macrolide
resistant and contained either an ermB gene or a mefE gene; the third was macrolide
sensitive and was negative for both genes. The selection of telithromycin resistant
strains varied not only by their telithromycin MICs but also the frequency of
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isolation. The mutants derived from the NCTC 13593 (macrolide sensitive) parent
were not telithromycin resistant but the MICs increased from 0.016mg/L for the
parent to 0.5mg/L for the final generation mutants. This was the lowest telithromycin
MIC ofall the final generation mutants created. However, the NCTC 13593 mutants
had the highest mutation frequencies, so although the MICs were not telithromycin
resistant the mutants were the easiest to propagate and resulted in the largest number
of isolates. Therefore, even though the macrolide sensitive parent strain did not
produce telithromycin resistant mutants, it did produce mutants with elevated
telithromycin MICs in large numbers.
The mutants with the highest telithromycin MICs were generated from the ermB
positive parent. The second-generation mutants had telithromycin MICs from 4mg/L
to >32mg/L and so were all telithromycin resistant. The second-generation mutants
derived from the mefE positive parent had telithromycin MICs of2mg/L or 4mg/L.
These results indicated that it only required two generations for an ermB positive or
mefE positive strain to become telithromycin resistant. Therefore, while
telithromycin had excellent activity against both ermB positive and mefE positive
S. pneumoniae resistance to telithromycin developed over two generations.
The mutation frequencies of the ermB positive, the mefE positive and the macrolide
sensitive parents all differed. The first generation mutation frequency of the ermB
positive mutants was 1 x 10"3,which then decreased to 1 x 10"6 for the next
generation. This suggested that a two-fold mutation occurred, the first mutation in
order to achieve the first generation mutants and a further mutation to obtain the
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second-generation mutants with the higher telithromycin resistance. For the mefE
positive and the macrolide sensitive mutants, the mutation frequencies are within
10-fold of each other for each generation and thus the strains adapted gradually to
telithromycin.
To date telithromycin resistant mutants have usually been derived from macrolide
susceptible parent strains, which could explain why the results of this study vary
from those previously published. A macrolide susceptible strain required 24 passages
on telithromycin for a mutant with a telithromycin MIC of 8mg/L to emerge,
whereas a strain with an ermB gene required only 3 passages in telithromycin to
result in a mutant with a telithromycin MIC of 8mg/L (Davies et al., 2000b).
The mechanism(s) used by the mefE positive strains to become resistant is not stable
as the mutants reverted to the lower telithromycin MICs when telithromycin selective
pressure was removed. This has previously been noted by Davies et al (2000b), when
the macrolide and telithromycin MICs ofmefpositive S. pneumoniae mutants
generated by passage on MLSb antibiotics and telithromycin reverted back to
baseline MICs after 10 passages on antibiotic-free media. The resistance mechanism
used by the mefE positive strains generated from 02J1175 appeared to be induced by
telithromycin as the revertant telithromycin MICs returned to those of the original
mutants when they were reintroduced to a telithromycin environment. The ermB
positive mutants were stable; their resistance mechanism(s) were stable and were not
turned off by removing the selective pressure of telithromycin. This has also
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previously been found in macrolide and telithromycin resistant S. pneumoniae by
Davies et al (2000b).
When the mutants were checked for ermB or mefE genes, the macrolide sensitive
mutants contained neither gene, the mutants derived from the ermB positive parent
contained only the ermB gene and those generated from the mefE positive parent
only the mefE gene. Therefore, cross-contamination or transfer of either gene did not
occur. The nucleotide sequences of the selected ermB positive mutants revealed no
changes from the parent strain. The changes that were identified did not appear to
have a role in telithromycin resistance as they were in telithromycin sensitive and
resistant strains.
The disc diffusion induction experiments showed that telithromycin resistance could
be induced by erythromycin or clarithromycin for the ermB positive parent, 02J1095
and mutant J II 1. The resistance levels of the ermB positive mutants with higher
telithromycin MICs strains were constitutively expressed, as they had no zones of
inhibition around the three discs. This indicated that they were resistant to all three
antimicrobial agents. The results of the different induction experiments varied but
disc diffusion is used as the primary experiment to test for induction ofMLSb
resistance. If the disc diffusion results are taken alone then erythromyc in and
clarithromycin induce telithromycin resistance. The clinical implications of this
finding are that telithromycin resistant strains could emerge from ermB positive
strains that had been induced by either erythromycin or clarithromycin. Therefore,
the main accolade of telithromycin, its ability to inhibit macrolide resistant
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S. pneumoniae that were also clindamycin resistant, would be removed.
Deletions in the erm gene attenuator region in S. pyogenes, S. pneumoniae and
S. agalactiae have all been associated with constitutive expression of their Erm
methylases. A number ofnucleotide changes were present in the region upstream
from the ermB gene in all ermB positive strains derived from 02J1095, which are
shown in appendix 3. In the ermB positive parent and the mutants (except J III 8)
four nucleotide changes were present, which were the same in each strain. Two of
these mutations were at nucleotides 318 and 319. The second-generation J III 8
mutant had a 207 base pair deletion in the ermB upstream region, which removed the
control peptide and the second ribosome-binding site. The cut was before nucleotide
113 and after nucleotide 319. It appeared that the telithromycin sensitive ermB
positive, parent strain may have characteristic mutations, which enabled it to develop
telithromycin resistance by having altered nucleotides and providing a nucleotide
sequence that could be cut and lead to a truncated ermB upstream region. When the
318, 319 nucleotides were mutated to AG and the sequence is read from 5' to 3' both
the four nucleotides just before the cut at 113 and before the cut at 319 would read
GATT. This implies that the mutated G is required as a signal to cut at that position.
The mutated nucleotides of the strains investigated at positions 292, 297 and 319 are
the same nucleotides as those of plasmid pAM 77 from S. sanguis and the nucleotide
change at position 318 was found previously in an oral streptococci (Rosato et al.,
1998; Rosato et al., 1999) as shown in appendix 3. These mutations were in the
parent 02J1095 and all the mutants, except J III 8, and as such do not appear to be
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involved in the development of telithromycin resistance. It is interesting to note the
nucleotide changes at 318 and 319 are just at the end of the deletion in J III 8. Two
previously reported S. pneumoniae isolates with the same 318 and 319 mutations
were both inducibly erythromycin resistant but sensitive to the ketolide HMR 3004
(Rosato et al., 1998). The nucleotide in the ermB upstream region at nucleotide
positions 292, 297, 318 and 319 were the same as those ofS. sanguis pAM77 ermB
upstream region. Thus, it appeared that this ermB upstream region had either adapted
in the same way as that ofS. sanguis pAM77 ermB upstream region or at some time
the ermB plasmid ofS. sanguis was transferred to the ermB positive parent 02J1095.
These mutations are not present in the upstream region of the ermB gene carried on
Tnl545.
The deletion in J III 8 removed the control peptide and one of the ribosome binding
sites. This therefore, ensures that the mRNA read from the DNA would not produce
the control peptide. The ribosome-binding site for transcription of the ermB gene
would also differ and thus change the ErmB methylase production. This deletion may
be partly responsible for the high telithromycin resistance of J III 8. However, this
type of deletion cannot be responsible for all telithromycin resistance in
S. pneumoniae as it was not present in the other highly telithromycin resistant
mutants. Thus, more than one mechanism of telithromycin resistance exists even
within a group of strains derived from the same parent.
The J III 8 strain deletion of 207 bps was very similar to that found with clindamycin
resistant S. pyogenes. In S. pyogenes deletions of 163 base pairs or 6 base pairs and a
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duplication of 101 base pairs in the erm(TR) upstream region resulted an increase in
clindamycin MIC from lmg/L to 128mg/L when transformed into E. coli. (Fines et
al., 2001) The S. pyogenes strains with mutated attenuators were mutants, which had
been selected on clindamycin, the parent strain was inducibly intermediate to
erythromycin and fully susceptible to clindamycin. Therefore, it was possible that a
mechanism of resistance exists that alters the ermB attenuator of strains inducibly
resistant to erythromycin in order to confer resistance to other antimicrobial agents
within the same group, such as clindamycin and telithromycin.
Tait-Kamradt et al., (2001) described two S. pneumoniae clinical isolates with
truncated ermB leader peptides of 15 and 19 amino acids. These 2 strains had
telithromycin MICs of lmg/L and 256mg/L respectively and both also had 3 amino
acid changes in the gene itself. The strain with the 256mg/L telithromycin MIC also
contained an L4 riboprotein amino acid mutation ofGlycine, Threonine and Glycine
at amino acids 69 to 71 to Threonine, Proline and Serine respectively. The results of
Tait-Kamradt et al., (2001) are also similar to the findings of this study in that the
telithromycin resistant strains both had truncated regions upstream from the ermB
gene. The other 02J1095 mutants investigated in my study, which were also highly
telithromycin resistant, did not however have such a deletion. Therefore, while the
mutation in the ermB attenuator may be at least partly responsible for telithromycin
resistance in J III 8, this is not the case for the other 5 highly telithromycin resistant
strains. The other single mutations in J III 1, J III 4, J III 7 and J III 9 have not
previously been associated with changes in resistance patterns, but as each strain has
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a different mutation it is not likely that these mutations individually lead to
telithromycin resistance.
In order to investigate the effect of the truncated ermB attenuator region on
telithromycin resistance, the corresponding PCR product would need to be
transformed into a sensitive strain and the telithromycin MIC of the transformants
tested. As the transformation experiments did not work it is impossible to assess the
effect of the mutation alone on telithromycin resistance.
Due to the discovery of this large deletion in the ermB gene upstream region in
J III 8, the mefE upstream and downstream regions were also amplified. No deletions
large enough to be noticed on the PCR product agarose gel were detected in either
region but sequencing of these regions would be required to determine if small
nucleotide deletions or mutations were present. The mefE upstream region contains a
putative promoter and the downstream region an orf called mel, which is
co-transcribed with mefE and could be the pump behind the mefE efflux pump as it
has amino acid homology to the erythromycin ATP-binding protein MsrA of
S. epidermidis. Therefore, alterations in either region would alter mefE expression
and could change to also efflux telithromycin. As the mefpositive mutants were not
stable the mechanism(s) used by these strains could have such a large cost to the cell
that it is only turned on as and when required. This idea would fit into the theory that
extra pumping pressure or an alteration in pump size, or both was required by these
strains to become telithromycin resistant.
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Further regions of the telithromycin resistant mutants were probed for alterations that
have previously been responsible for macrolide resistance and increased
telithromycin MICs or resistance. The peptidyl transferase region of the ribosome,
containing the domains II and V of the 23 S rRNA and the L4 and L22 riboproteins
are the main areas of interaction for the macrolides and ketolides, such as
telithromycin. They are also the main regions of interest to date for macrolide
resistance in S. pneumoniae. The area of consequence with regard to telithromycin in
domain II is the hairpin 35. A deletion in one adenine in the series of four located at
positions 749 to 752 resulted in a 500-fold increase in the telithromycin MIC of a
S. pneumoniae strain. In this case it became resistant to telithromycin (4 mg/1) (Canu
et al2002). Previously a single point mutation (U754A) in a laboratory strain of
E. coli resulted in the cells being resistant to telithromycin (Xiong et al., 1999). For
domain V there is less specificity with regard to one macrolide resistant region.
Mutations have been located at nucleotides 2058, 2059, 2062 and 2611
(Tait-Kamradt et al., 2000b; Depardieu & Courvalin, 2001; Farrell et al., 2002;
Pihlajamaki et al., 2002). These ribosomal mutations were identified in macrolide
resistant clinical isolates, which did not contain the ermB or mef'A genes.
Streptococcus pneumoniae has four copies of the 23S rRNA genes (Tait-Kamradt et
al., 2000b). These were amplified and sequenced from the ermB and mefE mutants,
in order to identify any alterations that may have prevented telithromycin binding to
its site of interaction. Mutations in domain V have been associated with increased
telithromycin MICs and alterations in domain II with telithromycin resistance (Canu
et al., 2002). No mutations were present in any of the mutants investigated in this
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study. Therefore, these results call into question the importance of previous
mutations associated with increased telithromycin MICs but not high-level
telithromycin resistance in the development of telithromycin resistance. This implies
that telithromycin resistance is mediated by alterations and adaptations in other
regions of the cell. There is also the possibility that alterations in other regions of the
23S rRNA, which had a lower cost to the strains, may have prevented telithromycin
from binding and so there was no need to alter the domains II or V of the 23 S rRNA.
Riboproteins L4 and L22 both line the nascent peptide exit tunnel of the ribosome
(Gabashvili et al., 2001). They have been associated with the erythromycin and
telithromycin binding sites of the ribosome. Mutations in both these riboproteins
have been associated with decreased macrolide and ketolide activity (Sutcliffe et al.,
2000; Tait-Kamradt et al., 2001; Canu et al., 2002; Farrell et al., 2002,). The L4
protein has been associated with large increases in telithromycin MIC in
S. pneumoniae. An insertion of 6 amino acids into a highly conserved area of
ribosomal L4 protein (63KPWRQKGTGRAR74) has been proven to cause a 500-fold
increase in the MIC of telithromycin (Tait-Kamradt et al., 2000b). Changes within
the L22 protein amino acid sequence have also been reported as a cause of increased
telithromycin MIC. A telithromycin MIC increase from 0.008mg/L to 0.25mg/L was
associated with three simultaneous amino acid mutations: Alanine-93 to Glutamic
acid-93, Proline-91 to Serine-91 and Glycine-83 to Glutamic acid-83 and a
Glycine-95 to Aspartic acid-95 mutation was associated with telithromycin MIC
increases from 0.004mg/L and 0.008mg/L to 0.12mg/L (Canu et al., 2002).
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The exit tunnel lined by L4 and L22 is thought to be blocked by erythromycin and
therefore most probably telithromycin (Gabshvili et al., 2001). Mutations in either
riboprotein could prevent telithromycin from blocking this tunnel. In this study no
mutations were identified in the L4 riboprotein. One mutation in the L22 was located
in the ermB positive J III 8 mutant. This resulted in a lysine to glutamine amino acid
change at position 94. Mutations at amino acids 93 and 95 have previously been
associated with increased telithromycin MICs (Canu et al., 2002).
The tip of the L22 is elongated and is mainly positively charged. The three amino
acids contributing to this positive charge at the L22 tip in Thermus thermophilus are
three arginines at amino acid positions 88, 90 and 92 (Unge et al., 1998). These
correspond to an arginine, a lysine and a serine respectively in S. pneumoniae. Both
arginine and lysine are positively charged and serine is neutral. The positive tip of
the L22 interacts with the negatively charged RNA. Therefore, alterations of amino
acid size or charge could change the tip of the L22 such that it did not bind to the
RNA or result in a conformation change of the L22 riboprotein; either of these
outcomes could then prevent telithromycin binding to the 23S rRNA.
In J III 8 the amino acid change from lysine to glutamine resulted in a charge change
from a positive lysine residue to a neutral glutamine amino acid residue. The lysine
corresponds to the arginine at position 90 in Thermus thermophilus, one of the three
amino acids responsible for the positively charged tip ofL22. The tip of the L22
extends into the nascent peptide chain exit tunnel. A change in charge would result in
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the L22 not binding to the RNA inside the tunnel, which could then block
telithromycin binding.
From the results generated in this study it can been seen that the highly telithromycin
resistant ermB positive mutant J III 8 developed at least two mechanisms of
resistance to telithromycin. One was a change in the ErmB methylase control
sequence and the other an alteration in the L22 riboprotein. If the ermB upstream
mutation lead to either an increase in ErmB methylase production or a change in the
position of methylation away from the adenine at nucleotide position 2058 in the
domain V of the 23 S rRNA to another position more closely associated with
telithromycin binding, then this could block telithromycin binding. If this was the
case then there would have been no need to alter the nucleotides in the domains II or
V of the 23 S rRNA and the L22 mutation would have been a secondary mutation as a
reaction to the ErmB methylation rather than a mutation caused directly by the
adaptation to telithromycin exposure.
The converse may also be true that the L22 mutation occurred as a telithromycin
resistance mechanism and blocked not only telithromycin but also the ErmB
methylase from binding to adenine 2058. Erythromycin resistance mutations in L22
riboprotein perturbed the conformation of residues in domains II, III and V (Gregory
& Dahlberg, 1999). Thus, the ermB upstream region was altered in order to allow
ErmB methylase to bind in a slightly different fashion or a larger amount produced
as less methylation could occur due to the altered L22.
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A third theory is that both the ermB upstream mutation and the L22 mutation are
merely further adaptations of the main resistance mechanism. This new mechanism
however, does not cause mutation in the 23S rRNA or the ermB gene itself. It would
seem feasible as no ermB upstream mutation or L22 mutation were located in the
other ermB positive telithromycin resistant mutants.
The ermB positive telithromycin resistant mutants, other than J III 8, did not have
either the ermB upstream region deletion or the L22 amino acid change. Therefore, it
appeared that these two mutations were linked together and were not two separate
steps involved in telithromycin resistance development. No mutations were located
in any of the mutants generated, in the 23S rRNA domains II and V, the L4
riboprotein or the ermB gene and only J III 8 contained mutations in the L22
riboprotein and the ermB upstream region. Therefore, none of the mechanisms
previously associated with macrolide resistance in S. pneumoniae or the ribosome
binding sites were adapted to provide these strains with a selective advantage over
telithromycin. It appeared that a new mechanism of resistance has been developed or
selected for to overcome telithromycin. This mechanism could be require a two-step
mutations in ermB positive strains as the telithromycin MIC increased to lmg/L for
the first generation mutants and >32mg/L for the second generation with mutation
frequencies decreasing from 10"3 to 10"6.
The mefE positive mutants also did not have alterations in the 23S rRNA or the L4 or
L22 riboproteins. In these strains it is most probable that the efflux pump mechanism
adapted to efflux telithromycin, as the mutants telithromycin MICs increased steadily
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over the generations. However, the mechanism(s) involved must have had a high cost
to the cell as the mechanism(s) was turned offwhen the pressure of telithromycin
was removed. No mutations in the mefgene or the mefchromosomal elements of
S. pneumoniae have been associated with either macrolide or ketolide resistance to
date.
11.1 Conclusions
Telithromycin had excellent in vitro activity against macrolide sensitive and resistant
Streptococcus pneumoniae. Telithromycin resistant ermB positive and mefE positive
mutants developed in vitro within two generations. When the strains were macrolide
sensitive the telithromycin MIC also increased greatly (30-fold) but did not result in
resistance. Erythromycin and clarithromycin induced telithromycin resistance. A
deletion of207 base pairs in the ermB upstream region and a lysine to glutamine
amino acid residue mutation at position 94 in L22 were present in a highly
telithromycin resistant ermB positive mutant. The final conclusion of this study is
that telithromycin must be used with caution against MLSb and macrolide resistant
S. pneumoniae. The results generated in this study suggested that telithromycin








Telith air Ery Clar Azith Clind Moxi
R5390 0.12 0.016 0.032 0.032 0.25 0.032 0.12
R5456 0.12 0.016 0.12 0.032 0.06 0.06 0.25
R5496 0.12 0.032 0.032 0.032 0.12 0.032 0.25
R5500 0.06 0.032 0.06 0.06 0.12 0.06 0.25
R5547 0.06 0.008 0.06 0.032 0.06 0.06 0.12
R5770 0.032 0.016 0.12 0.06 0.06 0.06 0.12
R5850 0.12 0.016 0.12 0.06 0.12 0.032 0.25
R5860 0.06 0.032 0.06 0.12 0.25 0.12 0.5
R5874 0.12 0.06 0.12 0.12 1 0.12 0.06
R5917 0.12 0.032 0.12 0.032 0.06 0.06 0.12
R5921 0.12 0.06 0.06 0.12 0.5 0.12 0.25
R5946 0.06 0.032 0.06 0.032 0.12 0.032 0.12
R5973 0.032 0.016 0.032 0.032 0.12 0.06 0.12
R6113 0.12 0.12 0.12 0.06 0.06 0.12 0.25
R6164 0.12 0.032 0.12 0.06 0.25 0.06 0.25
R6175 0.12 0.06 0.06 0.12 0.12 0.06 0.25
R6250 0.06 0.06 0.032 0.032 0.12 0.06 0.25
R6373 0.06 0.032 0.06 0.032 0.06 0.12 0.12
R6431 0.06 0.016 0.06 0.032 0.25 0.06 0.12
R7011 0.12 0.016 0.06 0.06 0.12 0.032 0.12
R7343 0.032 0.032 0.06 0.032 0.06 0.06 0.12
R7368 0.12 0.06 0.12 0.06 0.25 0.06 0.12
R7386 0.06 0.12 0.5 1 2 0.016 0.06
R7396 0.06 0.032 0.06 0.032 0.12 0.032 0.12
R7413 0.06 0.032 0.06 0.12 0.12 0.12 0.12
R7422 0.032 0.016 0.016 0.016 0.06 0.032 0.12
R7579 1 0.25 8 4 8 0.12 0.12
R7684 2 0.25 8 4 16 0.06 0.12
R7835 2 0.5 16 8 8 0.06 0.12
R7953 0.12 0.06 0.016 0.032 0.06 0.06 0.12
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R8066 0.12 0.016 0.016 0.032 0.12 0.016 0.06
R8127 0.12 0.032 0.016 0.032 0.25 0.032 0.032
R8128 0.12 0.032 0.016 0.032 0.12 0.016 0.12
R8129 0.12 0.06 0.06 0.032 0.06 0.016 0.12
R8453 0.032 0.008 0.12 0.032 0.06 0.06 0.12
R8537 0.016 0.008 0.12 0.032 0.06 0.032 0.06
R8686 0.016 0.008 0.06 0.016 0.06 0.06 0.12
R8717 1 0.12 8 4 16 0.032 0.12
R9030 0.032 0.008 0.06 0.032 0.06 0.032 0.12
R9295 0.12 0.016 0.06 0.06 0.25 0.032 0.06
R9325 0.25 0.032 4 1 0.25 0.06 0.12
R9612 0.25 0.12 1 1 1 0.016 0.12
R9806 0.016 0.008 0.12 0.06 0.06 0.06 0.12
R10582 0.12 0.032 0.06 0.06 0.12 0.032 0.25
R10758 0.25 0.032 0.06 0.032 0.06 0.016 0.12
R40700 0.12 0.032 0.12 0.032 0.06 0.032 0.25
R70828 0.12 0.032 0.12 0.06 0.5 0.008 0.25
R77271 0.12 0.032 0.06 0.06 0.12 0.032 0.25
R79933 0.12 0.032 0.12 0.06 0.06 0.016 0.25
R80267 0.12 0.032 0.12 0.06 0.06 0.032 0.12
L80750 0.06 0.032 0.06 0.016 0.06 0.06 0.12
L80785 0.25 0.12 64 32 16 0.12 0.25
L80788 0.06 0.016 0.06 0.032 0.25 0.032 0.25
L85035 0.12 0.032 0.032 0.12 0.06 0.06 0.25
L85911 0.06 0.032 0.06 0.06 0.12 0.06 0.12
L85925 0.12 0.032 0.06 0.06 0.12 0.016 0.12
L85937 0.032 0.06 0.032 0.016 0.06 0.016 0.12
L85943 0.032 0.06 0.06 0.032 0.12 0.06 0.12
L89631 0.032 0.06 0.06 0.06 0.016 0.032 0.25
L89697 0.032 0.008 0.12 0.032 0.12 0.016 0.25
L89727 0.06 0.032 0.06 0.12 0.06 0.032 0.25
L89852 0.12 0.008 0.25 2 2 0.06 0.25
L89859 0.032 0.008 0.032 0.032 0.06 0.06 0.25
L89883 0.032 0.008 0.06 0.032 0.25 0.016 0.12
L89927 0.032 0.016 0.032 0.032 0.008 0.008 0.25
L89939 0.016 0.06 2 0.5 4 0.06 0.25
L7085059 0.12 0.016 0.008 0.032 0.032 0.06 0.12
L7085066 0.12 0.032 0.06 0.032 0.032 0.06 0.12
L7085268 0.06 0.016 0.06 0.12 b.06 0.06 0.25
L7090685 0.06 0.032 0.12 0.12 0.032 0.032 0.25
L7090700 0.12 0.12 0.25 0.5 0.5 0.032 0.25
L17 0.032 0.032 0.06 0.06 0.25 0.06 0.25
L22 0.032 0.016 0.06 0.032 0.06 0.032 0.25
L24 0.12 0.032 0.06 0.06 0.12 0.06 0.12
L29 0.06 0.06 0.032 0.032 0.06 0.06 0.25
LI 0.032 0.032 0.06 0.12 0.12 0.032 0.25
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BPE 1 0.06 0.12 0.06 0.032 0.06 0.06 0.06
BPE5 2 1 16 8 16 0.032 0.25
BPE 6 0.25 0.12 0.06 0.032 0.25 0.06 0.12
BPE 13 2 0.25 4 2 4 0.06 0.12
BPE 14 0.12 0.032 2 1 2 0.016 0.12
BPE 17 2 0.12 16 8 16 0.06 0.12
BPE 22 0.25 0.06 0.06 0.032 0.06 0.06 0.12
BPE 23
0.12 0.06 0.12 0.032 0.12 0.032 0.12
BPE 25 0.06 0.032 0.06 0.032 0.12 0.06 0.12
BPE 89 0.06 0.06 128 32 16 2 0.06
BPE 158 0.12 0.016 0.06 0.016 0.06 0.032 0.12
BPE 249 0.12 0.06 0.06 0.032 0.032 0.032 0.12
BPE 251 0.25 0.06 0.06 0.06 1 0.016 0.12
BPE 563 0.25 0.12 128 16 16 32 0.25
BPE 565 0.25 0.06 0.5 0.12 0.5 0.008 0.12
BPE 779 0.12 0.06 0.06 0.032 0.12 0.06 0.06
BPE 6080 0.06 0.06 0.06 0.032 0.12 0.032 0.12
A919 0.12 0.032 128 32 16 32 0.12
A2905 0.12 0.06 0.06 0.032 0.032 0.008 0.032
A7184 0.12 0.06 0.06 0.032 0.06 0.032 0.12
A8442 0.12 0.12 128 32 16 0.06 0.25
A11080 0.06 0.12 128 32 16 32 0.12
A12825 0.25 0.032 128 32 16 0.12 0.06
A13678 0.25 0.032 4 1 16 0.12 0.06
Strains Levo Cipro Gemi Linez Amoxn Amoxv Farop
R5390 1 4 0.032 1 0.032 0.016 0.008
R5456 1 1 0.032 2 0.016 0.016 0.008
R5496 1 1 0.12 2 0.016 0.032 0.12
R5500 1 1 0.032 2 0.032 0.016 0.016
R5547 0.5 0.5 0.032 2 0.016 0.008 0.004
R5770 1 4 0.032 2 0.016 0.016 0.008
R5850 1 2 0.032 4 0.032 0.016 0.008
R5860 1 2 0.06 2 0.032 0.016 0.016
R5874 1 2 0.016 1 0.25 0.5 0.016
R5917 1 1 0.032 2 0.032 0.016 0.008
R5921 2 4 0.06 2 0.016 0.008 0.008
R5946 1 2 0.032 0.5 0.016 0.016 0.008
R5973 0.5 1 0.016 1 0.008 0.004 0.004
R6113 1 4 0.032 2 0.016 0.016 0.008
R6164 2 4 0.06 2 0.032 0.032 0.016
R6175 1 4 0.032 2 0.032 0.032 0.016
R6250 1 2 0.06 2 0.032 0.016 0.016
R6373 0.5 2 0.032 2 0.032 0.016 0.004
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R6431 0.25 0.5 0.008 1 0.008 0.004 0.002
R7011 1 4 0.032 2 0.032 0.016 0.016
R7343 1 1 0.016 2 0.016 0.008 0.008
R7368 1 1 0.016 4 0.032 0.032 0.016
R7386 1 0.5 0.008 0.25 0.032 0.032 0.008
R7396 0.5 1 0.008 2 0.016 0.016 0.008
R7413 0.5 4 0.06 0.5 0.032 0.032 0.016
R7422 1 0.5 0.032 1 0.032 0.016 0.008
R7579 0.5 1 0.06 2 0.032 0.016 0.008
R7684 1 1 0.032 2 0.032 0.016 0.016
R7835 0.5 2 0.032 1 0.032 0.016 0.008
R7953 1 2 0.016 1 0.008 0.008 0.004
R8066 0.5 1 0.008 0.5 0.016 0.016 0.008
R8127 1 0.5 0.016 0.5 0.016 0.008 0.008
R8128 0.25 0.5 0.016 1 0.016 0.008 0.008
R8129 0.5 1 0.016 1 0.032 0.016 0.008
R8453 0.5 0.5 0.032 2 0.032 0.016 0.008
R8537 0.12 0.5 0.016 1 0.004 0.004 0.002
R8686 0.5 1 0.06 0.5 0.032 0.016 0.008
R8717 1 1 0.06 1 0.032 0.016 0.008
R9030 0.5 1 0.032 1 0.032 0.016 0.008
R9295 1 1 0.032 1 0.032 0.016 0.004
R9325 0.5 0.25 0.008 2 0.016 0.008 0.004
R9612 1 2 0.032 1 0.25 0.12 0.12
R9806 1 2 0.016 2 0.032 0.016 0.008
R10582 0.5 0.5 0.032 1 0.032 0.032 0.016
R10758 1 0.5 0.032 1 0.032 0.032 0.008
R40700 0.5 0.5 0.032 2 0.032 0.016 0.016
R70828 0.5 0.5 0.032 1 0.016 0.004 0.004
R77271 1 1 0.06 1 0.032 0.032 0.016
R79933 1 1 0.032 2 0.016 0.008 0.008
R80267 0.5 1 0.016 1 0.016 0.016 0.004
L80750 1 2 0.032 1 0.016 0.008 0.008
L80785 0.5 1 0.032 0.5 0.016 0.008 0.016
L80788 2 2 0.06 1 0.016 0.016 0.008
L85035 1 2 0.06 2 0.016 0.008 0.016
L85911 1 2 0.032 2 0.016 0.008 0.008
L85925 1 1 0.032 0.25 0.016 0.008 0.004
L85937 2 0.5 0.032 0.5 0.016 0.008 0.004
L85943 2 2 0.032 0.5 0.016 0.008 0.008
L89631 2 2 0.032 0.5 0.032 0.032 0.016
L89697 2 0.25 0.032 0.25 0.032 0.016 0.016
L89727 2 2 0.032 2 0.016 0.008 0.008
L89852 1 4 0.12 0.25 0.016 0.008 0.12
L89859 1 2 0.016 1 0.016 0.008 0.016
L89883 2 0.5 0.008 0.25 0.032 0.032 0.008
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L89927 2 2 0.008 0.12 0.016 0.008 0.004
L89939 1 0.5 0.016 0.12 0.016 0.008 0.008
L7085059 2 2 0.008 1 0.008 0.008 0.002
L7085066 0.12 2 0.008 1 0.008 0.008 0.002
L7085268 1 4 0.06 2 0.016 0.008 0.016
L7090685 1 2 0.06 2 0.016 0.008 0.008
L7090700 1 4 0.06 1 0.5 0.25 0.12
L17 0.5 2 0.032 0.5 0.008 0.008 0.004
L22 2 2 0.06 0.5 0.008 0.008 0.004
L24 2 1 0.032 1 0.008 0.008 0.008
L29 1 1 0.032 2 0.032 0.06 0.008
LI 1 1 0.032 1 0.008 0.008 0.008
BPE 1 1 1 0.016 0.5 0.016 0.008 0.008
BPE 5 1 0.25 0.016 1 0.032 0.016 0.008
BPE 6 1 0.5 0.016 2 1 2 0.5
BPE 13 1 0.5 0.032 0.25 0.032 0.016 0.016
BPE 14 1 0.5 0.032 2 0.12 0.12 0.06
BPE 17 2 4 0.016 1 0.032 0.016 0.12
BPE 22 1 0.5 0.016 2 0.06 0.016 0.008
BPE 23 2 2 0.016 2 2 2 1
BPE 25 0.5 2 0.032 1 0.016 0.016 0.016
BPE 89 0.5 1 0.016 0.25 0.5 0.5 0.25
BPE 158 1 2 0.016 0.5 2 1 0.5
BPE 249 0.5 1 0.016 2 2 1 0.25
BPE 251 1 8 0.12 1 1 1 0.25
BPE 563 1 1 0.016 1 0.5 1 0.12
BPE 565 2 4 0.032 1 0.5 0.5 0.12
BPE 779 0.5 0.5 0.016 1 1 1 0.5
BPE 6080 1 4 0.032 1 0.25 0.25 0.25
A919 1 1 0.032 0.5 0.06 0.032 0.06
A2905 0.25 0.25 0.016 2 0.5 1 0.12
A7184 0.5 0.5 0.032 1 0.008 0.032 0.032
A8442 0.5 2 0.032 0.25 0.06 0.06 0.06
A11080 2 8 0.06 1 1 1 0.25
A12825 0.5 0.25 0.032 4 0.12 0.06 0.06





Telith air Ery Clar Azith Clind Moxi
R1227 0.06 0.06 0.12 0.06 0.032 2 0.016
R7504 0.12 0.06 0.25 0.12 0.06 2 0.06
R7544 0.12 0.06 0.12 0.06 0.06 2 0.06
R7829 0.12 0.06 0.25 0.12 0.06 2 0.06
R7962 0.25 0.12 0.12 0.12 0.06 2 0.06
R8041 0.12 0.12 0.25 0.25 0.06 2 0.06
R10699 0.12 0.06 0.25 0.06 0.06 2 0.06
R10703 0.06 0.06 0.12 0.12 0.06 2 0.06
R10836 0.12 0.06 0.25 0.12 0.06 2 0.06
R10848 0.12 0.06 0.12 0.12 0.032 2 0.06
R10853 0.12 0.06 0.25 0.12 0.06 4 0.06
R10855 0.12 0.06 0.12 0.12 0.06 2 0.032
R10863 0.06 0.06 0.12 0.06 0.06 2 0.06
R11871 0.06 0.032 0.12 0.06 0.06 2 0.06
R12039 0.06 0.032 0.12 0.12 0.06 2 0.032
R12194 0.032 0.032 0.12 0.06 0.032 2 0.032
R12234 0.12 0.06 0.12 0.12 0.06 2 0.06
R12774 0.12 0.06 0.12 0.12 0.032 2 0.06
R12797 0.12 0.12 0.12 0.06 0.06 2 0.06
R12830 0.12 0.06 0.12 0.06 0.25 2 0.06
R13703 0.06 0.06 0.12 0.06 0.06 1 0.032
BME 1 0.06 0.06 0.25 0.06 0.06 4 0.032
BME 2 0.12 0.032 0.12 0.032 0.06 1 0.06
BME 3 0.06 0.06 0.12 0.06 0.032 2 0.032
BME 5 0.12 0.06 0.25 0.12 0.25 2 0.032
BME 7 0.12 0.06 0.12 0.12 0.06 2 0.032
BME 8 0.12 0.06 0.25 0.12 0.06 4 0.06
BME 9 0.12 0.12 0.5 0.25 0.12 4 0.06
BME 10 0.06 0.06 0.12 0.12 0.06 4 0.032
BME 12 0.12 0.06 0.12 0.12 0.032 2 0.06
BME 21 0.12 0.06 0.25 0.12 0.06 2 0.06
BME 22 0.06 0.06 0.25 0.12 0.06 2 0.06
BME 24 0.06 0.06 0.25 0.12 0.06 2 0.06
BME 25 0.06 0.06 0.25 0.25 0.06 2 0.032
BME 26 0.06 0.06 0.25 0.12 0.06 2 0.06
BME 34 0.12 0.06 0.25 0.12 0.06 4 0.06
BME 37 0.06 0.06 0.12 0.12 0.06 2 0.06
BME 38 0.06 0.032 0.12 0.06 0.032 2 0.06
BME 39 0.06 0.06 0.25 0.12 0.06 2 0.06
BME 40 0.06 0.06 0.25 0.12 0.032 1 0.032
BME 41 0.12 0.06 0.25 0.06 0.032 1 0.032
BME 42 0.06 0.06 0.25 0.12 0.06 2 0.06
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BME 43 0.06 0.06 0.25 0.12 0.032 2 0.06
BME44 0.25 0.12 0.25 0.12 0.12 2 0.06
BME 45 0.06 0.06 0.12 0.06 0.032 2 0.032
BME 46 0.12 0.06 0.25 0.12 0.06 2 0.032
LM75591 1 0.5 1 0.25 0.25 8 0.032
LM75608 0.06 0.06 0.12 0.12 0.06 8 0.032
LM75735 0.25 0.12 0.25 0.12 0.06 1 0.06
LM75751 0.12 0.12 0.25 0.12 0.12 2 0.06
LM75758 0.12 0.06 0.12 0.032 0.06 2 0.06
LM80738 0.12 0.06 0.25 0.12 0.12 2 0.06
LM80752 0.12 0.06 0.12 0.06 0.032 2 0.06
LM80776 0.12 0.12 0.25 0.06 0.06 4 0.06
LM82359 0.12 0.12 0.12 0.06 0.06 2 0.06
LM83095 0.25 0.12 0.25 0.12 0.06 4 0.06
LM83096 0.25 0.12 0.25 0.12 0.06 1 0.06
LM83106 0.25 0.12 0.25 0.12 0.12 2 0.06
LM83760 0.25 0.12 0.25 0.12 0.06 2 0.06
LM83791 0.25 0.25 0.25 0.12 0.06 4 0.06
LM85824 0.25 0.25 0.25 0.12 0.12 2 0.06
LM85899 0.25 0.12 0.25 0.12 0.06 2 0.032
LM85919 0.12 0.06 0.12 0.06 0.12 4 0.016
LM86000 0.12 0.06 0.12 0.06 0.06 2 0.06
LM89310 0.25 0.12 0.12 0.12 0.06 2 0.06
LM89517 0.25 0.25 0.25 0.12 0.06 1 0.06
LM89539 0.12 0.06 0.25 0.06 0.12 4 0.12
LM89724 0.12 0.06 0.06 0.032 0.06 4 0.06
LM89727 0.25 0.25 0.25 0.12 0.12 1 0.06
LM89784 0.06 0.032 0.12 0.032 0.032 2 0.06
LM89798 0.25 0.12 0.25 0.06 0.06 2 0.032
LM89848 0.12 0.06 0.25 0.12 0.06 2 0.06
LM89886 0.12 0.12 0.25 0.06 0.06 2 0.06
LM7085099 0.12 0.12 0.25 0.12 0.25 8 0.06
LM7085273 0.12 0.12 0.25 0.06 0.12 4 0.06
LM48 0.12 0.12 0.25 0.06 0.06 2 0.06
BMW 1 0.25 0.06 0.12 0.12 0.06 2 0.12
BMW 2 0.12 0.06 0.12 0.06 0.06 2 0.06
BMW 3 0.12 0.06 0.12 0.06 0.06 1 0.06
BMW 4 0.12 0.06 0.12 0.06 0.06 2 0.06
BMW 5 0.12 0.06 0.12 0.06 0.06 4 0.016
BMW 6 0.25 0.06 0.25 0.12 0.06 2 0.06
BMW 7 0.25 0.06 0.25 0.06 0.06 2 0.06
BMW 8 0.12 0.12 0.25 0.06 0.06 2 0.032
BMW 9 0.12 0.12 0.25 0.12 0.06 2 0.06
BMW 10 0.25 0.12 0.25 0.12 0.06 2 0.06
BMW 12 0.12 0.06 0.25 0.12 0.06 2 0.06
BMW 15 0.12 0.12 0.25 0.06 0.06 2 0.06
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BMW 16 0.25 0.06 0.12 0.12 0.032 1 0.06
BMW 18 0.12 0.032 0.12 0.06 0.032 1 0.06
BMW 20 0.25 0.06 0.12 0.06 0.06 2 0.06
BMB 15 0.25 0.12 0.25 0.12 0.06 4 0.06
BMB 16 0.25 0.12 0.12 0.06 0.06 2 0.06
BMB 26 0.25 0.12 0.12 0.06 0.032 1 0.06
BMB 27 0.25 0.12 0.25 0.06 0.06 2 0.06
BMB 30 0.25 0.06 0.25 0.12 0.06 1 0.06
BMB 34 0.12 0.12 0.12 0.12 0.06 2 0.032
BMB 37 0.12 0.06 0.12 0.12 0.032 1 0.032
BMB 38 0.25 0.12 0.12 0.12 0.06 2 0.032
BMB 39 0.25 0.12 0.12 0.12 0.032 1 0.032
Strains Levo Cipro Gerni Linez Amoxn Amoxv Farop
R1227 0.032 0.016 0.002 4 0.5 0.008 0.12
R7504 0.032 0.032 0.008 4 2 0.06 0.25
R7544 0.032 0.032 0.004 4 4 0.12 0.5
R7829 0.06 0.032 0.016 4 2 0.06 0.25
R7962 0.032 0.032 0.008 4 0.5 0.008 0.06
R8041 0.032 0.032 0.008 4 2 0.25 0.5
R10699 0.06 0.032 0.016 4 0.25 0.004 0.032
R10703 0.032 0.016 0.008 2 1 0.06 0.25
R10836 0.032 0.032 0.016 4 2 0.06 0.25
R10848 0.032 0.032 0.016 4 0.5 0.008 0.032
R10853 0.06 0.032 0.016 8 0.5 0.004 0.032
R10855 0.032 0.016 0.008 4 0.25 0.004 0.032
R10863 0.032 0.032 0.016 4 1 0.008 0.06
R11871 0.032 0.032 0.008 2 0.5 0.004 0.032
R12039 0.032 0.032 0.004 4 0.016 0.002 0.032
R12194 0.032 0.032 0.008 2 0.016 0.002 0.032
R12234 0.032 0.032 0.008 4 2 0.06 0.25
R12774 0.032 0.032 0.008 4 2 0.12 0.25
R12797 0.032 0.032 0.016 4 2 0.06 0.25
R12830 0.06 0.032 0.008 4 0.12 0.002 0.06
R13703 0.032 0.032 0.008 4 1 0.06 0.5
BME 1 0.06 0.032 0.016 8 1 0.004 0.032
BME 2 0.032 0.032 0.008 4 4 0.032 0.25
BME 3 0.032 0.032 0.008 4 2 0.25 1
BME 5 0.032 0.032 0.016 4 2 0.032 0.12
BME 7 0.032 0.016 0.008 4 0.12 0.002 0.032
BME 8 0.06 0.06 0.016 8 0.5 0.008 0.06
BME 9 0.06 0.032 0.016 4 4 0.25 0.5
BME 10 0.032 0.032 0.008 4 1 0.016 0.06
BME 12 0.06 0.032 0.016 4 4 0.12 0.5
BME 21 0.032 0.032 0.008 4 8 0.25 1
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BME 22 0.032 0.06 0.008 4 4 0.25 1
BME 24 0.06 0.06 0.008 4 0.5 0.008 0.06
BME 25 0.032 0.032 0.008 8 4 0.25 0.5
BME 26 0.06 0.06 0.016 8 1 0.008 0.06
BME 34 0.032 0.032 0.008 8 1 0.008 0.06
BME 37 0.032 0.032 0.016 4 2 0.12 0.25
BME 38 0.06 0.032 0.008 4 0.5 0.016 0.06
BME 39 0.06 0.032 0.016 4 0.5 0.016 0.06
BME 40 0.032 0.032 0.016 4 0.5 0.002 0.032
BME 41 0.032 0.032 0.008 4 4 0.12 1
BME 42 0.06 0.032 0.016 4 0.25 0.004 0.06
BME 43 0.06 0.032 0.016 4 4 0.25 1
BME 44 0.12 0.06 0.016 4 4 0.032 0.25
BME 45 0.032 0.032 0.016 4 0.5 0.002 0.032
BME 46 0.032 0.032 0.016 4 4 0.12 0.5
LM75591 0.06 0.016 0.008 4 2 0.032 0.25
LM75608 0.032 0.032 0.004 8 1 0.032 0.12
LM75735 0.032 0.032 0.008 4 4 0.12 1
LM75751 0.032 0.016 0.008 4 4 0.032 0.5
LM75758 0.032 0.032 0.016 4 0.016 0.002 0.06
LM80738 0.06 0.016 0.008 4 0.5 0.002 0.06
LM80752 0.032 0.032 0.008 4 2 0.06 0.25
LM80776 0.032 0.032 0.016 4 4 0.12 0.5
LM82359 0.032 0.032 0.008 4 2 0.032 0.25
LM83095 0.06 0.032 0.008 4 0.5 0.004 0.06
LM83096 0.032 0.032 0.016 4 4 0.12 1
LM83106 0.032 0.032 0.016 4 0.5 0.004 0.06
LM83760 0.032 0.032 0.008 4 4 0.12 0.5
LM83791 0.06 0.032 0.016 8 4 0.06 0.25
LM85824 0.032 0.032 0.008 4 4 0.12 0.5
LM85899 0.032 0.016 0.004 4 1 0.004 0.25
LM85919 0.016 0.016 0.002 4 1 0.032 0.25
LM86000 0.032 0.032 0.008 8 0.5 0.004 0.032
LM89310 0.06 0.06 0.016 4 1 0.06 0.5
LM89517 0.06 0.032 0.016 4 4 0.25 1
LM89539 0.06 0.032 0.016 2 0.5 0.002 0.06
LM89724 0.06 0.06 0.016 4 1 0.06 0.25
LM89727 0.06 0.06 0.016 4 2 0.12 1
LM89784 0.06 0.032 0.016 4 2 0.06 1
LM89798 0.032 0.032 0.008 4 1 0.008 0.06
LM89848 0.06 0.032 0.016 4 4 0.12 1
LM89886 0.032 0.032 0.016 4 2 0.004 0.25
LM7085099 0.06 0.032 0.016 4 1 0.06 0.25
LM7085273 0.06 0.032 0.016 4 0.016 0.004 0.06
LM48 0.06 0.032 0.016 4 2 0.06 0.5
BMW 1 0.032 0.032 0.016 4 4 0.06 0.5
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BMW 2 0.032 0.06 0.016 2 0.06 0.06 0.25
BMW 3 0.016 0.06 0.016 2 0.5 0.004 0.032
BMW 4 0.032 0.06 0.016 4 0.06 0.032 0.12
BMW 5 0.016 0.016 0.002 2 2 0.06 0.12
BMW 6 0.032 0.032 0.016 2 4 0.032 0.5
BMW 7 0.032 0.032 0.016 4 2 0.032 0.12
BMW 8 0.032 0.032 0.008 2 2 0.12 0.25
BMW 9 0.032 0.06 0.016 2 0.25 0.008 0.06
BMW 10 0.032 0.032 0.016 2 0.016 0.008 0.06
BMW 12 0.06 0.06 0.016 8 8 0.016 0.5
BMW 15 0.032 0.032 0.016 4 0.5 0.008 0.06
BMW 16 0.016 0.032 0.008 2 4 0.032 0.25
BMW 18 0.032 0.032 0.008 2 0.25 0.008 0.032
BMW 20 0.032 0.06 0.016 2 0.25 0.008 0.06
BMB 15 0.032 0.032 0.008 4 0.5 0.004 0.06
BMB 16 0.032 0.032 0.008 4 1 0.004 0.06
BMB 26 0.016 0.032 0.008 2 4 0.25 0.5
BMB 27 0.032 0.032 0.016 4 1 0.008 0.06
BMB 30 0.032 0.06 0.008 2 1 0.002 0.032
BMB 34 0.032 0.032 0.004 4 4 0.12 0.25
BMB 37 0.032 0.032 0.004 2 4 0.06 0.5
BMB 38 0.032 0.032 0.004 2 0.5 0.002 0.032





Telith air Ery Clar Azith Clind Moxi
R5580 4 1 4 16 1 4 0.008
R7410 2 0.5 4 8 2 4 0.016
R7434 2 1 4 16 2 4 0.016
R7456 4 2 1 8 4 1 0.016
R7466 2 0.5 2 4 0.5 1 0.008
R7491 8 2 8 8 1 2 0.016
R7508 2 0.5 2 4 0.5 4 0.008
R7517 2 2 8 1 2 8 0.016
R7544 0.12 0.12 0.25 0.12 0.25 2 0.12
R7832 2 0.5 2 8 1 4 0-016
R7859 8 4 8 8 1 1 0.016
R7953 0.008 1 4 8 1 2 0.008
R7974 4 1 4 8 2 8 0.016
R8013 4 1 2 4 1 1 0.032
R8189 4 4 1 8 2 1 0.016
R8280 8 4 1 16 4 1 0.032
R8687 2 1 4 8 2 2 0.016
R8701 2 1 2 8 1 8 0.016
R8714 2 1 8 8 1 8 0.008
R8923 1 1 2 4 1 2 0.004
R8953 1 0.25 1 4 0.5 1 0.008
R9006 2 1 2 4 0.5 1 0.016
R9027 2 1 4 8 1 4 0.016
R9030 2 0.5 2 2 0.5 8 0.016
R9032 1 0.25 4 8 1 2 0.008
R9033 2 0.5 4 4 1 2 0.016
R9270 2 1 4 16 1 4 0.016
R9289 2 0.5 4 4 1 8 0.008
R9300 1 0.5 2 8 2 8 0.008
R9309 4 4 1 16 8 32 0.016
R9318 1 0.5 2 4 1 4 0.008
R9325 2 1 1 16 2 1 0.016
R9341 4 0.5 4 8 1 8 0.016
R9359 2 0.25 4 8 1 4 0.004
R9360 2 1 8 4 0.5 2 0.004
R9365 2 0.5 2 2 0.5 2 0.016
R9506 2 1 8 16 4 1 0.016
R9575 0.5 0.25 4 4 0.5 2 0.032
R9601 2 0.5 8 8 2 2 0.008
R9846 4 2 1 16 1 1 0.016
R63403 1 0.5 4 4 1 4 0.004
R71113 2 0.5 4 4 1 1 0.008
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BHG 1 2 1 4 8 1 8 0.016
BHG2 0.06 0.032 0.25 0.06 0.06 1 0.004
BHG 3 0.5 0.5 2 4 0.5 4 0.004
BHG 4 1 0.5 4 4 0.5 2 0.016
BHG 6 4 2 1 16 2 1 0.016
BHG 7 2 0.5 4 8 0.5 8 0.016
BHG 9 0.5 0.5 0.5 2 1 1 0.004
BHG 13 2 0.5 2 4 0.5 2 0.008
BHG 14 8 2 4 8 1 8 0.008
BHG 15 1 0.5 2 2 0.5 2 0.008
BHG 17 1 1 4 2 0.5 1 0.008
BHG 18 2 1 8 4 1 1 0.016
BHG 19 2 0.5 2 2 2 2 0.016
BHG 20 1 1 4 2 0.5 0.25 0.016
BHG 21 2 1 2 2 0.5 0.5 0.008
BHG 22 2 0.5 4 8 1 1 0.016
BHG 23 2 2 8 8 2 4 0.004
BHG 24 2 0.5 4 8 0.5 8 0.016
BHG 25 2 1 4 8 0.5 4 0.016
BHG 26 0.12 0.25 0.5 1 0.12 1 0.016
BHG 27 2 2 4 8 1 8 0.016
BHG 29 2 1 4 8 1 8 0.016
BHG 30 1 1 2 4 0.25 1 0.016
BHG 32 1 1 2 1 0.25 1 0.008
BHG 34 1 1 4 8 1 8 0.004
BHG 35 2 2 8 8 1 4 0.016
BHG 37 4 1 2 4 0.5 2 0.016
BHG 38 1 1 4 4 0.5 2 0.016
BHG 40 4 2 8 8 4 1 0.008
BHG 42 1 0.5 2 2 0.5 2 0.016
BHG 43 1 0.5 4 2 1 4 0.016
BHG 44 0.5 0.25 2 0.5 0.25 1 0.016
BHG 45 2 1 4 16 1 4 0.016
BHG 46 2 1 4 8 4 1 0.004
BHG 47 0.5 0.25 2 4 1 8 0.008
BHG 48 0.5 0.25 8 16 2 4 0.032
BHG 49 2 0.5 4 4 2 2 0.016
BHG 50 2 0.5 4 8 2 2 0.016
BHG 51 2 1 4 4 1 4 0.032
BHG 55 4 2 1 16 2 32 0.016
BHG 56 0.06 0.032 0.12 0.06 0.12 0.032 0.12
BHG 57 1 0.5 2 2 0.5 1 0.016
BHG 58 2 1 2 4 1 2 0.032
BHG 62 0.5 0.5 2 2 0.5 2 0.016
BHG 65 4 4 8 8 1 4 0.032
BHG 66 2 0.2 0.5 2 0.5 1 0.016
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BHG 70 4 4 8 8 2 4 0.016
BHG72 1 0.5 2 4 0.5 4 0.016
BHG 74 1 1 4 4 1 4 0.008
BHG 75 0.5 0.25 2 2 0.5 1 0.008
BHG 77 4 2 4 8 1 2 0.016
BHG 78 0.5 0.12 2 1 0.2 2 0.016
BHG 80 2 1 4 4 2 4 0.016
BHG 81 2 1 4 4 2 4 0.016
BHG 82 1 0.5 2 2 0.2 2 0.004
BHG 89 1 1 4 8 1 8 0.016
BHG 92 1 0.5 2 4 0.5 4 0.008
BHG 94 4 2 4 8 2 4 0.008
Strains Levo Cipro Gemi Linez Amoxn Amoxv Farop
R5580 0.008 0.008 0.002 1 1 0.5 0.5
R7410 0.008 0.008 0.002 8 0.5 0.5 0.5
R7434 0.008 0.008 0.002 2 1 4
R7456 0.016 0.008 0.002 1 0.5 1
R7466 0.008 0.004 0.002 2 0.1 0.12
R7491 0.01 0.008 0.002 2 0.5 0.2
R7508 0.008 0.008 0.002 0.5 0.5 0.5
R7517 0.008 0.008 0.002 0.5 0.5 1
R7544 0.12 0.032 0.016 4 4 0.06 2
R7832 0.008 0.008 0.002 8 1 0.5 0.5
R7859 0.008 0.008 0.002 32 1 0.5 2
R7953 0.008 0.002 0.002 1 0.5 0.5 0.5
R7974 0.016 0.008 0.002 4 0.5 0.25 0.25
R8013 0.016 0.016 0.004 64 4 0.5 0.5
R8189 0.016 0.016 0.004 32 1 2 1
R8280 0.016 0.008 0.008 8 32 1 2
R8687 0.016 0.016 0.004 4 0.5 0.5 1
R8701 0.016 0.008 0.002 4 0.5 0.5 1
R8714 0.008 0.008 0.002 1 0.5 0.25 0.5
R8923 0.016 0.008 0.002 8 0.2 0.1 0.25
R8953 0.008 0.004 0.002 2 0.5 0.5 0.25
R9006 0.008 0.008 0.002 4 1 1 1
R9027 0.008 0.008 0.002 1 0.5 0.5 0.5
R9030 0.016 0.008 0.002 4 0.5 0.5 0.5
R9032 0.016 0.008 0.002 8 2 0.5 0.5
R9033 0.008 0.008 0.002 1 0.5 0.5 1
R9270 0.008 0.004 0.002 32 0.5 0.5 1
R9289 0.016 0.008 0.002 4 1 2 0.5
R9300 0.008 0.008 0.004 4 2 2 0.5
R9309 0.016 0.008 0.002 32 1 1 1
R9318 0.008 0.004 0.004 8 0.5 0.25 0.25
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R9325 0.016 0.016 0.004 1 2 0.25 0.1
R9341 0.016 0.008 0.004 4 1 0.5 0.5
R9359 0.008 0.008 0.002 8 0.25 8 0.25
R9360 0.008 0.004 0.002 8 0.25 0.25 0.5
R9365 0.016 0.016 0.004 32 0.25 0.25 0.5
R9506 0.016 0.008 0.002 32 0.5 0.5 1
R9575 0.016 0.032 0.004 1 1 1 1
R9601 0.008 0.008 0.002 1 0.5 0.5 1
R9846 0.016 0.008 0.002 1 2 0.5 0.25
R63403 0.008 0.004 0.002 8 0.5 0.1 0.5
R71113 0.008 0.008 0.002 8 0.5 0.25 0.5
BHG 1 0.008 0.008 0.002 8 0.5 0.25 0.5
BHG 2 0.008 0.004 0.002 4 0.032 0.016 0.06
BHG 3 0.008 0.008 0.002 4 4 0.5 0.5
BHG 4 0.016 0.008 0.004 4 0.5 0.5 1
BHG 6 0.008 0.008 0.004 8 0.5 0.06 0.12
BHG 7 0.008 0.008 0.002 8 8 0.2 0.5
BHG 9 0.016 0.008 0.002 4 0.1 0.5 0.5
BHG 13 0.008 0.008 0.002 4 0.5 0.5 0.5
BHG 14 0.008 0.008 0.004 1 0.25 0.25 0.25
BHG 15 0.008 0.008 0.002 8 0.5 0.25 0.25
BHG 17 0.008 0.008 0.002 4 1 1 0.5
BHG 18 0.016 0.008 0.002 1 0.5 0.5 1
BHG 19 0.016 0.004 0.002 8 0.5 0.5 0.5
BHG 20 0.008 0.004 0.004 4 1 0.5 2
BHG 21 0.008 0.004 0.002 4 2 1 2
BHG 22 0.008 0.004 0.002 4 1 0.5 0.5
BHG 23 0.008 0.002 0.002 8 0.5 0.5 0.5
BHG 24 0.016 0.008 0.002 4 0.5 0.5 0.5
BHG 25 0.016 0.016 0.002 4 0.25 0.5 0.25
BHG 26 0.016 0.016 0.002 4 8 0.2 0.5
BHG 27 0.016 0.008 0.004 8 8 0.25 0.25
BHG 29 0.016 0.008 0.002 1 2 2 4
BHG 30 0.016 0.016 0.004 8 0.5 0.5 1
BHG 32 0.016 0.008 0.002 4 0.25 0.1 0.25
BHG 34 0.008 0.004 0.004 1 0.5 1 0.5
BHG 35 0.016 0.008 0.002 8 1 1 1
BHG 37 0.016 0.008 0.002 4 0.5 0.12 0.25
BHG 38 0.016 0.008 0.002 1 0.5 0.2 0.5
BHG 40 0.016 0.008 0.002 8 0.5 2 4
BHG 42 0.016 0.016 0.002 8 0.2 0.25 0.5
BHG 43 0.016 0.008 0.002 8 0.5 0.5 0.5
BHG 44 0.016 0.008 0.002 4 0.5 1 0.5
BHG 45 0.016 0.008 0.002 4 8 0.25 0.5
BHG 46 0.008 0.004 0.002 1 0.5 1 0.5
BHG 47 0.016 0.008 0.002 8 0.5 0.5 0.25
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BHG48 0.016 0.032 0.004 1 0.12 0.25 0.25
BHG49 0.008 0.008 0.002 2 0.5 0.5 0.5
BHG50 0.008 0.008 0.002 2 0.5 0.5 0.5
BHG 51 0.016 0.008 0.002 8 0.5 1 0.25
BHG55 0.016 0.008 0.002 32 0.5 0.5 1
BHG 56 0.5 0.5 0.12 0.5 0.032 0.016 0.06
BHG 57 0.016 0.008 0.004 4 0.25 0.25 0.5
BHG 58 0.032 0.016 0.004 8 0.5 0.5 0.5
BHG 62 0.016 0.004 0.002 8 0.5 0.5 0.25
BHG 65 0.12 0.12 0.032 32 4 0.5 2
BHG 66 0.016 0.004 0.002 2 0.5 0.25 1
BHG 70 0.016 0.008 0.004 1 4 0.25 0.5
BHG 72 0.016 0.008 0.002 4 0.25 0.12 0.06
BHG 74 0.008 0.008 0.002 4 4 0.25 0.25
BHG 75 0.008 0.008 0.002 8 0.5 0.25 0.5
BHG 77 0.016 0.008 0.004 4 0.5 0.5 0.5
BHG 78 0.016 0.008 0.002 4 0.25 0.25 0.12
BHG 80 0.016 0.01 0.002 4 0.5 0.25 0.5
BHG 81 0.016 0.008 0.004 4 0.5 0.25 0.5
BHG 82 0.008 0.004 0.002 1 0.25 0.5 0.25
BHG 89 0.016 0.008 0.002 8 0.5 0.25 0.5
BHG 92 0.008 0.008 0.002 1 0.5 0.25 0.12
BHG 94 b.016 0.008 0.002 4 0.5 0.25 0.5
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Appendix 2
Macrolide Resistant Strains MICs
Strains Telith Ery Clar Azith Clind Country of
origin
5649 0.5 8 4 32 0.12 USA
5970 0.06 >64 >64 >64 >8 USA
950672 0.5 16 16 16 0.12 Belgium
950673 0.12 >64 >64 >64 >8 Belgium
950871 0.032 >64 >64 >64 >8 Belgium
950881 0.5 16 8 32 0.06 Belgium
02J1095 0.06 >64 >64 >64 >8 USA
02J1175 0.5 32 16 64 0.12 USA
59C072 0.25 16 16 32 0.12 Belgium
59C093 0.12 >64 >64 >64 >8 Belgium
59C113 0.06 16 16 >64 >8 Belgium
59C115 0.06 >64 >64 >64 >8 Belgium
917 0.06 >64 >64 >64 >32 Italy
931 0.06 64 64 >64 >32 Italy
950 2 >64 >64 >64 >32 Italy
951 2 >64 >64 >64 >32 Italy
1010 2 >64 >64 >64 >32 Italy
1035 0.5 16 4 >64 >32 Italy
6662 0.25 >16 >16 >32 >16 Canada
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6719 0.032 >16 16 >32 2 Canada
6823 0.032 4 1 8 0.25 Canada
6926 0.032 >16 >16 >32 >16 Canada
6942 0.12 >16 16 >32 >16 Canada
7218 0.12 >16 >16 >32 >16 Canada
7332 0.25 4 2 8 0.12 Canada
7380 0.12 8 4 16 0.12 Canada
7488 0.06 >16 >16 >32 >16 Canada
7642 0.5 8 4 16 0.25 Canada
8185 0.12 >16 >16 >32 >16 Canada
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Chlamydophila pneumoniae (formerly
Chlamydia pneumoniae) is an intracellular
pathogen responsible for respiratory tract infec¬
tion. A recent British survey of the microbial
aetiology of community-acquired pneumonia
(CAP) indicated that C. pneumonia is responsi¬
ble for 13% of CAP and is the second highest
bacterial cause of CAP L It has been associated
with bronchitis, pharyngitis, sinusitis, myocardi¬
tis, endocarditis and coronary artery disease 2.
In order to treat C. pneumoniae infections
it is first essential to know the efficacy of the
available antimicrobial agents against this
pathogen. Minimum inhibitory concentration
(MIC) tests are used to investigate the in vitro
capabilities of antimicrobial agents on bacteria.
Therefore, MIC testing of C. pneumoniae
needs to be carried out before an antimicrobial
agent is used to treat the infection. Culturing of
C. pneumoniae must occur before MIC tests
can be performed. C. pneumoniae is known to
be very difficult to culture and is far more diffi¬
cult than other chlamydial species 2. Many
methods of culturing C. pneumoniae have
been proposed with differing cell lines, centrifu-
gation conditions and incubation times. There
is no standard method for culturing C. pneu¬
moniae nor for testing the MIC of antimicrobial
agents against it. There is no agreement on
optimal culture conditions between different
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laboratories and even within the same laborato¬
ry. For C. pneumoniae to be a viable organism
in the sense that it may be tested with regulari¬
ty in vitro, a reliable method of culturing is
required.
Molecular techniques, particularly PCR, are
used to detect C. pneumoniae instead of cul¬
turing. However, in the case of antimicrobial
testing this is not an alternative to culturing.
This partly results from the fact that all the pos¬
sible mechanisms of antibiotic resistance are
not yet known. Therefore, testing for antibiotic
resistance by investigating the presence or lack
of certain genes is not appropriate. The
absence of genes associated with resistance
does not necessarily mean that the organism is
sensitive to the antimicrobial agent. In contrast,
the presence of a resistance gene does not nec¬
essarily mean that it is resistant. Only pheno-
typic testing such as MIC tests will indicate if an
organism is sensitive or resistant. Thus we
return to culturing.
Three different culture methods were inves¬
tigated for their reproducibility using four differ¬
ent strains. TW 183, ATCC 2023 and AR 39
were collected from the American Type Culture
Collection, the fourth strain, D 1, was received
from Ninewells Hospital, Dundee. The D 1
strain had been successfully cultured using an
in-house culture method in Dundee. All strains
were stored at -70°C. HL (source: the
Washington Research Foundation) and HEp-2
cells were used.
The first method was that of Sriram et a I 3,
the second was a method used by Roblin et a I
4 and the third method was an in-house
method used by Ninewells Hospital, Dundee, as
described. A monolayer of HL cells were grown
up in shell vials for 24 or 48 hours prior to
inoculation. The growth medium was removed
from the shell vials and the cells were rinsed
with 1-2 mL of filter sterilised phosphate buffer
solution (PBS). Each shell vial was inoculated
with 300 piL of inoculum of TW 183, ATCC
2023, AR 39 or D 1. The vials were then cen-
trifuged at 2400 X g and 35°C for 1 hour. The
medium was replaced with medium containing
1.3 jig/mL cycloheximide. The vials were incu¬
bated at 37°C for 7 days with additional cen-
trifugation on days 3, 4 and 5. On day 7 the
© E.I.F.T. srl - Firenze ISSN 1120-009X
culturing CHLAMYDOPH1LA PNEUMONIAE 313
vials were sonicated in an ultrasonicating water
bath. 300 |iL of the sonicated medium were
added to freshly prepared monolayers. All neg¬
ative controls were processed before examina¬
tion of those thought to contain C. pneumoni¬
ae. Negative controls consisted of a shell vial
containing uninoculated cells. The cultures were
fixed and stained using direct and indirect anti¬
body tests. No inclusions were found in any of
the vials tested. The cells were washed and the
growth medium and PBS were filtered in order
to eliminate bacterial contamination. Three dif¬
ferent methods with four different strains, two
different cell lines and two different strains did
not result in identification of a single C. pneu¬
moniae inclusion. The lack of inclusions sug¬
gests that either the C. pneumoniae were not
viable or the methods used are not easy to
reproduce. As the D 1 strain had previously
been cultured this strain was viable and so
should have resulted in the identification of
inclusions.
Thus none of the methods attempted could
be reproduced. This lack of reproducibility is a
common problem with C. pneumoniae, and
should be highlighted. Development of new
methods will not alter the problem of C. pneu¬
moniae culturing. Standardisation of the exist¬
ing methods so that they are reproducible not
only in the same laboratory but also in different
laboratories is the only way that data, particu¬
larly information about the antibiotic profile of
C. pneumoniae, may be generated.
Standard, reproducible methods, which are
agreed upon by more than one laboratory are
needed not only for culturing but also for the
investigation of antibiotic resistance in C. pneu¬
moniae. A working party of Chlamydophila
scientists is needed that will create culture
guidelines with defined parameters similar to
those available for antimicrobial agent testing.
Thus accurate and valid information on cultur¬
ing would be available.
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The Influence of the erm and mefgenes on Telithromycin Resistance in
Streptococcus pneumoniae.
F. Walsh1, J. Willcock2, S. G. B. Amyes1.
'University ofEdinburgh, UK. 2Aventis Pharma Ltd., UK.
Objectives: To investigate the effects of the presence oferm and mefgenes on the
ability to select for telithromycin resistance in Streptococcus pneumoniae.
Methods: The S. pneumoniae strains chosen for investigation were 02J1095
containing the erm gene, 02J1175 with the mefgene and a macrolide sensitive strain
NCTC 13593. Mutants were selected from plates containing telithromycin at the
MIC or twice the MIC and subcultured twice on agar plates containing telithromycin.
This procedure was repeated for each generation until telithromycin resistance
occurred or successive generations resulted in the same MIC.
The erm and mefgenes from the parent and the mutant strains were amplified using






02J1095 (erm) 0.06 Parent
JI 1 1 x 10"3
J II >32 1 x 10"6
02J1175 (mef) 0.5 Parent
MI 2 2x 10"4
Mil 4 3 x 10"5
Mill 8 3 x 10-6
M IV 8 3 x 10"5
NCTC 13593 0.016 Parent
NI 0.032 2x 10-2
Nil 0.12 3 x 10"2
N III 0.5 6 x 10"'
NIV 0.5 2 x 10~2
The strains 02J1095 and 02J1175 were both sensitive to telithromycin although they
were resistant to macrolides due to the presence of the erm and mefgenes
respectively. Telithromycin did not select for resistance in the macrolide sensitive
NCTC 13593 strain after four generations ofmutation. However, resistance to
telithromycin occurred in both 02J1095 and 02J1175 mutants. Second generation
02J1095 mutants had high-level telithromycin resistance whereas the highest
telithromycin MIC was 8mg/L after four mutant generations of 02J1175.
There were no nucleotide differences between the erm genes from the parent
(02J1095) and the corresponding mutant strains. The mefgenes from each of the four
mutant 02J1175 generations also showed no changes to the parent 02J1175 mefgene.
Conclusions: Therefore, these results suggest that telithromycin does not select for
resistance in strains lacking the erm or mefgenes but will select for resistance in
strains containing either gene. Thus in order to select for telithromycin resistance the
strain must first be macrolide resistant due to an erm or mefgene. Also, high level
resistance to telithromycin is selected with fewer generations in S. pneumoniae
containing the erm gene rather than the mefgene.
Comparative in vitro Activity of Faropenem against
Streptococcuspneumoniae, Moraxella catarrhalis and
Haemophilus influenzae Isolated in the United Kingdom.
F. Walsh1, S.G.B. Amyes1.
'University ofEdinburgh, Edinburgh, United Kingdom.
Abstract
Faropenem is a new carbapenem. The agar dilution method was used to determine
the susceptibility ofStreptococcuspneumoniae, Haemophilus influenzae and
Moraxella catarrhalis to faropenem, a macrolide, a beta-lactamase inhibitor and four
fluoroquinolones. The bacteria were collected from various regions of the United
Kingdom. The Streptococcus pneumoniae (total n = 100) were collected from
Edinburgh and Leeds, the Haemophilus influenzae (total n = 100) from Edinburgh
and Glasgow and the Moraxella catarrhalis (total n = 100) from Edinburgh, Leeds
and Wales. The in vitro tests were carried out in air incubators. The final inoculum
for Streptococcuspneumoniae was 105 cfu per spot whereas Haemophilus influenzae
and Moraxella catarrhalis were both 104 cfu. The antimicrobials tested were
faropenem, amoxiclav, clarithromycin, moxifloxacin, levofloxacin, ciprofloxacin and
gemifloxacin.
Antimicrobial Streptococcus Moraxella Haemophilus




Faropenem 0.002-1 0.032-1 0.06-4
0.008/0.25 0.12/0.5 0.5/1
Amoxiclav 0.004-2 0.002-0.25 0.016-2
0.016/0.5 0.016/0.25 0.25/0.5
Clarithromycin 0.008->32 0.032-0.25 <0.06-16
0.06/2 0.12/0.12 4/8
Moxifloxacin 0.032-0.5 0.016-0.12 0.004-0.25
0.12/0.25 0.06/0.06 0.008/0.016
Levofloxacin 0.12-2 0.016-0.12 0.004-1
1/2 0.032/0.06 0.008/0.016
Ciprofloxacin 0.032-8 0.016-0.6 <0.004-2
1/4 0.032/0.06 0.008/0.016
Gemifloxacin 0.008-0.12 0.002-0.016 0.002-0.12
0.032/0.06 0.008/0.016 0.002/0.004
Streptococcuspneumoniae is the most susceptible of the three species to Faropenem.
It has an mic90 of 0.25 mg/L. ForMoraxella catarrhalis and Haemophilus
influenzae faropenem has mic90 of 0.5 and 1 mg/1 respectively. They are both one
fold higher than amoxiclav.
For Haemophilus influenzae clarithromycin is poorly active whereas the quinolones
exhibited strong activity. Levofloxacin and ciprofloxacin were moderately active
against S. pneumoniae, but moxifloxacin and gemifloxacin had excellent activity.
However, in contrast to beta-lactams quinolones cannot be used for treatment of
paediatric infections or in pregnant women.
Faropenem has low MIC90 values for all three bacteria and might be a suitable
alternative for treatment of respiratory infections caused by Streptococcus

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Comparative In Vitro Activity of Telithromycin against
Streptococcuspneumoniae, Moraxella catarrhalis and
Hemophilus influenzae Isolated in the United Kingdom.
F. WALSH1, J. WILLCOCK2, S. G. B. AMYES1
'University ofEdinburgh, Edinburgh, United Kingdom; 2Aventis Pharma
Ltd., United Kingdom.
Abstract
Telithromycin (Tel) is a semisynthetic 14-membered ring macrolide
derivative belonging to the ketolide family. The in vitro activity of Tel
against Streptococcus pneumoniae, Moraxella catarrhalis and
Hemophilus influenzae was compared to that of a wide variety of
antimicrobial agents.
The bacteria tested were collected from different areas of the United
Kingdom: Streptococcus pneumoniae (n=100) from Edinburgh and
Leeds, Hemophilus influenzae (n=100) from Edinburgh and Glasgow
and Moraxella catarrhalis (n=100) from Edinburgh, Leeds and Wales.
The susceptibilities of these organisms to the antimicrobial agents were
tested using the agar dilution method. The in vitro tests for Tel utilised
both ambient air and 5% carbon dioxide incubation, all other
antimicrobial agents were tested in the ambient air.
Antimicrobial Streptococcus Moraxella Hemophilus
agents pneumoniae catarrhalis influenzae
MIC90 MIC90 MIC90
(mg/L) (mg/L) (mg/L)
Telithromycin air 0.12 0.12 2
Erythromycin 8 0.25 16
Clarithromycin 4 0.12 16
Azithromycin 16 0.12 2
Clindamycin 0.12 4 16
Moxifloxacin 0.25 0.06 0.032
Gemifloxacin 0.06 0.016 0.004
Linezolid 2 8 16
Amoxicillin 0.5 4 4
Amoxiclav 0.5 0.12 1
Tel has one of the lowest MIC values of the antimicrobial agents tested
and is consistently lower than erythromycin for Streptococcus
pneumoniae, Moraxella catarrhalis and Hemophilus influenzae.
Therefore, Tel has the potential to be a potent drug in the fight against
respiratory tract infections.
Keywords: telithromycin, Streptococcus pneumoniae
